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Abstract 
Histone acetylation by histone acetyltransferases (HATs) and deacetylation by 
histone deacetylases (HDACs) regulate gene expression by activating or repressing 
transcription, respectively. HDAC inhibitors (HDACIs) are a diverse class of drugs 
used to treat haemoglobinopathies, urea cycle disorders and several types of 
malignancies. Recent evidence from genome-wide as well as gene-specific epigenetic 
studies suggest a model whereby active genes are more likely than silent genes to be 
hyperacetylated and increase their transcription levels in response to HDACIs, a 
process underpinned by the dynamic recruitment and antagonistic activities of HATs 
and HDACs. Based on this model and from a therapeutic perspective, I hypothesised 
that the ability of HDACIs to increase expression of active genes might be relevant 
for diseases caused by genes that encode proteins with enzymatic function. HDACI-
mediated increase in gene transcription, even in the presence of missense, disease-
causing mutations, might lead to increased enzymatic activity and amelioration of the 
cellular and clinical phenotype. I tested this hypothesis on a group of genes involved 
in the glycolytic and pentose phosphate pathway (GPPP) which, when mutated, cause 
chronic or episodic haemolytic anaemia.  
Using RT-qPCR (B cell lines) and gene expression profiling (primary, in vitro 
generated human erythroid precursors and CD4+ T cells) I found that of the 17 GPPP 
genes, only Glucose-6-Phosphate Dehydrogenase (G6PD) mRNA levels increased in 
response to HDACIs in a time-dependent manner. Epigenetic analysis in B cells by 
ChIP-qPCR showed that histone hyper-acetylation and increased recruitment of HATs 
and HDACs underpin the selective G6PD transcriptional activation in response to 
HDACIs.  Pharmacological and genetic assays showed that increase in G6PD 
transcription was also dependent on Sp1, a generic transcription factor known to 
recruit both HDACs and HATs. 
Finally, I directly tested the hypothesis that HDACIs may increase enzymatic 
activity in G6PD deficient cells. Using B cell lines and primary erythroid cells from 
patients with G6PD deficiency, I found that HDACIs induce the same epigenetic 
changes in the mutant as in the wild type G6PD gene; more importantly, they lead to 
increased levels of the mutant mRNA and protein, associated with an up to 3-fold 
increase in enzymatic activity. These findings are potentially of great therapeutic 
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significance for correction of G6PD deficiency in up to 300 million individuals 
worldwide with the polymorphic variants of G6PD deficiency (e.g., G6PDMed and 
G6PDA-). 
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The antagonistic action of two classes of enzymes, histone aceyltransferases 
(HATs) and histone deacetylases (HDACs), is known to regulate transcription 
through acetylation and deacetylation (Brownell and Allis, 2001). It has been recently 
shown that these enzymes co-exist in active housekeeping genes and dynamically 
regulate their expression (Wang et al., 2009). Inhibitors of HDACs (HDACIs) have 
been widely used for the treatment of cancers and more recently non-malignant 
diseases (Cang et al., 2009; Wagner et al., 2010; Wiech et al., 2009). 
Within our lab, we have characterised inherited glycosylphosphatisylinositol 
(GPI) deficiency (IGD), a disease caused by a C>G transversion in the promoter of 
Phosphatidylinositol glycan anchor biosynthesis, class M (PIGM), a housekeeping 
gene essential for GPI biosynthesis (Almeida et al., 2006). This mutation results in 
histone hypo-acetylation and repression of gene transcription via inhibition of Sp1 
binding. HDACIs were shown to restore acetylation, Sp1 binding and ultimately GPI 
production providing a valuable treatment for patients with IGD (Almeida et al., 
2007). This work provided the first direct in vivo evidence of the importance of 
histone acetylation and its relation to the transcription factor Sp1.  
However, little is known about the genome-wide effects of HDACIs on 
housekeeping genes in cell lines or, more importantly, in primary human cells. To 
address this, I will investigate the effect of HDACIs on the transcriptional regulation 
of genes in a key housekeeping pathway, the ubiquitously active glycolytic and 
pentose phosphate pathway (GPPP). This pathway plays a key role in the function of 
red blood cells and is frequently disrupted in a number of inherited disorders. The 
most common of these diseases, Glucose-6-Phosphate dehydrogenase (G6PD) 
deficiency represents the most prevalent enzyme disorder, affecting 400 million 
people worldwide. Through this work I plan to explore the potential therapeutic 
benefits of HDACIs for the treatment of GPPP disorders. 
1.1 Chromatin and transcriptional regulation 
The term epigenetics is used to describe changes in the gene expression profile 
and overall phenotype of a cell or organism, which are controlled by mechanisms 
other than those causing changes in the underlying DNA sequence (Bonasio et al., 
2010; Goodell, 2013); thus, the name is derived from the Greek επί- meaning over or 
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above and is used to emphasise the additional level of transcriptional control other 
than that of the DNA sequence. 
In eukaryotic cells, genomic DNA is hierarchically packaged into a 
nucleoprotein complex called chromatin. The basic repeating unit of chromatin is that 
of the nucleosome, consisting of 147 base pairs of DNA wrapped around an octamer 
of histone proteins (made of two molecules of each H2A, H2B, H3 and H4 histones; 
Figure 1-1A; Campos and Reinberg, 2009; Kornberg and Thomas, 1974). Histone 1 
(H1) is responsible for the stabilisation of the nucleosomal structure and small linker 
DNA molecules join the nucleosomes together to form a “beads-on-a-string” fiber as 
shown by high-resolution X-ray analysis (Luger et al., 1997). The nucleosomal unit is 
responsible for the compaction of the DNA sequence of a cell into chromosomes, 
through a dynamic folding process of these DNA-protein complexes, i.e. nucleosomes, 
into higher order structures (Figure 1-1A; Lenhard et al., 2012). However, not only 
does the nucleosome facilitate DNA compaction, but it also plays a crucial role in the 
regulation of the transcriptional control of gene expression, as it determines the 
accessibility and the binding of transcription factors (TF) to cognate DNA motifs in 
the gene regulatory areas including promoters, enhancers and more distal elements 
such as locus control regions (Bannister and Kouzarides, 2011; Thurman et al., 2012). 
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Figure 1-1 The structure and covalent modifications of the mammalian 
nucleosome. (A) The structure of a typical nucleosome is shown on the right. A DNA 
molecule is wrapped around histones H2A (yellow), H2B (light red), H3 (blue) and 
H4 (green), which form an octamer. The residues comprising the charged pocket are 
shown in dark red. Not shown here are the N-terminal histone tails protruding outside 
the nucleosome, which are freely accessible to post-translational modifications. These 
nucleosomes are packaged into higher order structures as shown on the left, resulting 
in the formation of the individual chromosomes. (B) Schematic representation of the 
main histone post-translational modifications: acetylation (blue), methylation (red), 
phosphorylation (yellow) and ubiquitination (green). Numbers in grey under the 
amino acids represent the position in the protein sequence. (Adapted from (Caterino 
and Hayes, 2007; Portela and Esteller, 2010)) 
 
 
A. 
B. 
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Epigenetic marks (Figure 1-1B), such as DNA methylation at cytosine 
residues and post-translational modifications (PTMs) in the tails of histones or in the 
globular regions of histones, critically determine the accessibility of DNA to TFs and 
thus regulate transcriptional control of gene expression (Bannister and Kouzarides, 
2011; Berger, 2007). Study of these epigenetic marks and their effector proteins as 
well as the distribution of these marks throughout the genome has resulted in a greater 
understanding of epigenetic regulation. 
1.1.1 Histone modifications and acetylation 
Histone PTMs include acetylation, methylation, phosphorylation, 
ubiquitination, sumoylation, Adenosine diphosphate (ADP) ribosylation, deamination 
and proline isomerization (Figure 1-1B; Berger, 2007; Bernstein et al., 2007; Canzio 
et al., 2013; Kouzarides, 2007; Li and Reinberg, 2011; Margueron and Reinberg, 
2010; Weake and Workman, 2008; Zhu and Reinberg, 2011). Every histone PTM is 
reversible; consequently there are mechanisms in place for their removal as well as 
their addition (Berger, 2007). Histone PTMs have various functions; they may alter 
the charge of a residue to disrupt DNA-protein, protein-protein and nucleosome-
nucleosome interactions and they may also form surfaces to which other proteins can 
bind (Bannister and Kouzarides, 2011). PTMs enhance binding to chromatin by a 
variety of protein domains: bromodomains can preferentially bind acetylated lysines, 
forkhead domains can recognise phosphorylated threonines and serines and tudor 
domains can bind methylated lysines and arginines (Taverna et al., 2007). In this PhD 
thesis, I will focus on the transcriptional control of gene expression through the action 
of histone acetylation. 
Allfrey and colleagues (Allfrey et al., 1964) were the first to describe histone 
acetylation in 1964. Since then it has been established that histone acetylation is 
dynamically regulated by the antagonising actions of two classes of enzymes, HATs 
and HDACs (Brownell and Allis, 2001). Nuclear HATs use acetyl coenzyme A 
(acetyl-coA) to catalyse the transfer of an acetyl group to the ε-amino group of 
selective lysine residues in the extruding amino-terminal tails of the core histone 
proteins (Allfrey, 1966; Hodawadekar and Marmorstein, 2007). The negatively 
charged acetyl groups neutralise the highly positive charge of the histones and 
stabilise the influence of the electrostatic contacts between the histones and the 
negatively charged DNA, leading to the loosening of the histone-DNA interactions 
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(Luger et al., 1997) thus opening up the chromatin and facilitating transcription by 
allowing TFs to access the promoter. In addition, acetyl-modified histones function as 
'marks' that encourage binding of co-activator complexes and chromatin remodellers 
such as SWI/SNF, which can further facilitate access to free DNA by promoting 
sliding or eviction of nucleosomes (Agalioti et al., 2002; Li and Reinberg, 2011; 
Nightingale et al., 1998). By removing the acetyl groups, HDACs have the opposite 
effects, i.e., restoration of the positive charge of the lysine residues leading to 
chromatin compaction and transcriptional repression. 
1.1.2 HATs and HDACs 
1.1.2.1 HATs 
There are two major classes of HATs: type A and type B, depending on the 
mechanism of catalysis and also on the cellular localisation (Table 1-1). The members 
of the HAT A family are located in the nucleus and are responsible for the transfer of 
an acetyl group from acetyl-coA to an –NH2 of the amino-terminal tail of a histone. 
The A family can be further classified into the Gcn5-related N-acetyltransferase 
(GNAT), MYST and CREB binding protein (CBP)/p300 subclasses, based on their 
homology with yeast proteins (Hodawadekar and Marmorstein, 2007; Peserico and 
Simone, 2011). Some HATs, such as GCN5, contain bromodomains that read specific 
acetylated sites on core histones and form components of chromatin-remodelling 
complexes (Lee and Workman, 2007). Moreover, some HATs, such as P300/CBP-
associated factor (PCAF) and CBP/p300 have been shown to target non-histone 
proteins, for example the transcription factors p53 and MyoD (Glozak et al., 2005; 
Zhang and Dent, 2005). Conversely, the HAT B family is primarily cytoplasmic and 
function to acetylate free histones that are not part of chromatin. These HATs 
acetylate newly synthesised histones, regulating histone deposition in the chromatin 
(Parthun, 2007; 2012).  
 
 
 
 
  28 
Table 1-1 Members of the HAT family. (Adapted from(Peserico and Simone, 
2011)) 
Mammalian HATs 
Class Subclass Yeast 
Homology 
Members  Mechanism of 
action 
Cell 
localisation 
A 
GNAT Gcn5 GCN5 PCAF Transfer acetyl 
groups to 
histone N-tails 
after assembly 
into 
chromosomes 
Nucleus 
MYST Esa1;Sas2;Sas3 
Tip60 
MOF 
HBO1 
CBP/p300 HAT1;Elp3; Hpa2;Nut1 
CBP 
p300 
TFIIIC complex 
ATF2 
B  Hat1 HAT1 
Transfer acetyl 
groups to free 
histone N-tails 
before DNA 
deposition  
Cytoplasm 
 
1.1.2.2 HDACs 
To date, 18 human HDACs have been identified, which, based on 
phylogenetic analysis, fall into four classes according to their yeast counterparts 
(Figure 1-2; de Ruijter et al., 2003; Gregoretti et al., 2004). HDACs within the 
classical family depend on Zn2+ for deacetylate activity and comprise classes I, II and 
IV. Class I HDACs are homologous to the yeast Rpd3 and comprise HDAC1, 
HDAC2, HDAC3 and HDAC8. Class II HDACs share homology with the yeast Hda1 
and are subdivided into the subclass IIa (HDAC4, HDAC5, HDAC7 and HDAC9) 
and the subclass IIb (HDAC6 and HDAC10).  Class IV contains only HDAC11. 
Finally, class III HDACs consist of seven sirtuins, which require NAD+ cofactor for 
deacetylase activity. Of note, HDACIs have been designed for the treatment of 
several diseases and these target the Zn2+ domains of the Zn2+-containing HDACs 
(Smith and Workman, 2009). The work in this thesis focuses on HDAC class I, II and 
IV. 
Class I HDACs are ubiquitously expressed and located in the nucleus (de 
Ruijter et al., 2003; Delcuve et al., 2012). Knockout studies have shown that these 
HDACs play a key role in cell proliferation and survival (Bhaskara et al., 2008; 
Haberland et al., 2009; Knutson et al., 2008; Montgomery et al., 2007). Except for 
HDAC8, which generally has low levels of expression, class I HDACs are 
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components of multiprotein complexes. Due to recent evolutionary gene duplication, 
HDAC1 and HDAC2 share significant sequence homology resulting in 85% similarity 
in their protein products (Bradner et al., 2010; Gregoretti et al., 2004). Consequently, 
HDAC1 and HDAC2 can form homodimers and heterodimers and form components 
of the same complexes (Sin3, Nucleosome remodeling deacetylase (NuRD) and 
CoREST transcriptional repressing complexes; Delcuve et al., 2012). However, Wang 
and colleagues (Wang et al., 2009) have recently shown by a genome-wide study in 
CD4+ T cells  that these two HDACs are differentially distributed along coding and 
regulatory regions. Furthermore, HDAC3 is part of the nuclear receptor co-respressor 
1 (NCoR) and SMRT complexes (Delcuve et al., 2012).  
 
Figure 1-2 Human HDACs superfamily. HDACs fall into four classes, based on 
their homology to yeast proteins. Specific domains, characteristic for each class, are 
presented in this schematic representation. (Obtained from (Barneda-Zahonero and 
Parra, 2012))  
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Class II HDACs shuttle between the nucleus and the cytoplasm and exhibit 
tissue-specific expression and function (Yang and Seto, 2008). Class IIa HDACs can 
be found in both the nucleus and cytoplasm, as they contain intrinsic nuclear import 
and export signals that control the dynamic trafficking. Furthermore, they are signal 
transducers, containing two or three evolutionary conserved serine residues in their N-
terminal domain, which are subject to reversible phosphorylation (Verdin et al., 2003; 
Yang and Gregoire, 2005). Once phosphorylated, they are dissociated from the genes 
to which they are bound and are exported from the nucleus leading to de-repression of 
their target genes. Class IIa HDACs have minor intrinsic deacetylase activity and 
usually interact with their target genes through TFs (Verdin et al., 2003), such as the 
Myocyte enhancer factor-2 (MEF2) family, transcriptional co-repressors, the 
heterochromatin protein HP1a and the NCoR and SMRT complexes in association 
with HDAC3 (Fischle et al., 2002). Nevertheless, it has been recently suggested that 
they are indeed able to bind acetylated lysines by acting as bromodomains and further 
recruit chromatin-modifying enzymes (Bradner et al., 2010).  
Class IIb HDACs have duplicated catalytic activity domains, although 
duplication is only partial in HDAC10. HDAC6 shuttles in and out of the nucleus and 
is localised in the cytoplasm in the absence of a stimulus (Verdel et al., 2000). 
Similarly, HDAC10 is mainly cytoplasmic, but it can translocate to the nucleus upon 
stimulation (Kao, 2001). Although little is known about the function of HDAC10, it is 
now known that HDAC6 is able to bind to the regulatory and coding areas of genes 
and thus directly regulate transcription (Wang et al., 2009).   
In addition, although it is known that HDAC11 has significant sequence 
similarity with classes I and II (de Ruijter et al., 2003; Gregoretti et al., 2004), very 
little is currently known about its function. 
1.1.3 Transcriptional regulation by histone acetylation 
Extensive work on individual genes has shown that the dynamic balance of 
histone acetylation and deacetylation is a critical determinant of transcriptional 
regulation, i.e., activation versus repression. Furthermore, HDACs have been 
traditionally considered to act as co-repressors that inhibit transcription through 
binding to gene promoters; HDACs are then replaced by co-activator HATs to drive 
transcription upon signal transduction (Berger, 2007; Xu et al., 1998). Genome-wide 
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analysis in yeast has shown that HAT binding is positively associated with gene 
transcription (Kurdistani et al., 2004). Nevertheless, the exact role of HDACs has 
been controversial as conflicting studies suggest that HDACs can be associated with 
both gene repression (Kadosh and Struhl, 1997) and gene activation (Wang, 2002). 
A recent detailed genome-wide study by Wang and colleagues (Wang et al., 
2009) that involved ChIP-seq analysis of primary CD4+ T cells provided new insights 
into the role of histone acetylation and deacetylation of active (or housekeeping), 
primed (or poised) and inactive (or repressed) genes (Figure 1-3). Specifically, it was 
found that active genes are associated with high binding levels of both HATs and 
HDACs to the promoters and gene bodies; it was speculated that in this context, 
HDACs are required to reset the chromatin status by removing the acetyl groups after 
the completion of each round of transcription to prevent hyper-acetylation of the gene. 
Conversely, the promoters of primed genes demonstrate low levels of HATs and 
HDACs in association with H3K4 trimethylation, thus maintaining genes in a poised 
state, primed for activation. Repressed genes have no detectable HATs and HDACs 
and are maintained in a repressed transcriptional state primarily by the Polycomb 
complex and the H3K27me3 repressive mark. This study provided new perspectives 
on the roles of HDACs, especially for transcriptional control of active genes, 
suggesting that HDAC inhibition might be a simple means to influence their 
transcription.  
  32 
 
Figure 1-3 Dynamic regulation of gene transcription. High levels of HATs and 
HDACs are associated with active genes. HDACs remove the acetyl groups to reset 
chromatin state. Low levels of HATs and HDACs and the presence of H3K4 
methylation show how HDACs inhibit transcription by polymerase II. Silent genes 
have neither HATs nor HDACs detected on their promoters. In some cases polycomb 
group complexes are present. (Adapted from (Wang et al., 2009)) 
 
1.1.4 The role of acetylation in housekeeping genes 
1.1.4.1 The gene-specific example of inherited GPI deficiency 
Although the role of histone acetylation in individual genes has been studied 
in different in vitro cellular systems, the dissection of the molecular pathogenesis of 
IGD provided the first direct proof of the importance of histone acetylation and its 
relation to the TF Sp1 in humans in vivo. 
Specifically, in 2006 our lab demonstrated the genetic and biochemical basis 
of IGD, a rare autosomal recessive disorder (Almeida et al., 2006). IGD, characterised 
by life-threatening thrombosis and treatment-intractable epilepsy, is caused by the 
disruption of the biosynthesis of GPI, a glycolipid to which tens of proteins are 
attached before they are expressed on the cell surface as GPI-linked molecules. The 
genetic defect in IGD is a C>G transversion in the promoter of PIGM, a housekeeping 
gene essential for GPI biosynthesis. This point mutation disrupts binding of the TF 
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Sp1 to the core promoter, reducing levels of histone acetylation at the promoter and 
transcriptional activity of PIGM, therefore constituting the first example of a gene-
specific histone hypo-acetylation disease.  
Furthermore, it was demonstrated that HDACIs, including butyrate, which is 
approved for clinical use, are able to effectively restore histone acetylation, 
transcriptional activity and synthesis of GPI as well as the expression of GPI-linked 
proteins on the surface of IGD patient cells in vitro (Almeida et al., 2006; 2007; 
Caputo et al., 2013). Additionally, a clinical trial of butyrate in a child with IGD 
suffering from treatment-intractable epilepsy resulted in restoration of the PIGM 
promoter acetylation, transcription and GPI biosynthesis in vivo and importantly in 
prompt and complete resolution of all epileptic episodes for the first time in 12 years 
(Almeida et al., 2007). The findings from this work have wider ramifications for 
understanding gene transcriptional and epigenetic regulation and the principles of 
epigenetic therapy.  
1.1.4.2 Sp1: Overview and its interactions with HATs and HDACs 
Sp1 (Specificity protein 1) is a TF and member of the Specificity 
Protein/Kruppel-like Factor (Sp/KLF) family, whose members share a highly 
conserved DNA binding domain (DBD) with three Cys2His2- type zinc fingers that 
allow binding to GC- and GT-rich boxes (Black et al., 2001; Philipsen and Suske, 
1999; Wierstra, 2008). The Sp/KLF family is divided into the Sp family, which 
favours GC-rich domain binding and the KLF family. The Sp family is subdivided 
into the Sp1-4 and Sp5-9 classes that are distinguished by the presence or absence of 
glutamin-rich reporter domains (TADs), respectively (Bouwaman and Philipsen, 
2002; Davie et al., 2008; Li and Davie, 2010; Tan and Khachigian, 2009). Within the 
Sp1-4 class, Sp1 and Sp3 are ubiquitously expressed, whereas Sp2 and Sp4 display a 
tissue-specific expression pattern (Hagen et al., 1992). 
Sp1 has two isoforms, with isoform α having a longer N-terminal domain than 
isoform b (Figure 1-4A). It is an 110kDa nuclear TF that binds to GC-rich motifs 
(such as the 5’-G/T-GGGCGG-G/A-G/A-C/T-3’ or 5’G/T-G/A-GGCG-G/T-G/A-
G/A-C/T-3’; Briggs et al. 1986) and positively or negatively regulates the 
transcription of both TATA-less and TATA-containing genes. Sp1 exhibits 90% DBD 
homology to Sp3, therefore these two members of the Sp family often compete for 
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binding to the same GC-boxes. Consequently the Sp1:Sp3 ratio often plays a key role 
in gene regulation (Black et al., 2001; Bouwaman and Philipsen, 2002; Resendes and 
Rosmarin, 2004; Li and Davie, 2010); on some promoters Sp1 cooperates with Sp3, 
whereas in others Sp3 suppresses the Sp1-mediated activation.  
Sp1 is known to be a transactivator (Kadonaga et al., 1988). It binds to other 
Sp1 molecules to form tetramers and has the ability to transactivate via a single Sp1 
binding site (Courey and Tijan, 1988; Courey et al., 1989), to transactivate 
synergistically with itself via two or more binding sites (Courey and Tijan, 1988; 
Courey et al., 1989), and finally to superactivate the Sp1-mediated transcription with 
one Sp1 molecule binding to the DNA and the other Sp1 molecules interacting with it 
(Pascal and Tjian, 1991). Four domains of Sp1 (Figure 1-4A) are involved in 
transcriptional activation: domains A and B contain the TADs and are required for all 
the above transactivation activities, domain C possesses low transactivation potential 
and domain D is essential for synergistic transactivation (Courey and Tijan, 1988; 
Courey et al., 1989; Wierstra, 2008). Of note, a significant difference between Sp1 
and Sp3 is that Sp3 cannot synergistically activate transcription of promoters 
containing more than one Sp1/Sp3 binding sites.  
Through its binding to the GC-rich motifs, Sp1 is shown to regulate 
transcription through protein-protein interactions with other transcription factors 
(Figure 1-4B), such as c-myc (Parisi et al., 2007), c-jun, Stat-1 (Canaff et al., 2008) 
and Ets-1 (Rosmarin et al., 1998), and with components of the basal transcriptional 
machinery. Indeed, the two TADs directly interact with both TBP (TATA-binding 
protein) and TAF4 (TBP-associated factor 4; Courey and Tijan, 1988; Courey et al., 
1989; Wierstra, 2008). However, Sp1 does not interact with TAF1, TAF2 and TFIIB 
(Baniahmad et al., 1993; Chen et al., 1994), indicating its importance for the 
recruitment of the TBP/TFIID complex and therefore stimulation of transcription 
initiation but not elongation (Wierstra, 2008). 
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Figure 1-4 Structure, modifications and interactions of Sp1. (A) This schema 
shows the structural characteristics and the known post-translational modifications of 
human Sp1. The domains A, B, C and D that are involved in transcriptional activation 
are highlighted. (B) Interaction partners of Sp1 are shown under the corresponding 
site of interaction. (Adapted from (Li and Davie, 2010; Wierstra, 2008)) 
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Sp1 has also been linked to chromatin remodelling due to its interactions with 
HATs and HDACs. Sp1 is shown to directly bind to the HAT p300, which acts as a 
co-activator for the two TADs and is required for example in the transactivation of the 
p21 promoter by Sp1 (Kundu et al., 2000).  Sp1 also synergises with CBP even 
though they do not interact directly (Kundu et al., 2000). Furthermore, Sp1 recruits 
the chromatin remodelling complex SWI/SNF, via direct binding to the subunits 
BAF155, BAF170 and BRG1 (Kadam, 2000). Sp1 can positively regulate gene 
expression also through binding to the nucleosomal DNA to serve as a boundary for 
the spreading of heterochromatin (Ishii and Laemmli, 2003). Similarly, Sp1 has been 
shown to protect CpG islands from methylation (Brandeis et al., 1994), although 
recent data from our lab shows that this may not be the case (Caputo et al., 2013). Sp1 
has also been demonstrated to negatively regulate gene expression through direct 
binding to HDAC1 and HDAC2 though the Sin3 complex (described in 1.1.2.2) and 
DNA methyltransferase 1 (DNMT1) and has been shown to repress genes, among 
which are human telomerase reverse transcriptase (hTERT) and thymidine kinase 
(TK; Doetzlhofer et al., 1999; Hou et al., 2002).  
Although Sp1 was initially thought to serve as an activator of housekeeping 
and other TATA-less genes, it is now known to target genes that have key roles in cell 
proliferation and oncogenesis, i.e. they are required for growth, anti-apoptosis, 
angiogenesis and metastasis. For example, Sp1 activates the transcription of the genes 
encoding Cyclin E, Cyclin-dependent kinase2 (Cdk2), E2F-1 and c-myc, and 
therefore induces the transition from the G1-phase to the S-phase in quiescent cells 
(Wierstra, 2008). Additionally, it activates the transcription of the seven cyclin-
dependent inhibitors, p15INK4B, p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1, p27KIP1 
and p57KIP2 that are responsible for cell cycle arrest and required for transient 
senescence and long-term quiescence (Sherr and Roberts, 1999). Sp1 has also been 
implicated in non-malignant diseases, such as Huntington’s disease, through the 
disruption of Sp1 binding on the dopamine D2 receptor gene (Dunah, 2002) and 
recently in our lab, with IGD via the mutation of an Sp1 binding site, resulting in the 
silencing of PIGM, a housekeeping gene (described in 1.1.4.1).  
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1.2 HDAC inhibitors 
HDACIs are a class of compounds shown to interfere with the activity of 
histone deacetylases. Inhibitors of the Zn2+ -dependent HDACs, i.e. classes I, II and 
IV, were originally discovered by their ability to promote differentiation and cell 
cycle arrest in cultured erythroleukaemic cells and only later were identified as 
histone deacetylase inhibitors (Friend et al., 1971; Marks, 2010; Richon et al., 1996). 
Soon after, it was recognised that HDACs are upregulated in a number of cancers or 
are aberrantly recruited to DNA loci upon chromosomal translocations, especially in 
haematological malignancies, such as non-Hodgkin’s lymphoma and acute leukaemia. 
Consequently, the specificity of HDACIs towards tumour cells led to their 
development as anticancer drugs (Cang et al., 2009; Wagner et al., 2010). More 
recently, clinical studies that use HDACIs have been extended to non-cancer diseases, 
such as sickle cell anaemia, cystic fibrosis, inflammatory disorders, 
neurodegenerative disorders and HIV infection (Wiech et al., 2009). To date, four 
pharmacological HDACIs have been approved by the Food and Drug Administration 
(FDA) [SAHA (Zolinza, Vorinostat), Merck Research Laboratories, Romidepsin or 
depsipeptide or FK228 (Istodax), Gloucester Pharmaceuticals, sodium phenylbutyrate 
(Buphenyl), Ucyclyd Pharma and Valproic Acid (Depakene), Abbot Laboratories] 
and more than ten compounds are in clinical trials, such as depsipeptide and 
trichostatin A (Glaser, 2007; Smith and Workman, 2009). 
1.2.1 Mechanism of HDAC inhibition and selectivity 
The active site of Zn2+ -dependent HDACs consists of a tubular pocket with 
two histidine residues, two aspartic acid residues, one tyrosine residue (the latter is 
substituted by another histidine in class IIa HDACs) and a Zn2+ ion located at the base 
of the pocket (Finnin et al., 1999). HDACIs fit into the pocket and inhibit the 
deacetylase activity (Figure 1-5; Finnin et al., 1999). Generally, HDACIs display 
three common structural characteristics, which are in line with the “cap-linker-
chelator” pharmacophore model (Figure 1-5). They contain a Zn2+-binding moiety, an 
alkyl-, aryl- or vinyl- chain linker spanning the length of the tubular pocket, and a cap 
that blocks the active site by interacting with the external surface of the HDAC 
(Finnin et al., 1999; Marks, 2007; Marks and Breslow, 2007). 
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Figure 1-5 Structural features of HDACIs. (A) An example of a hydroxamic acid 
HDACI displaying the common “cap-linker-chelator” structure of HDACIs. (B) 
Representation of the crystal structure of the HDACI SAHA, inserted into the tubular 
pocket of the enzyme. (Obtained from (Marks, 2010)) 
 
Depending on their Zn2+ -binding group, HDACIs fall into six structurally 
diverse classes (Table 1-2). These are: short-chain fatty acids [e.g. the butyrates and 
valproic acid (VPA)], hydroxamic acids [e.g. Trichostatin A (TSA) and 
suberoylanilide hydroxamic acid (SAHA)], cyclic tetrapeptides containing a 2-amino-
8-oxo-9,10-epozy-deconoyl (AOE) moiety [e.g. Depsipeptide FK228], epoxides not 
containing an AOE moiety [e.g. Depudexin], benzamides [e.g. MS-275] and 
electrophilic ketones [e.g. Trifluoromethyl ketones](de Ruijter et al., 2003; Delcuve et 
al., 2012; Marks, 2010; Marks et al., 2000). 
 
 
 
A. 
B. 
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Table 1-2 HDAC inhibitor classification. a 
Group Compounds In vitro IC50 range 
Short-chain fatty acids 
Sodium Butyrate mM 
Phenylbutyrate mM 
Valproic Acid mM 
Hydroxamic acids 
Trichostatin A µM 
SAHA nM 
Scriptaid µM 
Oxamflatin nM 
Cyclic tetrapeptides 
Depsipeptide nM 
Trapoxin nM 
Epoxides Depudexin µM 
Ketones Trifluoromethyl ketones µM 
Benzamides MS-275 µM 
a Examples of compounds falling into each of the six structural HDACI classes and 
their in vitro concentrations used are listed in this table. (Adapted from (Bantscheff et 
al., 2011; Bertrand, 2010; de Ruijter et al., 2003; Dzierzak and Philipsen, 2013)) 
 
A controversial issue in the literature regarding HDACIs has been that of their 
isoform selectivity. HDACIs have generally been considered pan-inhibitors, implying 
inhibition of all Zn2+-containing HDACs. However, a recent study by Badner and 
colleagues (Bradner et al., 2010) has shown that almost all classical inhibitors fail to 
target class IIa HDACs. Furthermore, a very detailed study by Bantscheff and 
colleagues (Bantscheff et al., 2011), which took into account the fact that HDAC 
activity is mostly associated with multiprotein complexes (as described in 1.1.2.2), 
was carried out using 16 HDACIs with different chemical structures tested in 6 
human cell lines and 6 mouse tissues. Even though this study confirmed the results by 
Bradner et al. regarding class IIa HDACs, it conflicted with the selectivity data seen 
in other studies (Bertrand, 2010; Blackwell et al., 2008). Nevertheless, it confirmed 
the fact that different HDACIs have varied potency against each HDAC.  
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1.2.2 Butyrate  
Butyric acid (butyrate) is a naturally occurring short-chain fatty acid produced 
during the natural synthesis and the breakdown of longer-chain fatty acids in vivo. 
Significant sources of butyrate in the diet include dairy products, fruit and vegetables, 
which are metabolised by the endogenous intestinal bacterial fragmentation of fibers 
in the human body (Heerdt et al., 1999; Miller, 2004b; Santillo and Albenzio, 2008).  
In terms of HDAC inhibition, butyrate was the first HDAC inhibitor to be 
identified in 1949 (Candido et al., 1978; Sealy and Chalkley, 1978; Stadtman and 
Barker, 1949) and since then butyric acid and its derivatives have been used for the 
treatment of haemoglobinopathies (Perrine et al., 2010), urea cycle disorders 
(Batshaw et al., 2001), sickle cell anaemia (Dover et al., 1994) and most recently for 
the treatment of IGD (Almeida et al., 2007). Additionally, it is currently in advanced 
clinical trials for the treatment of cancers (Andriamihaja et al., 2009; Perrine et al., 
2007; Yoo and Jones, 2006). The compound used for pharmaceutical purposes is 
sodium phenylbutyrate, which is a prodrug, rapidly metabolised to the active form 
phenylacetate. Despite its therapeutic potential, the form of sodium phenylbutyrate 
currently marketed and used for the treatment of diseases has a short half-life and is 
subjected to first pass hepatic clearance, explaining the milligram doses the patients 
are required to take in order to achieve therapeutic concentrations in vivo (Yoo and 
Jones, 2006). 
Sodium butyrate (NaBu), a sodium salt of butyric acid and member of the 
short chain fatty acids, is the form used for laboratory research. It has been reported to 
have potency in the mM range (Bolden et al., 2006) and is shown to inhibit most 
classes of HDAC except class III (SIRT) and has very low potency for class IIb 
HDACs (Blackwell et al., 2008). It is now known from crystallographic data, kinetic 
analysis and co-immunoprecipitation studies that butyrate is a competitive and 
reversible inhibitor of histone deacetylases (Sekhavat et al., 2007).  
1.2.3 Trichostatin A and SAHA 
A class of HDACIs that is more potent than the short-chain fatty acids is that 
of the hydroxamic acids (Bantscheff et al., 2011), the most potent of which is 
Trichostatin A (TSA), which is effective at nanomolar concentrations (Bantscheff et 
al., 2011; Yoshida et al., 1990). Although initially used as an anti-fungal agent, it was 
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later shown to have proliferation inhibitory properties against cancer cells (Chang et 
al., 2011; Vigushin et al., 2001). TSA is shown to inhibit class I and II HDACs, with 
very low efficiency against class IIa (Bantscheff et al., 2011; Blackwell et al., 2008; 
Bradner et al., 2010).  
Another HDACI of the same class is SAHA, which was the first to earn 
regulatory approval by the FDA in 2006 and since then has been used for the 
treatment of cutaneous T cell lymphoma (Mann et al., 2007). Since FDA approval, it 
has been extensively used in research and shown to act against other types of 
haematological and solid tumour cancers (Marks, 2007; Siegel et al., 2009), as well as 
to have therapeutic potential for other non-malignant conditions (Zhao et al., 2012). 
SAHA is a potent inhibitor used at micromolar concentrations and similarly to TSA it 
is shown to inhibit class I and II HDACs, with very low efficiency against class IIa 
(Bantscheff et al., 2011; Blackwell et al., 2008; Bradner et al., 2010). Interestingly, 
recent studies regarding SAHA, have raised concerns regarding its absorption and 
metabolism (Fraczek et al., 2013). 
1.2.4 Impact of butyrate on gene expression 
Although HDACIs, including butyrate, can lead to widespread histone hyper-
acetylation, transcription of only 2-25% of genes is shown to be affected (Davie, 
2003; Delcuve et al., 2012; Mitsiades et al., 2004; Sealy and Chalkley, 1978; 
Sekhavat et al., 2007; Van Lint et al., 1996). The time in culture, the concentration 
and type of HDACI used as well as the type of cells used determine the number of 
genes altered in transcription. The number of affected genes increases as time and 
concentration increase likely as a result of downstream rather than direct effects 
(Peart et al., 2005).  
Strikingly, Mariadason and colleagues (Mariadason et al., 2000) reported for 
the first time that butyrate upregulates and downregulates equal number of genes in 
colonic epithelial cells. Following this study, other researchers showed similar results 
of equal number of genes being upregulated and downregulated by butyrate and other 
inhibitors (Joseph et al., 2004; Peart et al., 2005). To further enrich our knowledge, 
Rada-Iglesias and colleagues (Rada-Iglesias et al., 2007) performed a combination of 
Chromatin Immunoprecipitation (ChIP) with microarrays (ChIP-chip) in 
hepatocarcinoma (HepG2) and adenocarcinoma (HT-29) cell lines. Treatment with 
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HDACIs, including butyrate, in these cells showed that a number of genomic regions 
close to transcription start sites were deacetylated, as opposed to the global 
acetylation increase that was observed. Interestingly enough, these promoter regions 
correspond to genes that are downregulated under butyrate exposure.  
It is important to highlight that to date almost all the genome-wide studies 
conducted to evaluate the gene expression changes in response to HDACIs involved 
cell lines rather than primary human cells. The exception to this, is the study by Wang 
and colleagues (Wang et al., 2009), also discussed in 1.1.3, in which primary human 
CD4+ T cells were treated with NaBu and TSA to evaluate global gene expression of 
genes in response to HDACIs. 
Butyrate responsive elements have been characterised within the promoters of 
the butyrate-responsive genes (Davie, 2003; Majumdar et al., 2012; Siavoshian et al., 
1997). These can be categorised into two separate groups. The first group consists of 
genes that are either induced or repressed and have a common AGCCACCTCCA 
sequence, suggesting that they are bound by a common transcription factor. Examples 
of this group are cyclin D1 and intestinal trefoil factor genes that are repressed, as 
well as the metallothionein IIA and calbindin-D28k that are induced. In the 2nd group, 
there are genes, such as the IGF-binding protein 3 and the Cdk2 inhibitor p21Waf/Cip1, 
which share an Sp1/Sp3 binding site within the butyrate responsive elements. Sp1 and 
Sp3 are transcription factors that are ubiquitously expressed and act as both activators 
and repressors of gene expression and, as discussed above, Sp1 interacts with HATs 
and with HDACs.  
1.3 Erythropoiesis 
1.3.1 Human adult haematopoiesis 
Haematopoiesis is the process through which blood cells are formed. The liver 
forms the primary site of haematopoiesis during fetal life. From the second trimester 
onwards haematopoiesis begins in the bone marrow, where it remains throughout 
childhood and adult life. In adult life about 1012 haematopoietic cells are required 
each day. Therefore, to avoid depletion of the haematopoietic cells, a system to 
maintain a self-renewing stem cell pool, which can also differentiate into all types of 
mature blood cells is needed (Doulatov et al., 2012; Orkin and Zon, 2008).  
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Haematopoiesis is organised as a developmental hierarchy (Figure 1-6) with 
the multipotent haematopoietic stem cells (HSCs) at the apex. HSCs are rare long-
lived multipotent cells occurring at a frequency of approximately 1 cell per 106 and 
can be identified based on the expression of specific cell-surface markers 
(Gangenahalli et al., 2005). The cell-surface marker CD34 was the first marker found 
to enrich HSCs and is currently known to mark HSCs as well as more committed 
early progenitors. The need for the characterisation of additional markers to allow for 
fractionation of the stem cell and progenitor pool, led to the identification of the stem 
cell marker CD90 (Thy1; Baum et al., 1992). Further studies identified CD45RA and 
CD38 as markers of more differentiated non-HSC progenitors (Bhatia et al., 1997; 
Conneally et al., 1997), introducing a picture of human HSCs as CD34+CD38-
Thy1+CD45RA-. 
HSCs are necessary for lifelong blood production and have the capacity to 
self-renew, generating more HSCs or to differentiate. During their differentiation, 
HSCs give rise to a series of haematopoietic progenitors (Figure 1-6), which are 
restricted in their developmental potential and will undergo a gradual fate restriction 
to terminally differentiate into mature blood cells (Doulatov et al., 2012; Giebel and 
Punzel, 2008; Laurenti and Dick, 2012).  
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Figure 1-6 The haematopoietic hierarchy. Pluripotent haematopoietic stem cells 
(HSCs) give rise to multipotent progenitors (MPP), which will then divide 
symmetrically to self-renew or asymmetrically to differentiate into either a common 
lymphocyte progenitor (CLP) or a common myeloid progenitor (CMP). The CMP in 
turn gives rise to either a granulocyte-macrophage progenitor (GMP), or a 
megakaryocyte-erythroid progenitor (MEP). These progenitors further differentiate 
through multiple stages into mature haematopoietic cells.  Recently, it has been 
accepted that there is one more cell type, the lymphoid-primed multipotential 
progenitor (LMPP) that can give rise to both CLPs and CMPs. (Reproduced and 
adapted from (Dzierzak and Philipsen, 2013)) 
 
At present, the mechanisms underlying self-renewal and lineage specification 
are not well understood. A dominant model of haematopoiesis posits that lineage 
transitions are controlled by a small number of TFs that are sequentially expressed 
and restricted to specific lineages (Iwasaki and Akashi, 2007). However, recent 
genome-wide studies suggest that there is a more complex architecture in regulatory 
circuits, which involves a complex interplay of TFs that are expressed at varying 
levels across multiple lineages (Novershtern et al., 2011; Suzuki et al., 2009). This 
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differential expression of TFs seems to play a key role in developmental decisions 
during haematopoiesis. 
1.3.2 Erythropoiesis: From HSCs to erythroid progenitors and 
RBCs 
Erythropoiesis is the process that generates mature erythrocytes from HSCs 
through intermediary forms of progenitor and precursor cells that undergo terminal 
differentiation and maturation to give rise to red blood cells (RBCs; Hoffbrand et al., 
2005). During human ontogeny, erythropoiesis first appears in the embryonic yolk sac 
(primitive erythropoiesis), transfers to the fetal liver and then to the bone marrow 
before birth (definitive erythropoiesis; Palis and Segel, 1998; Palis, 2008). As the site 
of erythropoiesis changes, the globin genes being expressed change as well from 
embryonic to fetal and then adult. Production of haemoglobin is the hallmark of 
erythropoiesis and RBCs and is responsible for transferring oxygen to the tissues 
(Hoffbrand et al., 2005).  
As mentioned in 1.3.1, HSCs differentiate to generate progenitors that are 
committed to specific blood lineages, which can also be defined by a combination of 
cell surface markers. The erythroid lineage is derived from the bipotent MEPs, which 
can further differentiate and commit to either the erythroid or megakaryocytic 
lineages. Downstream erythroid progenitors functionally correspond to the erythroid 
bursts (BFU-E) that have the ability to produce large colonies in vitro and the more 
differentiated late erythroid progenitors corresponding to colony forming units-
erythroid (CFU-E; Hattangadi et al., 2011; Lodish et al., 2010; Wu et al., 1995). In 
Figure 1-7, surface markers that can be used to identify BFU-E/CFU-E and the 
morphologically distinct erythroid precursors are shown.  
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Figure 1-7 HSC commitment and terminal differentiation through the erythroid 
lineage. In the human bone marrow, the HSC self-renews and differentiates from the 
multipotent state, though common and erythroid-specific progenitors, to erythroid 
precursors and terminally matures to form the RBC.  The stages are those of the 
megakaryocyte-erythroid progenitor (MEP), burst-forming units (BFU-E), colony-
forming units (CFU-E), proerythroblasts (Pro-EB), basophilic erythroblasts (Baso-
EB), polychormatic erythroblasts (Poly-EB) and orthochromatic erythroblasts (Ortho-
EB). The latter gives rise to the reticulocyte and the pyrenocyte upon enucleation. The 
reticulocyte then enters the bloodstream and terminally matures to the RBC. The 
expression levels of cell surface markers used to distinguish the different cell types 
are shown. (Reproduced and adapted from (Dzierzak and Philipsen, 2013; Hoffbrand 
et al., 2005; Sinclair and Elliott, 2012)) 
 
Upon erythroid specification, the final phase of erythropoiesis leads to the 
maturation of committed erythroid progenitors in order to produce the fully 
differentiated RBCs. As erythroblasts mature, they decrease in size, undergo 
chromatin condensation, synthesise more haemoglobin and show altered gene 
expression patterns (Figure 1-7). The earliest recognisable erythroid precursor in the 
bone marrow is the proerythroblast (or pronormoblast), a large cell with a non-
granular, deep-blue cytoplasm and a large nucleus occupying a large proportion of the 
cell. This cell is characterised by expression of CD71 (transferin receptor 1), but lacks 
CD235-GlycophorinA (GlyA or GPA; Constantinescu et al., 1999; Jelkmann and 
Metzen, 1996; Sinclair and Elliott, 2012) i.e. it is a CD34lowCD71+GlyA- cell. After 
further divisions the proerythroblast differentiates into the basophilic normoblast, a 
similar cell to its ancestor, but with a more condensed heterochromatic nucleus 
(CD34-CD71+GlyAlow cell). Further divisions form early polychromatic (expressing 
both CD71 and GlyA surface markers) and then late orthochromatic normoblasts 
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(these have lost expression of CD71), with increasing development of a condensed 
pink cytoplasm nucleus due to the production of haemoglobin by the cell. The late 
orthochromatic normoblasts are non-dividing cells with deeply stained nuclei(Lodish 
et al., 2010; Ronzoni et al., 2008).  
During terminal differentiation, the nucleoli disappear, the nucleus further 
condenses and it is eventually extruded, through a procedure called enucleation(Ji et 
al., 2011; Migliaccio, 2010). The extruded nuclei (pyrenocytes) are phagocytosed and 
degraded by the macrophages of the bone marrow. The erythroid cells are now called 
reticulocytes, migrate outside the bone marrow, entering the bloodstream. Although 
lacking a nucleus, the mature reticulocytes do still possess mitochondria and 
ribosomes. These cells further mature to form the RBCs, which have no organelles 
and nucleus, but carry haemoglobin in very high concentrations. Over the 120 days of 
a RBC’s life, the activities of the various enzymes decrease, contributing to the ageing 
process of the cell (Hattangadi et al., 2011). 
Erythropoiesis takes place in specialised niches in the bone marrow, 
containing a macrophage, which is surrounding by maturing erythroid cells, a 
formation called erythroblastic island. The microenvironment in which erythroid cells 
lie plays a key role in red cell production, as it is a process tightly regulated by the 
expression of cytokines (Hattangadi et al., 2011; Sinclair and Elliott, 2012). 
Erythropoietin (EPO), a cytokine produced in the kidney in response to low oxygen 
pressure, is the principal regulator of erythropoiesis. Its binding to the EPO receptor 
(EpoR) allows signalling through a number of signalling pathways, including the 
signal transducer and activator of transcription 5 (Stat5), phosphoinositide-3 
kinase/Akt, and Shc/Ras/mitogen-activated kinase (MAPK) pathways (Hattangadi et 
al., 2011). Erythropoiesis is EPO-dependent from the stages of CFU-E differentiation 
up to the formation of the orthochromatic normoblasts (England et al., 2011; 
Hattangadi et al., 2011; Koury, 2011). Another very important regulator of 
erythropoiesis and HSC expansion is stem cell factor (SCF) or c-kit, which is a 
cytokine that binds to the c-kit receptor and supports expansion of HSCs and 
production of erythroid progenitors up to the stage of the formation of 
proerythroblasts (Hattangadi et al., 2011; Koury, 2011).  SCF binding to its receptor 
signals through the PI3 Kinase pathway (Huddleston, 2003).  
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1.3.3 Sodium butyrate in in vitro and in vivo erythropoiesis 
HDACIs have pleiotropic functions in human erythropoiesis. HDACIs TSA 
and VPA were shown to block enucleation, without affecting differentiation and 
proliferation of erythroblasts (Ji et al., 2010; Migliaccio, 2010), whilst VPA is also 
known to promote the decision for erythroid/megakaryocytic differentiation (Zini et 
al., 2012). Knocking down of HDAC 1, 2 and 3 also inhibited terminal enucleation 
(Figure 1-8).  In a recent study, combination of TSA and SAHA with cytokines 
(100ng/ml SCF, 100ng/ml fms-related tyrosine kinase 3 (Flt3) ligand, 100ng/ml Tpo 
and 50ng/ml IL-3) resulted in a considerably higher number of CD36+ cells generated 
from CD34+ HSCs than cytokines alone (Chaurasia et al., 2011), whereas in another 
study using primary G1ER cells SAHA permitted EPO-independent erythroid 
differentiation (Delehanty et al, 2012). On the other hand, Romidepsin inhibited the 
generation of CD36+GlyAhigh mature erythroblasts from CD34+ cells and induced 
apoptosis of both CD36+GlyAhigh and CD36+GlyAlow/- i.e., immature erythroblasts 
(Yamamura et al., 2006). 
 
Figure 1-8 HDACs in erythropoiesis. HDAC isoforms involved in erythroid 
maturation are shown in this graph. HDAC1, HDAC3 and HDAC2 regulate the 
decision between self-replication and maturation, the switch from γ- to β- globin 
expression and chromatin condensation prior to enucleation, respectively. These 
HDACs are the ones affecting erythropoiesis upon treatment with HDAC inhibitors. 
(Obtained from (Migliaccio, 2010)) 
 
Unlike the other inhibitors that have been studied so far, NaBu has diverse 
effects on metabolism and cell morphology in vitro, inhibits cells proliferation and in 
some cell lines causes differentiation followed by apoptosis.  Studies in the erythroid 
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J2E cell line, show that treatment with NaBu induces erythroid differentiation, 
coupled with increase of the haemoglobin expression, but blocks cell proliferation 
(Jaster et al., 1996). In human cervix tumour cell lines, NaBu causes cell death at 
concentrations higher than 0.5mM, whilst lower concentrations reduce proliferation 
without inducing apoptosis (Dyson et al., 1992).  
Despite the in vitro studies showing that erythroid differentiation is inhibited 
by HDACIs, their use in vivo and in clinical practice suggests otherwise. In vivo 
studies in anaemic mice and primates (baboons) have shown that short-chain fatty 
acid derivatives, including butyrate, stimulate γ globin gene expression and 
erythropoiesis by increasing the BFU-E and reticulocyte counts (Cao et al., 2005; 
Pace, 2002). Patients with sickle cell anaemia treated with sodium-4-phenylbutyrate 
(plasma concentration 0.5mM-1mM) experience increased reticulocyte counts 
(therefore, no differentiation block) and improvement of their anaemia (Dover et al., 
1994).   
1.4 Disorders of the red cell metabolism 
1.4.1 The glycolytic and pentose phosphate pathways 
Metabolism is broadly defined as a set of more than 8,700 biochemical 
reactions that either produce or consume energy and are responsible for maintaining 
the living state of cells and consequently organisms. Metabolic pathways can be 
classified into three categories: those that synthesise or polymerise molecules to form 
more complex macromolecules (anabolism); those that degrade molecules to release 
energy (catabolism); and those that are involved in the elimination of toxic waste 
(toxic disposal). In the mid-19th century the majority of such pathways were identified, 
including glycolysis, respiration, urea cycle and oxidative phosphorylation 
(Deberardinis and Thompson, 2012; Metallo and Vander Heiden, 2013). 
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Figure 1-9 The glycolytic pathway. The ten steps of the Embden-Meyerhof pathway 
of glycolysis are shown. For each glucose molecule entering the glycolytic pathway 
two ATP and two NADH molecules are produced. The enzymes involved in the most 
common disorders of the red cell metabolism are highlighted in red circles. 
(Reproduced and adapted from (Berg et al., 2002; Varki et al., 2009)) 
 
 
 
 
Glucose 
Glucose-6-phosphate 
Fructose-6-phosphate 
Fructose-1-6-biphosphate 
Dihydroxiacetone 
phosphate 
Glyceraldehyde  
3-phosphate 
1-3 biphosphoglycerade 
3-phosphoglycerade 
2-phosphoglycerade 
Phosphoenolpyruvate 
pyruvate 
2x 
Hexokinase 
(HK1) 
Phosphoglucose 
isomerase (GPI) 
Phosphofructokinase 
(PKFL) 
Aldolase (ALDOA) 
Triosephosphate 
isomerase (TPI) 
Glyceraldehyde 3-
phosphate dehydrogenase 
(GAPDH) 
Phosphoglycerate 
kinase (PGK1) 
2,3 Biphosphoglyceromutase 
(BPGM) 
Enolase 
(ENO1) 
Pyruvate kinase 
ATP 
ADP 
ATP 
ADP 
2 ADP 
2 ATP 
2 NAD+ +2Pi 
2 NADH +2H
+ 
2 ADP 
2 ATP 
Pentose 
Phosphate 
Pathway 
  51 
The glycolytic (Embden-Meyerhof pathway; Figure 1-9) and its closely 
associated pentose phosphate (Figure 1-10) pathways (GPPP) are the ubiquitous 
metabolic processes responsible for the generation of adenosine triphosphate (ATP), 
the cellular free energy donor, especially under conditions in which the mitochondria, 
the main source of ATP production are either unable to function (e.g., in the absence 
of sufficient O2 supplies) or absent (e.g., in mature RBCs; Berg et al., 2002; Varki et 
al., 2009). Energy is released once ATP is hydrolysed to adenosine diphosphate 
(ADP) and orthophosphate (Pi) or to adenosine monophosphate (AMP) and 
pyrophosphate (PPi). Similar to ATP that acts as an activated carrier of phosphoryl 
groups, electron carriers have a very important role in metabolic reactions, especially 
in anaerobic processes during which they assist in oxidation in the absence of oxygen. 
A major electron carrier for fuel oxidation is NADH, the reduced form of 
nicotinamide adenine dinucleotide (NAD+), whereas NADPH, the reduced form of 
nicotinamide adenine dinucleotide phosphate (NADP+) is an activated carrier for 
reductive biosynthesis.  While NADPH is redundant in biosynthetic (mainly anabolic 
metabolism) processes, NADH is oxidised for the generation of ATP.  
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Figure 1-10 The pentose phosphate shunt. The pentose phosphate shunt is 
connected to the glycolytic pathway through the G6PD enzyme and results in the 
production of two NADPH molecules in total. G6PD, the enzyme causing the most 
common enzymatic defect is highlighted. (Reproduced and adapted from (Berg et al., 
2002; Varki et al., 2009)) 
 
1.4.2 GPPP in erythroid cells 
The main function of the RBCs is to carry haemoglobin in the bloodstream in 
high concentrations, facilitating gas exchange in the lungs and the tissue capillaries. 
Haemoglobin is an iron-containing oxygen-transport metalloprotein, which contains a 
heme group (consisting of an organic molecule having an iron in its structure) that 
binds oxygen in the lungs and in peripheral tissues and it exchanges it for carbon 
dioxide in order to bring it back to the lungs. For this purpose, the RBC needs a 
supply of energy and also a source of reducing power.  
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The mature RBC has lost DNA and RNA due to nuclear extrusion. Moreover, 
it is incapable of protein synthesis and all the mitochondria present in the 
reticulocytes have now been lost. Therefore, the only source of energy in the form of 
ATP, needed for both the maintenance of the RBC complex three-layer membrane 
and for the regulation of ion and water exchange, comes from either the GPPP (Figure 
1-9 and Figure 1-10), or the glutathione cycle. Glycolysis takes place in the cytoplasm 
and generates ATP in anaerobic conditions through processing of glucose. Glycolysis 
is tightly connected with the pentose phosphate pathway through the enzyme glucose-
6-phosphate dehydrogenase (G6PD; Figure 1-10; Castagnola et al., 2010). Under 
physiological conditions, the glycolytic pathway metabolises about 90% of glucose 
and only 10% enters the pentose phosphate shunt. However, in cases of oxidative 
stress the contribution of the pentose phosphate pathway is significantly increased. 
The same applies for the RBCs, which lack mitochondria.  
For the RBC to ensure oxygen delivery, the cell has to maintain reducing 
power in the form of NADH over NAD to reduce methaemoglobin back to the 
functional state of deoxyhaemoglobin and to deal with the oxidative stresses that may 
occur during the circulation of the oxygen. Maintenance of higher levels of NADPH 
to NADP (produced by the pentose phosphate shunt) is also needed for the reduction 
of glutathione and protection against oxidative damage by the free oxygen molecules 
and hydrogen peroxide produced. The main role of the pentose phosphate shunt is to 
produce NADPH and the reduced form of glutathione, the major defence of the RBC 
against oxidative stress (Castagnola et al., 2010; Metallo and Vander Heiden, 2013). 
Moreover, optimal oxygen delivery is ensured by the high concentration of 2,3bis-
phosphoglyceric acid produced by the Rapoport-Luebering shunt, an additional 
pathway closely related to glycolysis (Hoffbrand et al., 2005; van Wijk, 2005). 
Mutations in most of the enzymes of the GPPP have been described and are 
generally associated with haemolytic anaemia. The most common disorders are 
caused by missense mutations on the coding regions of genes encoding GPPP 
enzymes. 
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1.4.3 G6PD deficiency: overview 
G6PD deficiency was first described in the 1950s and is now known to be the 
most common human enzyme deficiency, affecting more than 400 million people 
worldwide (Beutler, 2007; Hoffbrand et al., 2005). The global distribution of the 
deficiency (Figure 1-11) is highly equated with that of Plasmodium falciparum and 
Plasmodium vivax malaria, leading to the so-called malaria protection hypothesis, as 
it is shown to protect against lethal malaria, for female heterozygotes and male 
hemizygotes (46% and 58%, respectively), particularly in childhood (Ruwende et al., 
1995). The highest prevalence rates are found predominantly in Africa, the Middle 
East, Asia, the Mediterranean and South America. From the haematological point of 
view, G6PD is by far the most important enzyme in the GPPP. G6PD catalyses the 
first step of the pentose phosphate shunt in which glucose is converted into pentose 
sugars providing reducing power in the form of NADPH and is the one controlling the 
flux through this pathway. In addition, G6PD is essential for the regeneration of the 
reduced form of glutathione through the glutathione cycle (Cappellini and Fiorelli, 
2008; Tsai et al., 1998).  
 
Figure 1-11 World map distribution of G6PD deficiency. Heat map showing the 
G6PD deficiency distribution, which is equated with that of malaria. (Obtained from 
(Cappellini and Fiorelli, 2008)) 
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1.4.3.1 G6PD: Molecular Biology 
G6PD is a housekeeping gene, spanning 15.9kb, expressed in all cell types at 
varying levels. G6PD gene is X-linked, residing at the telomeric region Xq28, has 13 
exons and 12 introns and was cloned in 1986 (Martini et al., 1986; Persico et al., 
1986). There are two characterised mRNA variants; the larger variant 1 that is 
inactive, as exon 1 is non-coding (Galgoczy et al., 2001) and the shorter variant 2, 
which encodes for exons 2-13. Two transcription start sites (TSS) drive the expression 
of these variants; one of them - located upstream of exon 1 - has been recently 
identified by the Encyclopedia of DNA elements (ENCODE) project and the other 
one - located within exon 1 - was bioinformatically characterised in the past (Philippe 
et al., 1994). 
G6PD is evolutionary highly conserved and in humans is arranged in a ‘head 
to head’ configuration with NEMO (NFκB essential modulator; Figure 1-12), a gene 
that encodes a non-catalytic subunit of the cytokine-dependent IκB kinase, involved 
in the activation of the T Nuclear factor κ-light-chain enhancer of activated B cells (F 
NF-κB) (Jin and Jeang, 1999). Bioinformatics analysis has shown that four NEMO 
transcripts are transcribed due to alternative splicing of the 5’ exons 1A, 1B and 1C 
under the influence of 2 promoters (promoter A and B). Promoter B (868bp; including 
a 192bp core promoter (Philippe et al., 1994)) is housekeeping and has strong 
bidirectional activity driving the transcription of both G6PD and NEMO genes. 
The bidirectional G6PD gene promoter (Figure 1-12) is highly GC-rich (70%) 
and is embedded within a CpG island (1245bp; Fusco et al., 2006). It has been 
reported to contain two GC-boxes that drive its expression and also a non-canonical 
TATA-box (ATTAAAT) which is required for correct start of transcription but not 
for determining the level of gene expression (Ursini et al., 1990). However, a more 
recent bioinformatics analysis found that there is no TATA-box in the promoter 
(Galgoczy et al., 2001). Furthermore, 12 binding sites for the transcription factor Sp1 
are predicted within a region of 1327bp surrounding exon 1 of the G6PD gene (Fusco 
et al., 2006; Galgoczy et al., 2001; Philippe et al., 1994). Two of these Sp1 sites 
(located ∼100bp upstream of the TSS driving the exon 1 expression and overlapping 
with the two GC boxes) were previously experimentally validated and shown to be 
required for promoter activity (Franzè et al., 1998; Philippe et al., 1994). 
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Figure 1-12 The G6PD gene and its promoter features. This is a schematic 
representation of the “head-to-head” configuration of G6PD and NEMO genes. The 
overlapping region of the genes corresponds to their shared bidirectional promoter B. 
The transcription start sites (TSS) of G6PD, promoter A (NEMO only) and B (NEMO 
and G6PD), the CpG island and Sp1 binding sites (the 2 validated ones are circled) 
are shown. (Reproduced from (Franzè et al., 1998; Galgoczy et al., 2001; Philippe et 
al., 1994)) 
 
G6PD consists of 515 amino acids and has a molecular weight of 59kDa. 
Inside the cell, the enzyme is active as a tetramer or dimer, in a pH-dependent 
equilibrium. Studies on the three-dimensional and the crystal structure of G6PD 
revealed a NADP+- binding domain in each monomer and a second larger domain 
with the active catalytic domain between the two.  
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1.4.3.2 G6PD deficiency: clinical manifestations 
To date, more than 180 mutations have been identified in the coding region of 
the G6PD gene (exons 2-13; Figure 1-13), suggesting genetic heterogeneity (Minucci 
et al., 2012). Approximately 85% of those are single nucleotide substitutions, 
producing missense variants; the rest of the mutations are either multiple mutations 
(8%), or small in-frame deletions (5%), or mutations that affect the introns (2%). All 
mutations reported so far affect only the coding region, as no association has been 
reported with the promoter region (Menounos et al., 2003). The wild type gene is 
referred to as G6PD type B.  
 
 
Figure 1-13 Most common characterised mutation sites of G6PD. The numbered 
boxes in the gene map correspond to the G6PD gene exons. The white circles refer to 
classes II and III and white ellipses are mutations causing class IV variants. Red 
circles refer to class I mutations, whereas red squares are small in-frame deletions 
causing class I deficiency. The “f” indicate a splice site mutation. (Obtained from 
(Cappellini and Fiorelli, 2008)) 
 
G6PD deficiency is a typical X-linked trait, usually affecting males who are 
hemizygous for the gene. On the other hand, females who have two copies of the gene 
due to the presence of two X chromosomes can be homozygous for the normal gene, 
heterozygous, or homozygous for the G6PD-deficient allele in areas in which the 
frequency of the deficiency is high. Due to X chromosome inactivation, heterozygous 
females are genetic mosaics and this is the reason why they have less severe 
phenotype than affected males.  
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The G6PD variants have been classified by the World Health Organisation 
(WHO) into five groups according to their activity relative to type B (Table 1-3; 
working group, 1989). In the unstressed normal erythrocyte, the G6PD activity is only 
about 2% of the total expression capacity, which can be greatly increased to meet 
challenges such as oxidative stress. However, the G6PD deficient erythrocyte has 
significantly reduced G6PD activity. Class I and II include patients with severe 
deficiency (below 10% of normal enzymatic activity), associated with chronic non-
spherocytic haemolytic anaemia (CNSHA) and acute haemolytic anaemia, 
respectively. In class III there are the individuals with moderate deficiency (10-60% 
of normal) who usually present with neonatal jaundice, favism and drug-induced 
haemolytic anaemia.  Examples of drugs that have been shown to cause drug-induced 
haemolytic anaemia are the anti-malarials primaquine and pamaquine, dapsone, which 
is used in leprosy and the analgesic acetanilide. Lastly, in class IV are the normal 
individuals and in class V those with increased activity (working group, 1989). The 
majority of class I mutations affect exons 6, 10 and 13, encoding the parts of the 
enzyme that bind the substrate, dimer interface and NADP+ site, respectively 
(Minucci et al., 2012). 
 
Table 1-3 World Health Organisation (WHO) classification for G6PD deficiency. 
(Adapted from (working group, 1989)) 
Class Enzymatic activity Examples Clinical features 
I Severe (1–10% 
residual activity) 
Harilaou 
Serres  
Brighton 
CNSHA 
II Severe (1–10% 
residual activity) 
Mediterranean 
Canton 
Orissa 
Favism,  
Drug-induced acute 
haemolysis,  
Neonatal jaundice 
III Moderate (10–60% 
residual activity) 
A- 
Mediterranean 
Favism, 
Drug-induced acute 
haemolysis 
IV Normal activity (60–
150%) 
B (wild type) None 
V Increased activity 
(>150%) 
B (wild type) None 
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The most common variant of G6PD deficiency is G6PD A- (African), which 
results in class III deficiency caused by mutations at 202A and 968C positions on the 
exons 4 and 9, respectively (Table 1-3 and Figure 1-13).  This variant accounts for 
approximately 90% of G6PD deficiency in Africa and is also very frequent in 
America, in the West Indies and other areas where people of African origin are 
present. G6PD A- is also present, albeit less frequent, in Italy, Spain, Portugal, Egypt, 
the Middle East and Lebanon. The second most common variant is G6PD 
Mediterranean (G6PD Med), which is frequent in all the countries surrounding the 
Mediterranean Sea, such as Spain, Greece, Italy, Egypt, although it is not frequent in 
the Middle East, including Israel (Bayoumi et al., 1996). G6PD Med is caused by a 
563T mutation on exon 6 (Figure 1-13) and belongs to class II or III depending on the 
severity of the deficiency (Cappellini and Fiorelli, 2008). Favism, one of the clinical 
features associated with G6PD deficiency, caused by the consumption of fava beans, 
is now believed to be most frequently connected to G6PD Med, amongst all variants. 
However, both G6PD A- and G6PD Med variants have been associated with a very 
significant reduction in the risk of severe malaria caused by Plasmodium falciparum 
and Plasmodium vivax, as discussed in 1.4.3.  
The diagnosis of G6PD deficiency is based on the estimation of enzyme 
activity, by the quantification of the rate of NADPH production from NADP+ by 
spectrophotometric analysis.  Furthermore, the development of PCR, direct 
sequencing and denaturating gradient electrophoresis have allowed the detection of 
specific common mutations e.g. the Mediterranean type, population screening and in 
some severe cases prenatal diagnosis (Mason, 1996).  
1.4.4 Other common deficiencies of the GPPP 
Enzymatic disorders associated with point mutations on the exons of genes 
encoding enzymes of the GPPP have been characterised for almost all the GPPP 
enzymes (Table 1-4), with the exception of 6-phosphogluconate dehydrogenase 
(PGD), ribose-5-phosphate-3- epimerase (RPE) and transketolase (TKT). 
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Table 1-4 Enzyme disorders of the GPPP. 
Enzyme Pathway Genetics Haematologic 
phenotype 
References 
Hexokinase (HK1) Glycolytic 10q11.2 
autosomal 
recessive 
CNSHA (de Vooght et al., 
2009) 
Glucose phosphate 
isomerase (GPI) 
Glycolytic 19q13.1 
autosomal 
recessive 
CNSHA (Climent et al., 2009; 
Kugler and Lakomek, 
2000; Repiso et al., 
2006) 
Phosphofructokina
se, liver (PFKL) 
Glycolytic 21q.22.3 
autosomal 
recessive 
Erythrocytosis,  
Minimal 
haemolysis 
(García et al., 2009; 
Ronquist et al., 2001) 
Fructose 
diphosphate 
aldolase (ALDOA) 
Glycolytic 16p11.2 
autosomal 
recessive 
CNSHA (Esposito et al., 2004; 
Kish et al., 1987; 
Yao, 2004) 
Triose phosphate 
isomerase (TPI) 
Glycolytic 12p13 
autosomal 
recessive 
CNSHA, 
Susceptibility to 
infections 
(Oláh et al., 2005; 
Orosz et al., 2009; 
Ralser et al., 2006) 
Phosphoglycerate 
kinase (PGK1) 
Glycolytic Xq13.3 
X-linked 
CNSHA (Pey et al., 2013; 
Svaasand et al., 2007) 
Biphosphoglycero
mutase (BPGM) 
Glycolytic 7q33 
autosomal 
recessive 
Erythrocytosis (Hoyer et al., 2004; 
Lemarchandel et al., 
1992) 
Glyceraldehyde-3-
P-dehydrogenase 
(GAPDH) 
Glycolytic 12p13 
autosomal 
dominant 
None reported (Phadke et al., 2009; 
Pretsch and Favor, 
2007) 
Enolase (ENO1) Glycolytic 1p36.2 
autosomal 
dominant 
CNSHA (Stefanini, 1972) 
Pyruvate kinase, 
liver/ RBC (PK) 
Glycolytic 1q21 
autosomal 
recessive 
CNSHA (Zanella et al., 2007a; 
2007b) 
Glucose-6-
phosphate 
dehydrogenase 
(G6PD) 
Pentose 
phosphate 
Xq28 
X-linked 
CNSHA, 
Drug-induced 
HA, Favism 
(Cappellini and 
Fiorelli, 2008; 
Minucci et al., 2012; 
Verhoeven et al., 
2001; vulliamy et al., 
1998; Wamelink et 
al., 2010) 
Phosphoglucolacto
nase (PGLS) 
Pentose 
phosphate 
19p13.2 
autosomal 
dominant 
CNSHA (Beutler et al., 1985) 
Ribose-5-
phosphate  
isomerase A 
(RPIA) 
Pentose 
phosphate 
2p11.2 
autosomal 
recessive 
None reported 
(single patient 
with 
encephalopathy) 
(Balasubramanyam, 
2004; 
Valayannopoulos et 
al., 2006) 
Transaldolase 
(TALDO1) 
Pentose 
phosphate 
11p15.5 
autosomal 
recessive 
Infantile liver 
failure 
(Verhoeven et al., 
2001; Wamelink et 
al., 2010) 
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Another common disorder of the red cell metabolism and the most common of 
the glycolytic pathway disorders is the pyruvate kinase (PK) deficiency, which is also 
associated with CNSHA and inherited as an autosomal recessive trait. Two 
housekeeping genes, one on chromosome 15 and the other one on chromosome 1 
have been shown to cause PK deficiency. These are responsible for the expression of 
four isoenzymes due to alternative splicing. The PK gene on chromosome 15 encodes 
for PKM1, present in skeletal muscles and PKM2, present in leukocytes. The second 
PK gene on chromosome 1 gives rise to the PKL in the liver and the PKR in the 
RBCs isoforms. Mutations on these genes indicate genetic heterogeneity as in G6PD 
deficiency; therefore the clinical features vary from severe anaemia and jaundice, 
severe CNSHA, moderate haemolysis to asymptomatic haemolysis or anaemia 
(Zanella et al., 2007a; 2007b).  
Compared to PK deficiency, the other disorders of the glycolytic pathway are 
very rare. Deficiency of glucose phosphate isomerase (GPI) is one of the commonest 
causes of CNSHA after G6PD and PK deficiencies. More than 20 mutations have 
been identified and affect protein stability (Repiso et al., 2006). Additionally, triose 
phosphate isomerase (TPI) is an enzyme that in its mutated form causes not only 
CNSHA but also neuromuscular defects and can even cause sudden death. These two 
genes are located on the chromosomes 19 and 12, respectively and are inherited as 
autosomal recessive genes. It is of great interest that these genes are expressed in a 
housekeeping manner and all of them contain several Sp1 binding sites on their 
promoters (Orosz et al., 2009).  
Children with inherited glycolytic enzyme deficiencies often suffer from life-
long, transfusion-dependent anaemia and those with TPI or GPI deficiency may have 
progressive, severely debilitating neuromuscular and central nervous system (CNS) 
complications, which begin in the first few years of life (Orosz et al., 2009; Repiso et 
al., 2006). Whilst anaemia can be treated with blood transfusion, this causes tissue 
iron overload and major end-organ damage particularly of the heart and liver, and no 
specific treatment is available for the neuromuscular or CNS complications.  There is 
therefore, a pressing need for effective treatment, which can be initiated before the 
onset of the severe complications in order to prevent the severe disability associated 
with glycolytic enzyme deficiencies. 
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1.5 Hypothesis 
According to the lessons learned from PIGM and IGD (as described in 1.1.4.1) 
and given that PIGM is a housekeeping gene and part of a ubiquitous biosynthetic 
pathway, I hypothesised that other genes required for GPI biosynthesis might be 
subjected to the same mechanism of Sp1-dependent transcriptional control. This 
notion was extended; therefore, I further hypothesised that Sp1-dependent control of 
histone acetylation and transcriptional activation may also apply for genes within 
other enzymatic biosynthetic pathways regulated in a housekeeping manner. If this is 
correct, characterisation of the Sp1-dependent epigenetic control of other genes with 
such characteristics could offer innovative therapeutic opportunities for inherited 
disorders of ubiquitous biosynthetic pathways such as that of the GPPP. 
My hypothesis further postulates that if increased transcription is achieved by 
HDAC inhibition, then this may result in increased production of the mutant protein, 
which will lead to increased enzymatic activity. Once the enzymatic activity exceeds 
a certain threshold, it could ameliorate the cellular and clinical phenotype. For 
example, research in our lab has shown in the past that in IGD an increase of the 
PIGM mRNA in the deficient B cell lines from 1% to as little as 5-10% of normal is 
associated with complete restoration of GPI expression on the surface of the cell 
(unpublished data). It should be noted that for most enzymes of the glycolytic 
pathway, red cell activity levels as low as 10-20% of normal are sufficient for 
abrogation of haemolysis. Hence, even a small increase in the overall activity after 
HDAC inhibition might have significant therapeutic value.  
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1.6 Aims 
 The aims of this PhD project are to: 
I. Test in vitro and in vivo the ability of HDACIs to enhance the gene expression 
and the enzymatic activity of GPPP genes and proteins, respectively. This will 
be tested in B cell lines and primary erythroid cells derived from patients with 
inherited glycolytic enzyme deficiencies and healthy donors. 
II. Explore the epigenetic events at baseline and in response to HDACIs to 
identify the epigenetic mechanism that drives gene expression. 
III. Explore the genome-wide implications of HDAC inhibition in primary 
erythroid cells and potentially identify novel targets of HDACIs outside the 
GPPP that could be of therapeutic value. 
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2 Materials and Methods 
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2.1 Cell lines, primary cells and patient samples 
2.1.1 Cell lines 
2.1.1.1 B lymphoblastoid and other cell lines 
Epstein Barr Virus (EBV)-transformed B lymphoblastoid cell lines, derived 
from patients with glycolytic enzyme disorders were used for the purposes of this 
project. To control these experiments, B lymphoblastoid cell lines derived from 
normal individuals not affected by glycolytic enzyme deficiencies were also used. 
Additionally, a B lymphoblastoid cell line derived from a patient with IGD was 
utilised as a control of NaBu treatment.  
Table 2-1 Cell lines used in the study. 
 
Cell line Type Culture 
features 
Individual Genotype Individual 
sex 
PP0007  
(or P7) 
B cell line Suspension Class I deficiency (G6PD 
Brighton - in frame exon 
13 deletion) 
Male 
PP0065  
(or P65) 
B cell line Suspension Homozygous for TPI 
mutation 
Male 
PP0054  
(or P54) 
B cell line Suspension Homozygous for TPI 
mutation 
Male 
PP0112  
(or P112) 
B cell line Suspension Homozygous for TPI 
mutation 
Male 
PP0267  
(or P267) 
B cell line Suspension Homozygous for TPI 
mutation 
Female 
PP0091  
(or P91) 
B cell line Suspension TPI mutation carrier Female 
PP0092  
(or P92) 
B cell line Suspension TPI mutation carrier Male 
PP0277  
(or P277) 
B cell line Suspension Normal B cell line Male 
PP0015  
(or P15) 
B cell line Suspension Normal B cell line Female 
YK B cell line Suspension Homozygous for PIGM 
mutation  
Male 
K562 Erythroid 
progenitors 
Suspension Erythroleukaemia 
(Chronic Myeloid 
Leukaemia patient in 
blast crisis) 
Female 
293T Embryonic 
Kidney  
Adherent Normal Embryonic 
Kidney  
Female 
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The human erythroleukaemia cell line K562 was used to determine the 
glycolytic enzyme gene expression in an erythroid environment. Furthermore, Human 
Embryonic Kidney 293 (293T) cells were utilised to transfect with the plasmid 
constructs. Information regarding the characteristics of all the cell lines used is listed 
in Table 2-1. 
2.1.1.2 Cell line culture 
The suspension cell lines, as listed in Table 2-1, were grown in Roswell Park 
Memorial Institute medium (RPMI) 1640 medium (Sigma-Aldrich Company Ltd., 
Dorset, UK) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma-Aldrich 
Company Ltd., Dorset, UK), 2mM L-Glutamine and 10ml/L Penicillin-Streptomycin 
(Stem Cell Technologies, Vancouver, Canada). Culturing took place in a moist 
incubator with 5% CO2 at 37°C. While in culture, the cells were maintained at a 
concentration of 4x105-5x105cells/ml in order to be in the exponential phase of their 
growth and were fed every three days. 
Adherent 293T cells were used for efficient plasmid construct transfections. 
They were grown in 75cm2 culture flasks in Dulbecco’s Modified Eagle Medium 
(DMEM; Sigma-Aldrich Company Ltd., Dorset, UK), supplemented with 10% Fetal 
Bovine Serum (FBS; Sigma-Aldrich Company Ltd., Dorset, UK), 2mM L-Glutamine 
and 10ml/L Penicillin-Streptomycin (Stem Cell Technologies, Vancouver, Canada). 
The cells were maintained at 75% confluency by splitting every three to four days, 
depending on confluency. 293T cells were detached by replacing DMEM with 
phosphate buffered saline (PBS) for an initial wash to remove the excess of cations 
and trypsin inhibitory proteins in the medium. This was followed by incubation of the 
cells with 1x trypsin- Ethylenediaminetetraacetic acid (EDTA) solution (Sigma-
Aldrich Company Ltd., Dorset, UK) at 37°C for 10 minutes to detach the cells. Cells 
were then re-plated at the desired concentration in full DMEM medium. 
The trypan blue (Sigma-Aldrich Company Ltd., Dorset, UK) exclusion method 
was used to count live cells on a Neubaeur haemocytometer to determine 
concentrations.  For counting, three squares (1mm2) were used to count cells and the 
average was then calculated for the final concentration. Dead cells, stained blue, were 
excluded from counting. 
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2.1.2 Primary cell sources 
The National Research Ethics Service approved this study (record reference 
1/LO/1050), which allowed for sample collection from healthy and deficient 
individuals. Site-specific approval was obtained from the consultants taking the 
samples. 
For this study, whole blood was obtained from healthy and deficient adult 
individuals in order to isolate peripheral blood mononuclear cells (PBMCs). Table 2-2 
shows the genotype, phenotype and enzymatic activity in the blood (as measured in 
Hammersmith Hospital at the time of collection of the blood samples) of the recruited 
patients. Furthermore, cord blood and GCSF-mobilised peripheral blood were also 
obtained for the isolation of mononuclear cells, which was then followed by the 
magnetic isolation of CD34+ stem and progenitor cells. Cord blood was provided by 
Queen Charlotte’s Hospital and GCSF-mobilised peripheral blood was provided by 
the John Goldman Stem Cell lab at Hammersmith Hospital. 
Table 2-2 G6PD deficient patients. 
Patient Genotype Clinical 
Phenotype 
Enzymatic 
activity in blood 
(our 
measurement) 
Hb (g/dl) Retics 
(%) 
Reference 
G6PD 
Brighton 
Exon 13;  
1488-1490 
deletion of 
GAA;  
Lys 
Class I; CNSHA 1.1 U/gr Hb 12.4 (8.1 
pre-
splenecto-
my) 
9.7 (McGonigle 
et al., 1998; 
vulliamy et 
al., 1988) 
G6PD Serres Exon 10;  
1082C->T;  
Ala->Val 
Class I; CNSHA 1.7 U/gr Hb 10.5 (6.6 
pre-) 
16.6 (Vulliamy et 
al., 1998) 
G6PD 
Harilaou 
Exon 7;  
648T->G; 
Phe->Leu 
Class I; CNSHA 0.5 U/gr Hb 9 (8.2 pre-) 17.1 (Poggi et al., 
1990) 
G6PD 
Mediterranean 
(Med) 
Exon6;  
563C->T; 
Ser->Phe 
Class II/III; 
Favism, 
Drug-induced 
acute 
haemolysis 
3.7 U/gr Hb 12 2 (Vulliamy et 
al., 1988) 
G6PD African 
(A- (202A)) 
Exon 4;  
202G->A; 
Val->Met 
Class III;  
Favism, 
Drug-induced 
acute 
haemolysis 
4.0 U/gr Hb 13.8  (Cappelini et 
al., 1996) 
Normal adult   7-10.4 U/gr Hb 13-16.8   
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2.1.3 Cryopreservation and thawing of cells 
When necessary, cells were cryopreserved in freezing medium that is FBS 
supplemented with 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich Company Ltd., 
Dorset, UK) at a maximum concentration of 107 cells per vial in 1ml of freezing 
medium. Immediately after resuspension in the freezing medium, they were frozen in 
-80°C in an isopropanol-containing Nalgene Cell Freezing Container (Sigma-Aldrich 
Company Ltd., Dorset, UK) for up to two days before long-term storage in liquid 
nitrogen. 
In order to thaw the cryopreserved cells, they were incubated for 1 minute in a 
37°C waterbath. They were then resuspended in appropriate warm medium. 
2.2 Primary cell selection 
2.2.1 Preparation of mononuclear cells 
Mononuclear cells were isolated by gradient density centrifugation from 
peripheral blood or cord blood using LymphoprepTM (Axis-Shield, Oslo, Norway). 
Blood samples were first diluted 1:2 in PBS (Gibco, Invitrogen, Paisley, UK) and 
then layered above the density gradient medium in Falcon tubes followed by 
centrifugation at 1500rpm for 30 minutes (break off).  Finally, mononuclear cells 
were recovered from the plasma-lymphoprep interface, washed with PBS, counted 
and then either immediately placed in culture or frozen in liquid nitrogen (as 
described in 2.1.3).  
2.2.2 Magnetic cell selection 
2.2.2.1 CD34+ cell selection 
CD34+ cell selection was carried out using the human CD34 MicroBead kit 
(Miltenyi Biotec Ltd., Surrey, UK) as per manufacturer’s instructions. Briefly, up to 
108 cells are resuspended in 300µl Robosep buffer and incubated with 100µl CD34 
Microbeads in the presence of 100µl FcR blocking reagent. Following a 30min 
incubation at 4°C in the dark, they were washed in Robosep buffer, resuspended in 
500µl of Robosep and then selected through a primed column attached to a magnet. 
The cells that were going to be selected were held in the column by the magnet and 
were washed three times with Robosep buffer before. To isolate them, the column 
  69 
was detached from the magnet, 1ml of Robosep was added in the column and the cells 
were collected with the help of a plunger. 
2.2.2.2 CD36+ cell selection 
CD36+ cell separation was performed using the MACS® technology 
(Miltenyi Biotec Ltd., Surrey, UK). Positive magnetic selection using anti-PE or anti- 
Allophycocyanin (APC) beads (Miltenyi Biotec Ltd., Surrey, UK) was used. The 
protocol followed was as per manufacturer’s instructions. In brief, up to 107 cells 
were resuspended in 100µl Robosep buffer (Miltenyi Biotec Ltd., Surrey, UK) and 
incubated with 10µl antibody for 10min at 4°C in the dark to stain. After washing 
with PBS, the cells were resuspended in 80µl Robosep buffer and 20µl of the beads 
against the specific antibody used, were added (Table 2-3). After incubating for 
15min at 4°C in the dark and washing with PBS, the CD36+ cells were separated 
using magnetic columns (Miltenyi Biotec Ltd., Surrey, UK) that are under the control 
of the MACS separator’s magnetic field.  
Table 2-3 Magnetic CD36+ cell selection antibodies and beads. 
Antibody Beads 
anti-CD36-PE (eBioscience Ltd., Hatfield, UK) anti-PE microbeads (Miltenyi Biotec Ltd., Surrey, UK) 
anti-CD36-APC (eBioscience Ltd., Hatfield, UK) anti-APC microbeads (Miltenyi Biotec Ltd., Surrey, UK)  
 
2.3 In vitro erythroid differentiation system 
The erythroid differentiation system used was adapted from previous 
publications (Ohene-Abuakwa, 2005; Ronzoni et al., 2008). It is a two-phase liquid 
culture system that models human adult erythropoiesis. Each phase lasts for seven 
days. At the end of Phase 1, CD36+ erythroid cell were selected as described in 
2.2.2.2 and replated in Phase 2 medium. Various sources were used for erythroid cell 
differentiation, including PBMCs and CD34+ cells isolated from cord blood (CB) and 
peripheral blood (PB) after Granulocyte-colony stimulating factor (G-CSF) 
mobilisation. 
2.3.1 Erythroid differentiation medium and cytokines 
Erythroid differentiation was performed using the serum-free stem cell 
maintenance and differentiation medium, StemSpan® SFEM (Stem Cell 
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Technologies, Vancouver, Canada), supplemented with a cytokine cocktail and 
10ml/L Penicillin-Streptomycin (Stem Cell Technologies, Vancouver, Canada). The 
cytokine cocktail used consisted of 10ng/ml IL-3, 100ng/ml SCF and EPO. The 
optimised EPO concentration was 0.5U/ml during Phase 1 of the culture and then 
4U/ml during Phase 2 to achieve later stages of differentiation in this highly EPO-
dependent stage. EPO was supplied from R&D (R&D Systems Europe, Abingdon, 
UK) and all other cytokines from Peprotech (Peprotech Inc, Rocky Hill, NJ, USA). 
The erythroid medium was prepared fresh before use. 
2.3.2 Plating and culturing 
Before plating the cells in the freshly made erythroid medium, they were 
counted using the trypan blue exclusion method. After optimisation, the PBMCs were 
plated (day 0) at a concentration of 2x106 cells/ml in 48-well plates for 7 days (Phase 
1 of culture). Every 2-3 days of culture half of the erythroid medium was replaced 
with fresh one. The PBMCs are floating cells, which tend to settle at the bottom of the 
well, facilitating the process of removing medium from the top. Usually, on day 2 
non-adherent cells were washed and split 1:2 in fresh medium. This process allowed 
removal of monocytes, which adhere and tend to be toxic for the culture. Additionally, 
on day 7 of the erythroid culture, the CD36+ cells were selected as described in 
2.2.2.2 and placed in culture at a concentration of 5x105 cells/ml for another 7 days 
(Phase 2 of culture). 
For the erythroid differentiation of CD34+ cells, those were plated at a 
concentration of 5x105 cells/ml at day 0. The rest of the differentiation proceeded as 
for the PBMCs except when the cultures reached 80% or more of differentiation at 
day 7 (assessed by flow cytometric analysis), in which case the cells were re-plated in 
Phase 2 medium without the CD36+ selection. 
2.4 Drug treatments 
The HDACIs used in this study were purchased from Sigma-Aldrich 
Company Ltd., Dorset, UK. They were all received in powder form and resuspended 
according to manufacturer’s advice. In particular, NaBu (98% purity; ref. 303410) 
was reconstituted fresh before use in phosphate buffered saline (PBS; Sigma-Aldrich 
Company Ltd., Dorset, UK) at a 600mM concentration and kept at -20°C for a 
maximum of a week to avoid loss of activity after long storage. SAHA (>98% purity; 
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ref SML0061) was reconstituted in DMSO at a 15mg/ml concentration and 
subsequently was diluted in PBS at a 600µM concentration and stored at -20°C. TSA 
(>98% purity; ref T8552) was initially reconstituted in ethanol at a 2mg/ml 
concentration, which was then diluted in PBS and stored at -20°C at a 10µM stock 
concentration. Table 2-4 shows the final concentrations the HDACIs are used in the 
cells. 
Table 2-4 Concentration of HDACIs used in cells. 
HDACI Concenantration used in cells 
NaBu 3mM in cell lines 
1mM in primary cells 
SAHA 4µM in cell lines 
1µM in primary cells 
TSA 100nM in cell lines 
1nM in primary cells 
 
Other than the HDACIs, chemical treatments using cycloheximide (CHX; ref 
C4859; Sigma-Aldrich Company Ltd., Dorset, UK) and mithramycin A (MTA; ref 
M6891; Sigma-Aldrich Company Ltd., Dorset, UK) were employed. Both chemicals 
were reconstituted in DMSO and further diluted in PBS. Final concentrations used in 
the cells were 10µg/ml and 1mM for CHX and MTA, respectively.  
2.5 Flow cytometry 
2.5.1 Staining 
Expression of extracellular markers was performed by flow cytometric 
analysis. Samples were analysed using a four-laser BD LSRFortessa™ cell analyser 
(Beckton-Dickinson, Oxford, UK). Each sample was stained with antigen-specific 
monoclonal antibodies and an unstained control of the cells was used to determine the 
negative expression of each cell surface marker. Compensation settings were set using 
single-stained samples. To stain the cells, they were resuspended in 100µl of PBS and 
upon adding 2µl of FcR blocking reagent (Miltenyi Biotec Ltd., Surrey, UK) they 
were incubated for 5min at room temperature. Without washing, the antibody cocktail 
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(Table 2-5) was added and staining took place for 20min at 4°C in the dark. After 
washing, resuspending in PBS and adding 1µl of 4',6-diamidino-2-phenylindole 
(DAPI), the cells were loaded on the flow cytometer for analysis. 
 
Table 2-5 Anti-human antibodies used for flow cytometric analysis. 
Antibody specificity Conjugate Supplier µl per test 
CD34 PerCP-Cy5.5 BioLegend, San Diego, USA 0.5µl 
CD36 PE BD Biosciences, Oxford, UK 1µl 
CD36 APC BD Biosciences, Oxford, UK 2µl 
CD71 PE eBioscience Ltd., Hatfield, UK 1µl 
GlyA eFluor450 
(Pacific Blue channel) 
eBioscience Ltd., Hatfield, UK 1µl 
CD33 PE-Cy7 eBioscience Ltd., Hatfield, UK 1µl 
CD61 FITC BD Biosciences, Oxford, UK 1µl 
FLAER Alexa® 488 
(FITC channel) 
Pinewood Scientific Services Inc., 
Victoria, Canada 2.5µl 
 
2.5.2 Annexin V apoptosis assay 
To estimate the apoptosis rates of the cells treated by NaBu, the AnnexinV 
protocol of eBiosciences was followed as per manufacturer instructions (eBioscience 
Ltd., Hatfield, UK). In brief, the cells were washed with PBS and then washed again 
in 1x binding buffer. These were then spun down and resuspended in 1x binding 
buffer at a concentration of 1-5 x 106 cells/ml. Only 100µl of these were used and 
stained with 1µl of AnnexinV –APC (eBioscience Ltd., Hatfield, UK) for 10min at 
room temperature in the dark. Next, the cells were washed in 1x binding buffer and 
loaded on the flow cytometer. 
2.5.3 Data analysis 
Data was analysed (Figure 2-1) using the FlowJo software version 9.3.2 (Tree 
Star Inc., Ashland, USA). Initial gating was set on live cells based on the forward 
(FSC-A) and side scatter (SSC-A) parameters. Following that, single cells were 
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selected and then DAPI+ dead cells were excluded from the analysis. This method 
was initially performed in an unstained cell sample, to set the negative expression for 
every cell marker. Then, these settings were applied to the stained samples for 
analysis. 
 
Figure 2-1 Flow cytometric analysis strategy. Live cells are selected on the forward 
(FSC-A) and side scatter (SSC-A). Gating on the forward scatters FSC-W and FSC-A 
allows exclusion of the duplets and out of those, the DAPI+ cells are excluded from 
the analysis too. The remaining cells are used for analysis of cell surface markers. 
 
2.6 Cytospins and histologic staining 
To determine the morphological characteristics of primary cells, cytospin 
slides were prepared, stained and observed under an optical microscope. Briefly, 
15.000 cells were resuspended in 200µl of full medium and then loaded into the 
cytospin cartridges. These were spun down for 5min at 400rpm in a Shandon 
Cytospin2 centrifuge (Block Scientific Inc, NY, USA). SuperFrost Ultra Plus (VWR 
International Ltd, Leicestershire, UK) slides were used. Upon centrifugation, the 
slides were removed from the cartridges and air-dried. Then they were fixed in 
methanol for one minute and stained in the May-Grunwald (Merck&Co, Hertfordshire, 
UK) solution for 7 min, followed by an additional staining in the Giemsa (Merck&Co, 
Hertfordshire, UK) solution for 20min. After May-Grunwald and Giemsa (MGG) 
staining, the slides were washed in distilled water and after air-drying they were 
mounted with PTX mountant (Sigma-Aldrich Company Ltd., Dorset, UK) and 
covered with a 50x25mm coverslip (VWR International Ltd, Leicestershire, UK).  
FSC-A 
SS
C
-A
 
FSC-A 
FS
C
-W
 
DAPI 
SS
C
-A
 
Live gate Single cells DAPI- cells 
33.1 96.3 
98.9 
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Staining solutions were optimally prepared 30min before use. Preparation 
involves filtering the dyes through a 0.2µm bore needle gauge and then dilution 1:2 of 
May-Grunwald and 1:10 of Giemsa in distilled water.  
The cytospin slides were visualised under a Nikon eclipse E400 microscope 
(Nikon, UK) and photos were taken using 40x and 100x magnification lenses.  
2.7 Gene expression assays 
2.7.1 RT-qPCR assays 
2.7.1.1 RNA extraction and cDNA synthesis 
Harvested cells, either primary or cell lines, were washed with PBS, pelleted 
down and then usually stored at -80°C prior to RNA extraction. When ready for 
extraction, the pellets were thawed and extraction was carried out using the 
GeneJET™ RNA Purification kit (Fermentas, York, UK) to process large samples. To 
process small samples, usually coming from primary cells (less than 105 cells), the 
RNeasy Plus Micro kit (Qiagen, West Sussex, UK) was used instead. When using the 
GeneJET™ RNA Purification kit, a DNase treatment step was added to the protocol, 
to eliminate any remaining DNA, as per manufacturer’s advise (Qiagen, West Sussex, 
UK). Upon RNA extraction, spectroscopic photometry using a NanoDrop machine 
(Thermo Scientific, USA) was carried out to estimate RNA concentration. Smaller 
samples went straight to cDNA synthesis. All RNA was stored at -80°C. 
Directly after RNA extraction, reverse transcription of up to 1µg of each 
sample was carried out in order to produce functional cDNA. The RevertAid™ 
Reverse Transcriptase kit (Fermentas, York, UK) was used following manufacturer’s 
instructions and using Oligo(dT)18 primers. cDNA synthesis samples were placed at -
20°C for long term storage. 
2.7.1.2 Primer design and testing 
Primers (Table 2-6) were purchased from Sigma-Aldrich Company Ltd. 
(Dorset, UK). They were designed using the Primer Express Software (Applied 
Biosystems, UK) and tested for the dimers and hairpins formation using the 
OligoCalc software  (http://www.basic.northwestern.edu/biotools/OligoCalc.html). 
Primers were designed to span two exons, amplify sequences shared by all splicing 
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variants, have annealing temperature of 60°C and have GC content 40-60%. The 
amplicons size was between 90bp and 150bp. Each primers pair was predicted to be 
specific for the target gene, as tested with BLAST (Basic Local Alignment Search 
Tool). 
Further primer testing was performed once the primers were received. Firstly, 
the annealing temperature was accurately determined by running a PCR using these 
primers, cDNA (as the primers are for reverse transcription quantitative PCR (RT-
qPCR), as opposed to ChIP primers that are tested in the same manner but using DNA 
template) and running the program at different annealing temperatures, such as 58°C, 
60°C and 63°C. The PCR was run with RT-qPCR conditions, but the end product was 
run on a 2% agarose gel to ensure that the product is unique, no dimers are formed 
and that the selected temperature forms a distinct band of the predicted size. The 
melting curve of the product was monitored as well by RT-qPCR. Secondly, the 
linearity of the primers was tested. For this step, RT-qPCR was run using the 
temperature determined at the previous step and using serial dilutions of the cDNA 
used, eg 10x, 1x, 0.1x and 0.01x. The threshold cycle (Ct) values obtained were 
plotted against the concentration and the linear regression formula was calculated on 
microsoft excel. If the 0.9<R2≤1, then the primers are amplifying in a linear manner, 
meaning that the Ct value obtained is dependent on the concentration of cDNA used 
in the reaction. Finally, although the primers were originally designed not to amplify 
genomic DNA, they were checked for genomic DNA amplification, running a RT-
qPCR reaction with template that was produced with or without the addition of 
reverse transcriptase during the cDNA synthesis. 
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Table 2-6 Primers used for RT-qPCR analysis. 
Human Gene Forward Primer Reverse Primer Annealing 
Temperature 
β-actin ACTCTTCCAGCCTTCCT
TCCTTCC 
GTTGGCGTACAGGTCTTT
GC 
60°C 
B2M ATGAGTATGCCTGCCGT
GTGA 
GGCATCTTCAAACCTCCA
TG 
60°C 
G6PD CGTCACCAAGAACATTC
ACG 
ACAGGGAGGAGATGTGG
TTG 
60°C 
GPI CACACGCCATGCTGCCC
TATG 
TGGTGGTCCACACGGGTT
CCA 
60°C 
TPI CGCCTGCATTGGGGAG
AAGCT 
ACCAATGGCCCACACAG
GCT 
60°C 
PK GCTGCAACTTGGCGGGC
A 
AGTCAGCCCCATCCAGC
AC 
60°C 
HK1 CACAGTCAAGATGTTGC
CAAC 
TGTGAACATTCTGGTTTT
TCTCATG 
60°C 
PFKL CTGGCTGTTCATCCCCG
AG 
CAATGGCACCCTCAGCG
ATG 
60°C 
ALDOA GATTGCCATGGCGACCG
TCA 
TGTTAATGGCATTGAGGT
TGATG 
60°C 
PGK1 CCGCTTTCATGTGGAGG
AAG 
ATAGACATCCCCTAGCTT
GGAA 
60°C 
PBGM TATGATGTCCCACCACC
TCC 
TGGCAATAGTATCCTTCA
GACTC 
60°C 
ENO1 TGGGGCGTCATGGTGTC
TCA 
TGGGGCGTCATGGTGTCT
CA 
60°C 
PGLS TCGATCACGCCGAGAG
CAC 
TTCTTGGCGTAGTCCTCA
GC 
60°C 
RPIA CCGAGGAGGCCAAGAA
GCT 
GGACAATTGTAGAACCA
CTTCC 
60°C 
RPE ATATAGAGGTCGATGGT
GGAGTA 
ATTGATCACAGATCTGGG
GTCTT 
60°C 
TKT GGCCAACCGCCTACGTA
TC 
ACTTGTAGCGCATGGTGT
GGA 
60°C 
PGD ACACCACAAGACGGTG
CCGAG 
GAGCGATGGGCCATACC
GGG 
60°C 
TALDO1 GATGCCCGCTTACCAGG
AG 
CTGCTCCAAACAACACA
AAAAGTT 
60°C 
NEMO TCGCTTGGAGGCTGCCA
CT     
GCTCACTCTCCAGCTGCC 60°C 
α-globin GAGGCCCTGGAGAGGA
TGTTCC 
ACAGCGCGTTGGGCATG
TCGTC 
60°C 
β-globin TACATTTGCTTCTGACA
CAAC 
ACAGATCCCCAAAGGAC 60°C 
 
2.7.1.3 RT-qPCR and data analysis 
The expression of G6PD and other GPPP genes was assessed using SYBR 
Green-based RT-qPCR. The Maxima® SYBR Green/ROX qPCR Master Mix (2X) 
(Fermentas, York, UK) was used and the reactions run in the Applied Biosystems 
7500 Real Time PCR Systems. The annealing temperature of the reaction was 
  77 
adjusted based on primers’ annealing temperature. The RT-qPCR run in three stages: 
stage 1: 95°C 10min, stage 2: 42 cycles of 94°C 15sec, annealing temp (60°C) 30sec, 
72°C 33sec, stage 3: 95°C 15sec, 60°C 1min, 95°C 15sec, 60°C 15sec. Data 
acquisition was performed in the 3rd Step of Stage 2.  
It is very important when running RT-qPCR assays to include a housekeeping 
gene in the analysis, which serves as an internal control, called reference gene. The 
reference gene is used to normalise differences in cell numbers, experimental 
treatment or RNA extraction efficiency. Since I very often treat the cells with 
pharmacological agents, it is crucial to ensure that the reference gene used remains 
stably expressed during the treatment. Upon validation, discussed in detail in 3.2.3, 
the reference gene used for this study is β-actin.  
The ABI software was used to analyse the RT-qPCR data and calculate the Ct 
of each reaction. Samples were run in triplicates and the mean average of the Ct 
values was used. For the relative quantification of expression the ΔCt equation was 
used. Specifically, the difference of Ct values between the target and reference gene 
was calculated ΔCt=Ctx – Ctβ-actin. Finally, the relative quantification of expression 
was calculated in the equation 2-(ΔCqx - ΔCq0).  Data is presented in error bars, showing 
the mean average and the standard error of mean, of n=3 independent experiments, 
unless stated otherwise. 
2.7.2 Genome-wide expression arrays 
For genome-wide gene expression analysis, RNA was isolated using the 
RNeasy Plus Micro kit (Qiagen, West Sussex, UK), as per manufacturer’s advice. The 
extracted RNA was subjected to quality control analysis, which involved firstly 
Nanodrop analysis to assess the concentration and quality (OD 260/280 ratio > 1.9) 
and secondly control analysis using an Agilent Bioanalyser 2100, to assess the quality 
of the RNA and to ensure it is not degraded.  
The extracted RNAs were used to run Affymetrix GeneChip Gene ST 2.0 
Array (Affymetrix UK Ltd., High Wycombe UK), which was performed in 
collaboration with Dr. Robert Geffers’ laboratory at the Helmholtz Centre for 
Infection Research, Braunschweig, Germany. For each run, 200ng of total RNA were 
used. 
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For data analysis, I used the Affymetrix Expression Console Software 
(Affymetrix UK Ltd., High Wycombe UK) to extract the data from the machine and 
then the GenePattern Software (Broad Institute, USA) for further analysis. For motif 
analysis, the MEME Suite (http://meme.nbcr.net/meme/) was used. 
2.8 Protein expression assay 
2.8.1 Western blot 
Using the trypan blue exclusion method, 105 cells were counted and harvested, 
washed with PBS and resuspended in 50µl 2x loading buffer (0.25M Tris-HCl, pH:6.8, 
20% β-mercaptoethanol, 40% glycerol, 16% SDS, and bromophenol blue). Protein 
was not quantified prior to western blotting, as the HDACI treatment alters the 
expression of only particular genes; therefore loading a particular number of cells in 
each well was decided to be a more accurate approach. After boiling the samples in 
90°C for 5min to lyse and denature them, 20µl were loaded on a 12% polyacrylamide 
gel (Table 2-7) and run at 150V in 1x SDS-running buffer (5x SDS-running buffer: 
15,1gr Trizma, 72gr Glycine, 5gr SDS in 1L water).  Along with the samples, 6µl of a 
prestained broad-range protein marker (Cell signaling technology, New England 
Biolabs Ltd, Herts, UK) was run. 
Table 2-7 Polyacrylamide gel protocol. 
Reagents Stacking gel (3%) Resolving gel 
(12%) 
Acrylamide (40%) 1.25ml 3ml 
Lower buffer  
(1.5M Tris-HCl pH 8.8, 0.4%SDS) 
   - 2.5ml 
Upper buffer 
(0.5Tris-HCl pH 6.8, 0.4%SDS) 
1.25ml    - 
Water 2.5ml 4.3ml 
Ammonium persulfate (APS; 10%) 75µl 200µl 
N, N, N', N'tetramethylethylenediamine 
(TEMED) 
10µl 20µl 
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Once the gel had run, the proteins were transferred onto a PVDF membrane 
that was pre-wet in 100%methanol. A semi-dry approach (BioRad, UK) was used in 
which a transfer stack (2 pre-wet in transfer buffer Whatman papers, the PDVF 
membrane, the gel and then another 2 pre-wet Whatman papers) was produced. The 
proteins were transferred at 15V for 40 min in 1x transfer buffer (5.92g Trizma, 2.93g 
Glycine in 1L water). Then, the membrane was removed from the transfer-blot and 
was blocked in 5% skim milk (Sigma-Aldrich Company Ltd., Dorset, UK) in 
PBS+0.1%Tween20 for 1hour at room temperature (or 4°C overnight). Following that, 
the membrane was rinsed in PBS+0.1%Tween20 twice for 5min and then incubated 
for 1hour at room temperature (or 4°C overnight) in the primary antibody (Table 2-8) 
at a 1:2000 dilution in PBS+0.1%Tween20. The membrane was washed three times in 
PBS+0.5%Tween20 for 5min and then incubated for 30min in the secondary antibody 
(Table 2-8) at a 1:2000 dilution in PBS+0.1%Tween20. After washing the membrane 
three times for 10min each in PBS+0.5%Tween20, it was incubated for 1min with 
ECL detection reagent (GE healthcare, UK) and then developed in the dark room on 
X-ray films (Kodak). 
Table 2-8 Antibodies used for Western blotting. 
Primary 
Antibodies 
Species Dilution Supplier 
α-human G6PD 
(ab993) 
Rabbit polyclonal  1:2000 Abcam, Cambridge, UK 
α- human  
β-actin (sc-1616) 
Goat polyclonal 1:1000 Santa Cruz Biotechnology 
Inc., Heidelberg, Germany 
Secondary 
Antibodies 
Species Dilution Supplier 
α -rabbit HRP Goat  1:2000 Dako, Cambridgeshire, UK 
α -goat HRP Rabbit  1:2000 Dako, Cambridgeshire, UK 
To re-blot the membrane with the loading control β-actin antibody, the 
membrane was stripped using a stripping buffer (Tris-HCl 20mM, pH 7.5, 6M 
Glutamic acid hydrochloride (GaHCl), 0.2% Nonyl phenoxypolyethoxylethanol-40 
(NP-40) and 0.1M β-mercaptoethanol added fresh) for 5min twice. Then, the 
membrane was washed for 1min with water. The primary antibody was added at a 
dilution of 1:1000 in blocking solution (5% milk in PBS+ 0.1%Tween20) and then 
the rest of the procedure was followed as with the first blotting.  
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2.8.2 Protein expression quantification 
To quantify the bands and estimate the fold difference in the expression of 
G6PD relative to the loading control β-actin, I used the Adobe photoshopCS3 and 
ImageJ software (http://rsbweb.nih.gov/ij/). Specifically, Adobe photoshopCS3 was 
used to select the bands. Following the selection, the ImageJ software quantified the 
background and each band’s intensity to provide numerical values. The estimated 
values of the bands were substracted from the background and then the G6PD values 
were normalised to β-actin loading control values. In that way the fold changes were 
estimated. 
2.9 G6PD enzymatic activity assay 
2.9.1 Preparation of cell lysates 
Cultured cells were harvested, washed in PBS and then the cell lysates were 
prepared by four cycles of flash-freezing-thawing of the cell pellets in freshly-made 
G6PD lysis buffer (Tris-HCl pH 7.4 10 mM, EDTA 1 mM, ε-aminocaproic acid 
(EACA) 1 mM, NaCl 10 mM, MgCl2 3 mM, NADP 20 mM). The freezing-thawing 
cycles took place in liquid nitrogen and then in a room temperature waterbath. Cell 
extracts were centrifuged (15.000 rpm, 10 min, 4°C) and the clear supernatants were 
assayed for G6PD activity. The protein lysates were stored at -80°C until assayed. An 
aliquot of each lysate (30µl) was used to measure total protein concentration by the 
Pierce BCA protein assay (Thermo Scientific, USA), as per manufacturer’s 
instructions.  
2.9.2 Spectrophotometric assay 
Total G6PD enzymatic activity was measured in duplicates by a 
spectrophotometric assay in the Hammersmith Hospital Diagnostic Haematology lab 
by Mr David Roper and Ms Lynn Robertson. In brief, cell extracts were added at the 
reaction solution (Tris-HCl pH 8.0 8.7 mM, MgCl2 8.7 mM, NADP 0.35 mM, 
Glucose-6-phosphate 1.33 mM). Then, the activity of G6PD is assayed by following 
the rate of production of NADPH, which unlike NADP has a peak of UV light 
absorption at 340 nm. The measured rate was converted to International Units, and 
divided by the amount of protein measured with the colorimetric Pierce BCA protein 
assay (Thermo Fisher Scientific, Rockford, IL), as per manufacturer’s instructions. 
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2.10 Chromatin Immunoprecipitation 
2.10.1 ChIP protocol 
To investigate the epigenetic status of the GPPP gene promoters I employed 
ChIP. The first step of the protocol involved the crosslinking of the chromatin and its 
sonication to obtain small fragments of chromatin (with the preserved protein status 
on the DNA).  This step was conducted using the Shearing ChIP kit (Diagenode, 
Cambridge, UK) as per manufacturer’s advice and was subjected to further 
optimisation to match my experimental conditions. Briefly, the cells were crosslinked 
in 1% final concentration of formaldehyde for 10min at room temperature, whilst the 
samples were rotating. Crosslinking was performed in 9ml PBS per 107 cells with the 
addition of 630µl buffer A. Crosslinking was quenched with the addition of glycine at 
a 0.125M final concentration and an extra incubation for 5min at room temperature. 
The cells were washed in ice-cold PBS (working on ice throughout the protocol is 
crucial in order to maintain the crosslinked chromatin and reduce the degradation of 
proteins) and incubated sequentially with buffers B and C (3ml per 107 cells), each 
followed by 10min incubation at 4°C. Incubation with buffers B and C ensured cell 
lysis in order to obtain cell nuclei. These are then resuspended in buffer D (107 cells 
/300µl), in which proteinase inhibitors have been added at a 1:100 concentration. 
Samples were sonicated using a standard Bioruptor® sonicator (Diagenode, 
Cambridge, UK), for 20min (0.5ON, 0.5OFF on high power) in with the aim of 
getting fragments of around 300bp. The sonicated sample was spun down to 
precipitate the debris and thus obtained a clear chromatin suspension, which was used 
for the immunoprecipitation. A 10µl sample was kept to assess sonication efficiency 
by running on an agarose gel. 
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Table 2-9 Non-commercial buffers used for ChIP. 
Dilution buffer Wash buffer A Wash buffer B Elution buffer 
50 mM Hepes pH 7.9 
140 mM NaCl 
1mM EDTA  
1% Triton X-100 
0.1% Na-deoxycholate  
+add proteinase 
inhibitors before use 
 
50 mM Hepes pH 7.9 
500 mM NaCl  
1mM EDTA  
1% Triton X-100 
0.1% Na-deoxycholate  
0.1% SDS  
20 mM Tris pH 8.0 
1 mM EDTA  
250 mM LiCl 
0.5% NP-40  
0.5% Na-deoxycholate 
50 mM Tris pH 8.0 
50mM NaCl 
1 mM EDTA 
+add 1% SDS on the 
day      
+add DNase-free 
RNaseA to 20µg/ml 
final on the day 
 
The next step of the ChIP protocol was the immunoprecipitation (IP). The 
chromatin was diluted 10 times in dilution buffer (Table 2-9), so that the amount of 
SDS coming from the lysis buffer would be low and would not affect the IP. For each 
IP, the diluted chromatin used was estimated to be that of 2million cells. Also, 1:10 of 
that amount was used as input control and temporarily stored at -80°C. Next, the 
antibody-bead complex was prepared by the incubation of 15µl protein G magnetic 
beads (Invitrogen, Paisley, UK) with 2.5µg antibody (Table 2-10) in 800µl dilution 
buffer for 2h at 4°C rotating. Following that, the supernatant was removed using a 
magnet and the chromatin was added to the antibody-bead complex and incubated in 
800µl dilution buffer overnight at 4°C rotating. The day after, the antibody-bead-
chromatin complex was washed sequentially 150µl in dilution buffer, wash buffer A, 
wash buffer B (Table 2-9) and TE buffer for 5 min at 4 °C on rotating wheel. From 
this stage on, the stored input control was processed together with the eluted 
chromatin. The washed chromatin was eluted from the beads and the crosslinks were 
reverted in 150 µl elution buffer (Table 2-9) for 4h at 68°C (shaking at 1400rpm).  
To extract the DNA, proteinase K was added to a final concentration of 
200µg/ml to the samples, which were incubated at 45°C for 2h. The DNA was 
recovered by phenol:chloroform extraction and ethanol precipitation. Equal volume of 
phenol:chloroform:isoamyl alcohol (Sigma-Aldrich Company Ltd., Dorset, UK) was 
added to the samples, they were spun down at full speed and the top aqueous fraction 
was collected and precipitated with 2x 100%ethanol, 1/10 Sodium Acetate and 1µl 
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glycogen. The pellet was finally washed in 70% ethanol, air dried and then 
resuspended in TE buffer prior to RT-qPCR analysis. 
 
Table 2-10 Antibodies used for ChIP. 
Antibody Species Supplier Antibody 
reference 
H4 Acetylation Rabbit polyclonal 
anti-human 
Millipore, Watford, UK 06-598 
H3 Acetylation Rabbit polyclonal 
anti-human 
Millipore, Watford, UK 06-599 
Sp1 Rabbit polyclonal 
anti-human 
Millipore, Watford, UK 07-645 
Pol II N-terminal Rabbit polyclonal 
anti-human 
Santa Cruz 
Biotechnology 
sc-899 
CBP Rabbit polyclonal 
anti-human 
Santa Cruz 
Biotechnology, 
Heidelberg Germany 
sc-369 
p300 Rabbit polyclonal 
anti-human 
Santa Cruz 
Biotechnology, 
Heidelberg Germany 
sc-584 
GCN5 Rabbit polyclonal 
anti-human 
Santa Cruz 
Biotechnology, 
Heidelberg Germany 
sc-20698 
HDAC1 Rabbit polyclonal 
anti-human 
Santa Cruz 
Biotechnology, 
Heidelberg Germany 
sc-6299 
HDAC3 Rabbit polyclonal 
anti-human 
Santa Cruz 
Biotechnology, 
Heidelberg Germany 
sc-11417 
HDAC4/5/7 Rabbit polyclonal 
anti-human 
Santa Cruz 
Biotechnology, 
Heidelberg Germany 
sc-11421 
HDAC6 Rabbit polyclonal 
anti-human 
Millipore, Watford, UK 07-732 
IgG Rabbit polyclonal Santa Cruz 
Biotechnology, 
Heidelberg Germany 
sc-2027 
 
2.10.2 ChIP primers and testing 
Primers (Table 2-11) were purchased from Sigma-Aldrich Company Ltd. 
(Dorset, UK). They were designed and tested for the dimers and hairpins formation 
using the OligoCalc software  (http://www.basic.northwestern.edu/ 
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biotools/OligoCalc.html). Primers were designed to amplify part of the gene’s 
promoter and in some cases the open reading frame or gene body. They have 
annealing temperature of 60°C and GC content 40-60%. The amplicons size was 
between 100bp and 150bp. Each primers pair was predicted to be specific for the 
target gene, as tested with BLAST (Basic Local Alignment Search Tool). 
 
Table 2-11 Primers used for ChIP analysis. 
Human 
Gene 
Forward Primer Reverse Primer Annealing 
Temperature 
G6PD.1 GGGAGCGGCGGACTGTGAA
C 
GGGGGCGGGGCTTGTG
TTTT 
60°C 
G6PD.2 AGGCGGGGAAACCGGACAG
T 
ATCCCCAATTCCGGCGG
GC 
60°C 
G6PD.3 TGTTGTGCTTGAGAACCGAG
CA 
TTGCCAAGCTGGGTGAC
CC 
60°C 
G6PD.4 TGGCAAGGGGAGGGCTGG TGGAACTGCGTGCCCA
GGA 
60°C 
G6PD.GB1 CCCAAGCCCATCCCCTATAT CCACTTGTAGGTGCCCT
CAT 
60°C 
G6PD.GB2 ACCCACGTGAGAGAATCTGC CTGCTGCGTCTGCTTTT
CTTA 
60°C 
GPI CCAGCCCCAGAGTTCTTACA AGGTGAAGACTGCAGT
GAGC 
60°C 
TPI GCCGGAGCTCACAGGTCT GCACTGTTCCGACGTTC
CC 
60°C 
GAPDH TACTAGCGGTTTTACGGGCG TCGAACAGGAGGAGCA
GAGAGCGA 
60°C 
PGLS CTGCGCATGTGCCAAAGACA
A 
GAGGAGGAAGCGCTCC
CTA 
60°C 
RPIA AGCAAGACCCGCGCAGCAG TCCGGCCTCCGCTGAAG
TC 
60°C 
DHFR TCGCCTGCACAAATAGGGAC AGAACGCGCGGTCAAG
TTT 
60°C 
p21 GTGGCTCTGATTGGCTTTCT
G  
CTGAAAACAGGCAGCC
CAAG 
60°C 
GW10 GGCTAATCCTCTATGGGAGT
CTGTC 
CCAGGTGCTCAAGGTCA
ACATC 
60°C 
 
Further primer testing was performed once the primers were received to 
establish the correct annealing temperature and the linearity of the primers. The 
process followed is the same as the one described in 2.7.1.2 for the RT-qPCR primers. 
The only difference to that protocol is that the input DNA used for testing is genomic 
DNA rather than cDNA, as the primers are not designed to amplify cDNA. 
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2.10.3 ChIP qPCR analysis 
To analyse the results from the ChIP experiments, the isolated DNA was used 
to run qPCR using the same conditions as described in 2.7.1.3. The DNA used was 
the genomic DNA purified at the last step of the ChIP protocol (DNA that resulted 
from IP against the specific antibodies and IgG, as well as the genomic DNA input 
sample) and the primers used are those listed in Table 2-11. The primers GAPDH, 
Dihydrofolate reductase (DHFR) and p21 were used as positive controls for certain 
modifications at baseline. Specifically, GAPDH is used as a positive control for 
acetylation and polymerase II binding, DHFR is known to be bound by Sp1 on its 
promoter and p21 promoter is bound by all the HATs and HDACs tested. The positive 
controls for the modifications were chosen based on ENCODE analysis of the 
promoters. Primers designed for the region named as GW10 (Table 2-11), amplify an 
intergenic region on chromosome 10 (AL392045); GW10 is not a gene. Therefore, 
GW10 is used as a negative control for promoter modifications. 
To analyse the qPCR results I used the percentage of input method. In this 
method, signals (measured as Ct values) obtained from the ChIP are divided by 
signals obtained from the input sample. Typically, 1% of starting chromatin is used as 
input. The formula used is the following: %input=(2^-IP/2^-input)*(DF/100), where 
DF is the dilution factor of the input, i.e. 100 when 1% of starting chromatin is used, 
IP is the Ct value obtained by either an antibody against a modification or against IgG 
and finally input is the Ct value obtained by the input control reaction. The %input 
obtained by an IP against a modification must be above the one obtained from the IgG 
sample that is the background in order to show presence of a given modification at the 
region tested by the specific primers. 
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2.11 Reporter assays 
2.11.1 Cloning 
2.11.1.1 Plasmid 
The pGL3-basic plasmid vector (Figure 2-2; Promega, Southampton, UK) was 
used for cloning of promoter fragments, as it is a luciferase gene-containing plasmid 
that is frequently used for reporter assays. It also contains a multi-cloning site 
upstream the luciferase gene.  
 
 
Figure 2-2 pGL3-basic plasmid vector. The plasmid (Promega, Southampton, UK) 
contains a multi-cloning site upstream the luciferase gene allows cloning of promoter 
fragments. Boxed in red are the BglII and NcoI restriction enzymes used to clone the 
promoter DNA. The plasmid is ampicillin-resistant. 
 
2.11.1.2 PCR amplification and purification of amplicons for 
cloning 
G6PD promoter DNA fragments were amplified using specific primers (Table 
2-12 and Figure 2-3; Sigma-Aldrich Company Ltd., Dorset, UK). A common reverse 
primer and different forward primers were used. During primer designing, restriction 
sites were added to the 5’ ends of primers (An NcoI site was added to the R primer 
and BglII sites were added to the F primers). The fragments were amplified by end-
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point PCR, using Ready-made Dream Taq Polymerase mix (Fermentas, York, UK), 
according to manufacturer’s instructions. The PCR cycle was as follows: 95°C 2min 1 
cycle; 95°C 30sec, 60°C 30sec, 72°C 30sec (F1, F2, F3) or 90sec (F4, F5, F6) 35 
cycles; 72°C 10min 1 cycle. Negative template controls were run for all different 
primers used. 
 
Table 2-12 PCR primers used for G6PD promoter amplification.a  
Primer Sequence Annealing 
Temperature 
Amplicon size 
amplified with R 
primer 
R ATCACCATGGACGCTGTCTGG
TGGAAGA 
60°C  
F1 ATCAAGATCTGAGCCCAGAG
CCAGCAGT 
60°C 200bp 
F2 ATCAAGATCTAGGGCTGGAG
CTGAACTC 
60°C 415bp 
F3 ATCAAGATCTGACGAAGCGC
AGGTAACC 
60°C 645bp 
F4 ATCAAGATCTGGTATGGCAGG
CAGCCGG 
60°C 908bp 
F5 ATCAAGATCTCTCCGGGGGAG
GAATCAAG 
60°C 1207bp 
F6 ATCAAGATCTGGTGTCATAGC
TGTGGGATC 
60°C 1464bp 
a In red are highlighted the restriction sites added to the 5’ end of each primers. NcoI sites for 
R and BglII sites for F. 
 
The amplified DNA was run on 1.5% agarose gel and the bands of interest 
were extracted using a Gel extraction kit (Fermentas, York, UK), according to 
manufacturer’s instructions. 
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Figure 2-3 Transactivation assay design. (A) Representation of the wider G6PD 
promoter B, spanning between G6PD exon 2 and NEMO exon 1B. The core promoter 
is also highlighted. In blue are the predicted Sp1 binding sites and marked with an 
asterisk are the two previously validated sites. The common reverse (R) and the 
different forward (F1-6) primers that were used to amplify six increasing in length 
parts of the promoter. (B) Picture of a 1.5% agarose gel showing the amplified 
fragments of the promoter and the NTC control. The fragments were gel extracted, 
digested with BglII/NcoI and cloned into a digested with BglII/NcoI and gel extracted 
pGL3-basic vector (vector shown in Figure 2-2). 
 
2.11.1.3 Digestion, Ligation and bacterial cloning 
Inserts and plasmid (Figure 2-2 and Figure 2-3) were digested with 1unit of 
BglII and NcoI (Fermentas, York, UK) for 1h at 37°C. Following the digestion and 
gel extraction, the inserts were ligated to the plasmid using T4 ligase (Fermentas, 
York, UK). Vector and insert amounts were determined based on the following 
formula: ng insert= (ng vector*kb insert*3)/ kb vector. 
To transform DH5a competent cells (Zymo Research, Freiburg, Germany) 
with the plasmid constructs, 1µl of contruct was mixed with 50µl DH5a competent 
cells and were incubated on ice for 30min. After a heat shock incubation at 42°C for 
500bp 
TSS TSS 
** 
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45sec and then an incubation on ice for 1min, 1ml of SOC medium (Invitrogen, 
Paisley, UK) was added to the cells and they were subsequently incubated at 37°C for 
45 min shaking. Following the incubation 100µl of cell suspension was plated on 
LB+Amp (100µg/ml) plates and there were incubated at 37°C overnight. The 
following day single colonies were picked and further grown in liquid LB+Amp 
(100µg/ml) overnight to prepare miniprep cultures. 
Plasmid DNA was purified using Qiagen mini prep kit according to 
manufacturer’s instructions. After purification, the clones were screened for the 
presence of the specific insert of interest by BglII/NcoI restriction enzyme digestion. 
DNA from positive minipreps was sequenced directly by using BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, UK) and run on ABI 3730 Genetic 
Analyzer, as described in DNA sequencing.  Once the clones were confirmed by 
sequencing, larger plasmid quantities were isolated using the Qiagen maxi prep kit 
according to manufacturer’s instructions. 
2.11.1.4 DNA sequencing 
The sequencing reaction was performed using a BigDye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems, UK). The reaction mix was prepared by adding 
1µl the purified PCR product (10 to 50ng DNA), 1µl of 8pmol/µl of template- specific 
primer, 0.5µl of BigDye Terminator ready reaction mix (containing the fluorescent 
dideoxy terminator nucleotides) and 2µl of 5x BigDye Terminator buffer to 5.5µl of 
distilled water in a 96-well plate. The cycle sequencing reaction was performed in an 
ABI 3130 thermal cycler (Applied Biosystems, UK). The reaction consisted of an 
initial denaturation step of 94 °C for 1 minute followed by 25 cycles of 96°C for 
10seconds, 50°C for 5 seconds and 60°C for 4 minutes. Reactions were held at 16°C 
until further use. DNA from the sequencing reaction was precipitated by adding 50µl 
of ice-cold 100% ethanol, 2µl of 3M Sodium acetate and 2µl of 125mM EDTA to 
each well, followed by centrifugation at 3400rpm for 30 minutes. A further 
precipitation step was performed by the addition of 50µl of ice-cold 70% ethanol and 
centrifugation at 3400rpm for 15 minutes. The alcohol was then removed by brief 
centrifugation and the precipitated DNA was resuspended in 10µl Hi-Di Formamide, 
a highly deionised formamide used for electrokinetic injection on capillary 
electrophoresis systems. Capillary electrophoresis was then performed on an 
ABI3700 DNA Analyzer. 
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The chromatograms resulting from the sequencing reactions were visualised 
with the 4peaks software (mekentosj.com/4peaks) and sequences were aligned using 
the NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
2.11.2 Cell transfections 
The 293T cells were used for transient transfections. On day 1, cells were 
seeded at concentration of 1.5-2x105 cells/well on a 24 well plate. On day 2, 
confluence of approximately 70% was obtained. One well was left untranfected, one 
well was transfected with pGL3-basic alone and the rest of the well were transfected 
with the plasmid constructs. The cells were co-transfected with the renilla plasmid 
control, which is essential for transfection efficiency control. Furthermore, they were 
co-transfected with a pEGFP-c1 plasmid in order to estimate transfection efficiency 
either visually with light microscopy or with flow cytometry. Plasmid DNA (450µg 
construct + 450µg pEGFP-c1 + 50µg renilla control plasmid) was diluted in 50µl 
Optimem medium (Gibco, Invitrogen, Paisley, UK). Additionally lipofectamine 
(2µl/well) was diluted in Optimem medium (50µl/transfection) and was incubated in 
RT for 5min before adding 50µl of it to the diluted plasmid. The diluted plasmid was 
incubated for 30 min at RT in the presence of lipofectamine. The media of the cells 
was replenished with 400µl antibiotics-free medium and then 100µl of the plasmid 
mixture was added to them. After 2h incubation at 37°C, the lipofection was removed 
by replenishing the medium with fresh full medium (containing antibiotics). The cells 
were incubated for 48h (when treating with NaBu, that was done during the last 24h 
of the incubation) and then transfection efficiency was estimated by flow cytometric 
analysis. GFP+ cells appear as FITC+. Transfection was above 90% for all replicate 
experiments.  
2.11.3 Luciferase assay 
Luciferase was measured using the Dual-Glo Luciferase assay system 
(Promega, Southampton, UK), as per manufacturer’s instructions. Briefly, 1x passive 
lysis buffer is added to the cells, which are incubated for 15min at RT shaking. 
Following stages were conducted on ice. Cells were spun at 14000 rpm 4°C for 5min 
to remove cell debris. 10µl of the supernatant were transferred to the Luciferase 
reaction plate (done in technical triplicates). 35µl of LARII reagent were added to 
each well, which acts as a substrate for luciferase, producing a luminescent signal 
measured by a fluoroscan (Qiagen, West Sussex, UK). Then, 35µl of Stop&Glo 
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reagent were added to each well, which quenches the luminescence from the construct 
and provides a substrate for renilla luminescence that is measured by the same 
machine. 
To analyse the results obtained by the luminometer, the average of each 
construct luciferase measurement was normalised against the equivalent renilla 
measurement. Results are shown relative to pGL3-basic vector. 
2.12 Mutagenesis assay 
To mutagenise Sp1 binding sites, I used the pGL3-Fr5 plasmid construct 
produced in Cloning using the primers R and F5 (Table 2-12). I then, as shown in 
Figure 2-4, conducted two rounds of PCR to insert the mutations. Specifically, I 
designed primers (Table 2-13) on the mutation region to insert more than three 
mismatches on each direction. These primers were first used in combination with the 
external primers R and F5 (Table 2-12). For example, to mutagenise site 1, primers R 
(Table 2-12) + 1F (Table 2-13) and primers F5 (Table 2-12) + 1R (Table 2-13) were 
used to amplify two fragments of the insert. For PCR amplification DreamTaq 
Polymerase (Fermentas, York, UK) was used because it does not have proofreading 
activity and therefore allows inserting mutations. For this purpose, the annealing 
temperature was also set as low as 55°C. Then a 2nd PCR was performed using 
primers R and F5 (Table 2-12) and the 2 gel extracted PCR products from the 1st 
round as template to obtain the whole mutated insert. This was further cloned into the 
pGL3-basic vector, sequenced and luciferase assays were performed, as described in 
2.11. 
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Figure 2-4 Mutagenesis assay strategy. pGL3-Fr5 construct produced in 2.11.1 is 
used as a template. Primers designed to insert mutations were used in combination 
with primers F5 and R to amplify the insert in two fragments. A 2nd PCR was 
performed using the external primers to connect the two fragments. The mutated 
fragment was then cloned in pGL3-basic vector. Luciferase assay was then carried out 
to measure the relevant promoter activity. 
 
 
 
 
 
 
 
 
 
Template: pGL3-Fragment 5 
1st PCR 
2nd PCR 
! Luciferase assay 
R 
F5 
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Table 2-13 Primers designed to insert Sp1 binding site mutations. a 
Primer Sequence 
1F GCC CAG GCG CCC GCC AAC GAT CCC GCC GAT TAA ATG GGC C 
1R GGC CCA TTT AAT CGG CGG GAT CGT TGG CGG GCG CCT GGG C 
2F GGG TGG TGG CCG AGG CTA CGA CAC GCA CGC CTC GCC TGA G 
2R CTC AGG CGA GGC GTG CGT GTC GTA GCC TCG GCC ACC ACC C 
 
3F CCG CCC CGC CCG CAC GAG AAG TGG TGG CCG AGG CCC CGC C 
3R GGC GGG GCC TCG GCC ACC ACT TCT CGT GCG GGC GGG GCG G 
4F CGC ACC TGC CCT CGC ATC GAT CCG CCC GCA CGA GGG GTG G 
4R CCA CCC CTC GTG CGG GCG GAT CGA TGC GAG GGC AGG TGC G 
 
5F GGA AAC CGG ACA GTA GGT ACT AGG CCT GGC CGG CGA TGG G 
5R CCC ATC GCC GGC CAG GCC TAG TAC CTA CTG TCC GGT TTC C 
6F CGA GGC CGC CGG GGC AAT CGA AGA AAC CGG ACA GTA GGG G 
6R CCC CTA CTG TCC GGT TTC TTC GAT TGC CCC GGC GGC CTC G 
7F GTG GCG CGG CAG AAG GCT ATG CAC AGG AGC CGA GGG ACA G 
7R CTG TCC CTC GGC TCC TGT GCA TAG CCT TCT GCC GCG CCA C 
a In red are highlighted the sites were Sp1 binding was disrupted.  
 
2.13 Dominant negative Sp1 expression plasmid 
Prof. Gerald Thiel kindly provided us with the pEBGV and pEBGV-Sp1.DN 
plasmids (Al-Sarraj et al., 2004). The pEBGV is an empty of insert control plasmid. 
The pEBGV-Sp1.DN encodes for a fusion protein consisting of GST-NLS and the 
zinc finger domain of Sp1. Therefore the expressed protein is able to bind to Sp1 
binding sites but lacks of transactivation domain. The plasmids were transfected into 
293T cells (2.11.2) and mRNA expression was determined using RT-qPCR (2.7.1.3). 
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2.14 Bioinformatic analysis 
2.14.1 Promoter and TF binding sites identification 
Core and extended promoter regions were obtained from the NCBI Gene tool 
(http://www.ncbi.nlm.nih.gov/gene) and were verified by analysis on the UCSC 
ENCODE genome browser (http://genome.ucsc.edu/ENCODE/). TF binding sites 
were predicted using the TF binding site prediction browsers TFSearch 
(http://www.cbrc.jp/research/db/TFSEARCH.html) and CONSITE 
(http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/). 
2.14.2 Statistical analysis 
Statistical analysis was conducted using the GraphPad Prism software. The p 
values were obtained from either one-way analysis of variance (ANOVA) or student’s 
t-test. The asterisks correlate to the p values as follows: * p≤0.05, ** p≤0.01, *** 
p≤0.001. Error bars represent either standard deviation (SD) for microarray analysis 
or standard error of the mean (S.E.M.) for all other analyses.  
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3 Results I: Glycolytic enzyme gene expression 
in human cell lines 
 
 
 
 
 
 
  96 
3.1 Introduction 
Currently, there is no specific treatment for haemolytic anaemias caused by 
mutations on the genes expressing enzymes of the GPPP. Symptomatic patients with 
chronic anaemia require regular blood transfusion, which carries the risk of 
transfusion-induced iron overload. Each red cell concentrate used for transfusion 
contains 250mg of iron; however, under physiological conditions, only 1-2mg of iron 
can be excreted each day. This leads to deposition of iron in essential organs, 
particularly the liver and heart, which can result in potentially life-threatening organ 
dysfunction.  New treatments for such conditions are therefore urgently required. 
HDACIs lead to histone hyper-acetylation and therefore can increase gene 
transcription. In a specific example studied in our lab, it was shown that a point 
mutation in the proximal promoter of PIGM abrogates binding of the TF Sp1, causes 
histone hypo-acetylation and transcriptional repression that is specific to PIGM. NaBu 
was shown to restore Sp1 binding to the core promoter, restore levels of histone 
acetylation and activate PIGM transcription (Almeida et al., 2006; 2007; almeida et 
al., 2009). PIGM is part of a housekeeping pathway, i.e. the GPI biosynthetic 
pathway; therefore, I hypothesised that NaBu could have therapeutic effects in other 
pathways with housekeeping functions, such as that of glycolysis. 
3.1.1 Aim of the chapter 
This chapter aims to determine the effect of HDAC inhibition on the GPPP in 
human cell lines. This was investigated at the levels of RNA, protein and enzymatic 
activity.  Ultimately, I intend to identify genes within the GPPP that are upregulated 
upon treatment with HDACIs.  
3.1.2 Experimental plan 
To address the hypothesis that HDACIs would increase mRNA expression 
followed by an increase in protein levels and enzymatic activity, I treated normal wild 
type (WT) B cell lines as well as B cell lines from patients with specific GPPP 
deficiencies (Table 2-1) with HDACIs and assessed the effect at different time points. 
First, I performed a series of control experiments aimed at a) determining the 
appropriate HDACI concentration, b) ensuring that NaBu used in individual 
experiments was active, and c) validating the reference genes that would be more 
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appropriate to use in RT-qPCR assays in samples treated with HDAC inhibitors, 
including NaBu. 
3.2 Control experiments 
3.2.1 Identification of NaBu concentration 
To date, various studies have been published using NaBu to increase 
transcriptional expression of genes. The concentration typically used to treat cell lines, 
including B cell lines, with NaBu by our lab (Almeida et al., 2007; Caputo et al., 
2013) and others (Bordonaro et al., 2011; deFazio et al., 2001; Miki et al., 2007; 
Robinson et al., 2012; Yu et al., 1998) is 3mM, as this was determined to be the 
lowest concentration to maintain cell viability whilst allowing HDAC inhibition. To 
establish that this concentration is appropriate for the purposes of my project and the 
particular cell line used, I titrated the concentration and determined the apoptosis rates 
as well as the effect on PIGM expression levels, which is known to be upregulated by 
NaBu(Almeida et al., 2007).  
The WT B cell line P277 was treated with 0.5mM, 1mM, 3mM NaBu for 24h. 
Cell death was assessed by flow cytometry after staining with AnnexinV and DAPI 
(Figure 3-1). AnnexinV-DAPI- events represent live cells, AnnexinV+DAPI- events 
represent early apoptotic cells, whereas AnnexinV+DAPI+ cells are late apoptotic cells. 
As shown and summarised in Figure 3-1, NaBu has a dose-dependent effect on the 
viability: in particular, 3mM NaBu results in the highest apoptotic and lowest survival 
cell rates amongst the concentrations tested (Figure 3-1A, B). Nevertheless, the 3mM 
concentration resulted in the highest increase in PIGM expression mRNA levels 
(Figure 3-1C), which was used as a control gene that is known to be upregulated by 
NaBu; therefore, I performed the rest of my experiments in B cell lines using 3mM 
NaBu. Further concentration optimisation was performed when NaBu was used in 
primary erythroid cells and adherent 293T cell lines as shown in Figure 4-5, Figure 
4-7 and Figure 6-8. 
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Figure 3-1 NaBu concentration titration in the P277 WT cell line. (A) Flow 
cytometric analysis of the Annexin V and DAPI-stained P277 normal cell line upon 
24h treatment with 0.5mM, 1mM and 3mM NaBu. (B) The table shows the 
percentage of live cells, estimated by the forward/side scatter (circled in 3-1A), the 
percentage of live cells (AnnexinV-DAPI-) and the percentage of apoptotic cells 
(AnnexinV+DAPI-). (C) Graph showing PIGM mRNA expression normalised to β-
actin and relative to the untreated cells. Mean and S.E.M. are shown for n=3. 
 
In order to confirm that NaBu was active in every single experiment, it was 
freshly reconstituted each week and was regularly tested for its ability to restore GPI 
expression on the surface of PIGM mutant, GPI deficient B cell lines, such as YK. 
The reason for regularly testing the effectiveness of NaBu arose from the observation 
that NaBu is unstable after long storage at -20°C. This can be assessed using flow 
cytometric analysis to measure staining with FLAER, an Alexa® 488-labeled variant 
of aerolysin, a unique protein that binds tightly and specifically to mammalian GPI 
anchors. Therefore, by treating PIGM mutant cell lines and observing restoration of 
surface GPI expression, I was able to confirm that NaBu used in my experiments was 
biologically active and efficient at inhibiting HDACs (Figure 3-2). 
Si
de
 s
ca
tte
r 
Forward scatter 
D
A
PI
 
Annexin V 
34.1 
34.3 
30.9 
24.1 
91 6.84 
0.47 1.69 
0.57 0.43 
92.4 6.59 
0.55 1.76 
90.6 7.04 
0.91 3.41 
76.2 19.5 
Data 1
0mM 0.5mM 1mM 3mM
0
5
10
15
PI
G
M
 R
N
A
 e
xp
re
ss
io
n
NaBu treatment (24h)
A. B. 
C. 
  99 
 
Figure 3-2 NaBu efficiency tested by GPI expression of the PIGM deficient cell 
line YK. The PIGM mutant and GPI deficient, YK cell line was treated with NaBu 
for 24h and 36h. Unstained YK and the GPI+ cell line P92 were also used as negative 
and positive controls, respectively. The gradual restoration of GPI expression by 
FLAER staining as shown by flow cytometry indicates active NaBu. 
 
3.2.2 Determination of SAHA and TSA dose 
Similarly to NaBu, I also optimised the concentrations of SAHA and TSA 
used for my experiments. To do so, I performed a flow cytometric assay using 
different concentrations of SAHA and TSA to restore GPI expression on the surface 
of the PIGM mutant GPI-deficient B cell line YK. Both the cell viability estimated by 
the live gate on a forward/side scatter during flow cytometric analysis and the 
upregulation of the GPI protein expression assessed by FLAER expression were taken 
into account to determine the appropriate drug concentrations.  
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YK cells were treated for 24h with 2.5nM, 10nM and 100nM TSA (Figure 
3-3) or with 2µΜ, 4µΜ, 6µΜ and 8µΜ SAHA (Figure 3-4), which are concentrations 
within the suggested by the manufacturer range.  As a positive control, the WT GPI-
expressing P92 cell line was used, whilst unstained YK cells and DMSO-treated YK 
cells were used as negative controls. DMSO-treated cells were used instead of 
untreated cells because both SAHA and TSA are dissolved in DMSO. Based on the 
cell viability resulting from the addition of the drug as well as the upregulation of the 
GPI expression, I chose the 4µM and 100nM concentrations for SAHA and TSA, 
respectively for subsequent experiments. The findings of this experiment are 
consistent with our prior knowledge from published research in our lab (Almeida et 
al., 2007) and unpublished work that has shown that at 24h post-treatment GPI 
expression is partly restored by approximately 30-60%, whereas for complete 
restoration of the GPI expression treatment for 36h is required. 
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Figure 3-3 TSA concentrations tested by GPI expression of the PIGM deficient 
cell line YK. The PIGM mutant and GPI deficient, YK cell line was treated with 
2.5nM, 10nM and 100nM TSA for 24h. Unstained YK and also YK treated with 
DMSO, which is what TSA is dissolved in are used as negative controls. The GPI+ 
cell line P92 is used as a positive control. The 100nM concentration was chosen for 
TSA treatments in cell lines. 
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Figure 3-4 SAHA concentrations tested by GPI expression of the PIGM deficient 
cell line YK. The PIGM mutant and GPI deficient YK cell line was treated with 2µM, 
4µM, 6µM and 8µM SAHA for 24h. Unstained YK and also YK treated with DMSO, 
which is what SAHA is dissolved in are used as negative controls. The GPI+ cell line 
P92 is used as a positive control. The 4µM concentration was chosen for SAHA 
treatments in cell lines. 
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3.2.3 RT- qPCR reference gene validation 
RT-qPCR typically produces relative quantification of the target gene 
expression in reference to an internal control gene (reference gene). The amount of 
RNA assayed may fluctuate due to differences in cell numbers, experimental 
treatment or RNA extraction efficiency. However, the conditions of the experiment 
should not influence the expression of the reference gene in order to ensure accurate 
results. To ensure accuracy of my future RT-qPCR experiments it was essential that I 
chose a reference gene that was not affected by NaBu treatment. I therefore tested 
whether NaBu treatment impacts on the expression of commonly used housekeeping 
reference genes: GAPDH, β-actin, 18S rRNA, β2-microglobulin and G6PD, with 
G6PD and GAPDH coincidentally being part of the GPPP. 
Total RNA was extracted after treatment of the wild type cell line P277 with 
3mM NaBu for 0h, 8h and 24h. Equal amounts were used for reverse transcription 
and cDNA synthesis. For each time point, three samples were prepared with serial 
dilutions (1:10, 1:100 and 1:1000) and each sample was tested in triplicate by qPCR. 
The ratio of Ct values at each time point to the Ct value of the untreated cells was 
calculated for each sample (fold change of expression in time).  The mean average Ct 
ratios ± S.E.M. for each time point is shown in Figure 3-5. 
The mRNA levels of the candidate reference genes GAPDH, β-actin, β-2-
microtubulin and 18S rRNA did not change significantly over time (p>0.05) and 
therefore could be used for qPCR analysis. From these, I chose to use β-actin as my 
reference gene in all following qPCR assays discussed in this thesis as it showed the 
most consistent expression (p = 0.91) and it is not involved in the GPPP, suggesting it 
is an impartial reference gene.  
This experiment also showed a significant increase in G6PD mRNA levels 
(p<0.05) with NaBu treatment (Figure 3-5). Furthermore, it shows that NaBu affects 
expression of only a few and not all housekeeping genes. 
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Figure 3-5 Effect of NaBu treatment of candidate qPCR reference genes. The 
P277 WT cell line was treated with NaBu for 8 and 24 hours. cDNA synthesised  for 
equal amounts of total RNA were used in each time point. Mean and S.E.M. are 
shown for n=3. Significance values between differences in gene expression at 
different time points were tested by one-way ANOVA. 
 
3.3 GPPP gene expression upon HDAC inhibition 
To assess the responsiveness of the glycolytic pathway genes to HDAC 
inhibition and test my initial hypothesis that HDACIs can be used for the treatment of 
disorders of the GPPP, I treated the WT cell line P277 with 3mM NaBu in a time 
course of 8h, 16h, 24h and 36h. Then, I employed RT-qPCR to examine the 
expression of all the GPPP genes. Student’s t-test was performed to examine the 
significance of each time point in comparison to its untreated condition. 
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Figure 3-6 GPPP expression upon NaBu treatment. The WT cell line P277 was 
treated with 3mM NaBu in a time course of 8h, 16h, 24h and 36h. Fold change in 
gene expression relative to the untreated cells’ expression for each gene is shown, as 
obtained by RT-qPCR analysis. Mean and S.E.M. are shown for n=3. Student’s t-test 
was employed to show the significance of each time point compared to its untreated 
condition. 
 
Figure 3-6 presents the effect of NaBu on the mRNA expression of all the 
GPPP genes, except PKLR, which is expressed only in erythroid and not B cells. It is 
apparent from this figure that NaBu selectively upregulates the mRNA expression of 
G6PD among 16 genes of the GPPP. In fact, there is a significant increase of G6PD 
after 24h of treatment, whereas no significant change was observed for the other 
genes. 
In order to confirm the G6PD-specific increase upon NaBu treatment, I 
decided to study the expression of two of the genes that remain unaffected in more 
detail. Therefore, I performed treatments of the normal B cell line P277 not only with 
3mM NaBu, but also with 4µM SAHA and 100nM TSA in a time course of 8h, 16h, 
24h and 36h. As shown in Figure 3-7A, no significant change of either the TPI or GPI 
mRNA expression was shown by RT-qPCR analysis. Moreover, since the GPPP is 
primarily important in erythroid cells, I repeated the same experiment using the 
erythroleukaemia cell line K562 (Figure 3-7B), in order to determine whether these 
genes could be upregulated in a cell type-specific manner. However, neither NaBu, 
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SAHA, nor TSA were able to induce changes in the mRNA expression of TPI and 
GPI.  
 
 
Figure 3-7 TPI and GPI expression in WT and deficient cell lines in response to 
HDAC inhibitors. (A) The normal B cell line P277 and (B) the erythroleukaemia cell 
line K562 were treated with 3mM NaBu, 4µM SAHA and 100nM TSA for 8h, 16h, 
24h and 36h. Following the treatments, the mRNA expression of the genes TPI and 
GPI was assessed by RT-qPCR. (C) TPI deficient cells lines derived from 
homozygote deficient (P65, P54, P112 and P267) and heterozygote deficient (P91 and 
P92) individuals as well as the normal B cell lines P15 and P277 we treated with 
NaBu, SAHA and TSA for 24h and 48h. The mRNA expression of TPI was assessed 
by RT-qPCR. The mRNA expression is shown relative to the untreated cells 
expression. Mean and S.E.M are shown for n=3. Student’s t-test was employed to 
show the significance of each time point compared to its untreated condition. 
 
K562 cells + NaBu
0 8 16 24 36 0 8 16 24 36
0.0
0.5
1.0
1.5
2.0
TPI GPI
(h)
NaBu 
Fo
ld
 c
ha
ng
e 
in
 m
R
N
A
K562 cells + SAHA
0 8 16 24 36 0 8 16 24 36
0.0
0.5
1.0
1.5
2.0
TPI GPI
(h)
SAHA 
Fo
ld
 c
ha
ng
e 
in
 m
RN
A
K562 cells + TSA
0 8 16 24 36 0 8 16 24 36
0.0
0.5
1.0
1.5
2.0
TPI GPI
(h)
TSA
Fo
ld
 c
ha
ng
e 
in
 m
R
N
A
A. 
B. 
P277 WT B cell line 
+NaBu +SAHA +TSA 
K562 WT erythroblastoid cell line 
+NaBu +SAHA +TSA 
P277 cells + NaBu
0 8 16 24 36 0 8 16 24 36
0.0
0.5
1.0
1.5
2.0
TPI GPI
(h)
NaBu 
Fo
ld
 c
ha
ng
e 
in
 m
R
N
A
P277 cells + SAHA
0 8 16 24 36 0 8 16 24 36
0.0
0.5
1.0
1.5
2.0
TPI GPI
(h)
SAHA 
Fo
ld
 c
ha
ng
e 
in
 m
R
N
A
P277 cells + TSA
0 8 16 24 36 0 8 16 24 36
0.0
0.5
1.0
1.5
2.0
TPI GPI
(h)
TSA
Fo
ld
 c
ha
ng
e 
in
 m
R
N
A
C. TPI deficient cell lines TPI def cells + NaBu
P6
5
P5
4
P1
12
P2
67 P9
1
P9
2
P1
5
P2
77
0.0
0.5
1.0
1.5
2.0
0h
24h
48h
homo- hetero- WT
Cell lines
Fo
ld
 c
ha
ng
e 
in
 T
PI
 m
R
N
A
TPI def cells + SAHA
P6
5
P5
4
P1
12
P2
67 P9
1
P9
2
P1
5
P2
77
0.0
0.5
1.0
1.5
2.0 0h
24h
48h
homo- hetero- WT
Cell lines
Fo
ld
 c
ha
ng
e 
in
 T
PI
 m
RN
A
TPI def cells + TSA
P6
5
P5
4
P1
12
P2
67 P9
1
P9
2
P1
5
P2
77
0.0
0.5
1.0
1.5
2.0
0h
24h
48h
homo- hetero- WT
Cell lines
Fo
ld
 c
ha
ng
e 
in
 T
PI
 m
R
N
A+NaBu +SAHA +TSA 
  107 
Furthermore, I explored the possibility that genes that are not affected by 
HDAC inhibition under physiological conditions might be more susceptible to HDAC 
inhibition under pathological conditions. Therefore, I took advantage of the TPI 
deficient cell lines that were available in the lab to test the TPI mRNA expression 
upon NaBu, SAHA and TSA treatment after 24h and 48h. For this experiment I used 
B cell lines derived from homozygous TPI deficient patients (P65, P54, P112 and 
P267) and heterozygous TPI mutant individuals (P91 and P92, who are the parents of 
P65) and compared these TPI deficient cell lines with the P277 and the P15 normal B 
cell lines. Treatment of these cell lines followed by RT-qPCR analysis (Figure 3-7C) 
showed that HDACIs do not affect the TPI mRNA expression levels in TPI deficient 
cell lines.  
Taken together, the results of the experiments presented above provide 
significant evidence that HDACIs increase mRNA expression of G6PD specifically 
amongst the 16 genes of the GPPP that were tested. This data generates further 
questions regarding the mechanistic basis of the marked difference between G6PD 
and the other GPPP genes. In addition, it raises therapeutic implications for G6PD 
deficiency, which will be studied later in this thesis. 
3.4 G6PD expression in normal and deficient cells 
Having established the G6PD-selective effect of HDAC inhibition in the 
GPPP and in order to understand the significance and therapeutic relevance of my 
findings, I next focused on the impact of HDACIs on G6PD deficient cell lines. First, 
I compared baseline mRNA and protein levels as well as enzymatic activity of G6PD 
deficient and normal cells. As discussed in 1.4.3.2 and shown in Table 1-3, according 
to criteria, the severity of G6PD deficiency has been classified based upon the G6PD 
enzymatic activity levels. However, little is known about the G6PD mRNA and 
protein expression in deficient cells as opposed to normal cells. To address this issue, 
I compared G6PD mRNA and protein expression of the G6PD deficient P7 cell line 
(derived from the patient with G6PD Brighton patient, previously characterised by Dr 
Mark Layton, Hammersmith Hospital (McGonigle et al., 1998)) to several B (P277, 
P91, P92, P54, P267, P15, P174 and C1R) and erythroid (K562) cell lines, which 
express normal G6PD activity. 
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Figure 3-8 G6PD expression and enzymatic activity at baseline.  The G6PD 
deficient B cell line P7 (shown in orange), the G6PD wild type B cell lines P277, P91, 
P92, P54, P267, P15, P174 and C1R (shown in blue) and the erythroid cell line K562 
(shown in red) were used to assess G6PD expression and enzymatic activity at 
baseline. The average of the wild type cell lines is shown in light blue and is labelled 
WT B. G6PD mRNA and protein expression levels are shown here normalised to the 
average of the WT. (A) RT-qPCR was employed to assess G6PD mRNA expression 
and (B) western blotting (top) was employed to assess the G6PD protein expression. 
G6PD protein levels were normalised against β-actin and subsequently against the 
average WT B; the ImageJ software was used for quantification (bottom). (C) The 
same cells were also tested for G6PD enzymatic activity, which were measured in 
units per milligram of total protein. Mean and S.E.M are shown for n=3. Student’s t-
test was employed to show the significance of the P7 cell line expression and activity 
compared to the average of the wild type cell lines. 
 
The G6PD deficient and wild type cell lines were tested for mRNA expression 
by RT-qPCR and protein expression by western blotting that was quantified using the 
ImageJ software. As shown in Figure 3-8A, the G6PD mRNA levels are comparable 
between G6PD Brighton and normal B cell lines; interestingly, G6PD mRNA levels 
are 6-fold higher in the erythroid K562 cells compared to B cells, possibly reflecting 
the essential role of G6PD in erythroid cells for protection against oxidative stress. 
Furthermore, these findings suggest that the specific coding mutation in G6PD 
Brighton does not affect production or stability of mRNA. However, looking at the 
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protein expression levels (Figure 3-8B), the G6PD protein levels in the G6PD 
deficient cells are 5-10 fold lower than those of the normal B cells and 25 fold lower 
than the erythroid cells, suggesting G6PD Brighton is associated with either 
ineffective protein translation or decreased protein stability. The higher expression of 
the G6PD protein in the K562 erythroblastoid cell line, as mentioned above, is 
expected as G6PD plays a key role in the erythroid lineage. Finally, the G6PD protein 
enzymatic activity was measured by a spectrophotometric assay based on the rate of 
production of NADPH, which unlike NADP has a peak of UV light absorption at 340 
nm. As expected, G6PD enzymatic activity is lower (approximately 3-fold) in G6PD 
Brighton than in their normal counterparts (Figure 3-8C). It should be noted that 
G6PD enzymatic activity in G6PD Brighton red cells is about 10% of normal 
(1.7U/gr Hb as measured in Hammersmith Hospital diagnostic lab (normal range 7-
10U/gr H); Table 2-2), consistent with WHO class I, i.e. severely deficient variant. 
The higher activity that I have found in the G6PD Brighton B cell line is likely to be 
due to the fact that B cells are nucleated cells and thus have the ability to constantly 
produce G6PD. By contrast, it is well established that in normal enucleated mature 
red cells, G6PD activity declines with time reaching low levels in aged red cells 
(Jansen et al., 1985; Piomelli et al., 1968).  
3.5 Impact of HDACIs on G6PD deficient cells 
In the next set of experiments I tested in more detail the effect of NaBu on 
G6PD mRNA, protein and enzymatic activity in the deficient G6PD Brighton cell line 
and the wild type (P277) B cell line. I found that G6PD mRNA levels, as assessed by 
RT-qPCR, increased in the WT line in a time-dependent manner, as shown in Figure 
3-9A. Importantly, the same time-dependent effect was also observed for the G6PD 
deficient cell line with the first increase detected at 8h and a 10-fold increase 
observed at 24h. Analysis of the G6PD protein levels by western blot and using an 
antibody specific against G6PD, showed that consistent with the mRNA, G6PD 
protein expression increases in both cell lines in a time-dependent manner showing a 
5-fold increase at 36h in the G6PD deficient cell line (Figure 3-9B). 
Furthermore, following NaBu treatment for 8h, 16h, 24h and 36h, the 
enzymatic activity of the G6PD protein was assessed in G6PD deficient and wild type 
cell lines. A time-dependent increase in the protein activity of both cell lines was 
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observed. The most striking observation is that the G6PD deficient line achieved 
normal levels of activity at 24h (Figure 3-9C).  
 
 
Figure 3-9 NaBu increases G6PD mRNA and protein expression and restores 
enzymatic activity to normal in cell lines. (A) Treatment of the G6PD deficient (P7) 
and wild type (P277) cell line with 3mM NaBu gradually increases G6PD mRNA 
levels as assessed by RT-qPCR and (B) G6PD protein levels assessed by western 
blotting (top; representative of 1 out of 3 independent experiments is shown) and 
quantified using the ImageJ software (bottom) show a time-dependent increase of the 
G6PD protein. (C) Treatment of the cell lines also increases G6PD enzymatic activity, 
which is restored to normal levels in the G6PD-deficient cell line. Mean and S.E.M. 
are shown for n=3. Student’s t-test was performed. 
 
To confirm these results, I repeated the same experiment using an alternative 
HDACI. In this case I treated the cells over the same time course with 4µM SAHA, 
instead of NaBu. Figure 3-10 presents the effect of SAHA on G6PD expression and 
enzymatic activity. Similarly to NaBu, treatment with SAHA increases the mRNA 
(Figure 3-10A) and protein (Figure 3-10B) levels of G6PD in both the wild type and 
the G6PD deficient cell lines. Specifically for the G6PD deficient cell line, G6PD 
mRNA and protein expression increase by 15-fold and 6-fold, respectively after 36h 
of treatment. In terms of the G6PD enzymatic activity (Figure 3-10C), this also 
increases in a time-dependent manner in both cell lines and indeed, in G6PD Brighton 
cells, it exceeds the normal levels after 36h of treatment with SAHA. 
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Figure 3-10 SAHA increases G6PD mRNA and protein expression and restores 
enzymatic activity to normal in cell lines. (A) Treatment of the G6PD deficient (P7) 
and wild type (P277) cell line with 4µM SAHA gradually increases the G6PD mRNA 
expression assessed by RT-qPCR and (B) G6PD protein levels assessed by western 
blotting (top; representative of 1 out of 3 independent experiments is shown) and 
quantified using the ImageJ software (bottom) show a time-dependent increase of the 
G6PD protein. (C) Treatment of the cell lines also increases the G6PD enzymatic 
activity and is restored to normal levels in the deficient cell line. Mean and S.E.M. are 
shown for n=3. Student’s t-test was performed. 
 
3.6 Importance of protein synthesis on the upregulation of G6PD 
Having determined (Figure 3-6) and described (Figure 3-9 and Figure 3-10) 
the selective effect of HDACIs on G6PD gene expression in detail, it is necessary to 
establish if HDACIs act on G6PD directly. Specifically, I next aimed to answer 
whether G6PD is upregulated by NaBu due to direct effect of the drug on G6PD 
transcription, or through an indirect pathway, e.g. upregulation of a TF that 
secondarily regulates G6PD transcription. Therefore, I used CHX, a protein synthesis 
inhibitor that interferes with translational elongation at the ribosome. In the presence 
of CHX, although protein production is blocked, the cell is still able to produce 
mRNA; thus, in the presence of both NaBu and CHX any changes in mRNA levels 
would reflect a direct effect of HDAC inhibition.  
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Figure 3-11 Translation-independent upregulation of G6PD by NaBu treatment. 
(A) The wild type (P277) and G6PD deficient (P7) cell lines were co-treated with 
3mM NaBu together with 10µg/ml CHX and the mRNA levels of G6PD were 
assessed by RT-qPCR. (B) Control experiments treating with NaBu and DMSO or 
CHX and PBS are shown. Mean and S.E.M. are shown for n=3. Student’s t-test has 
been performed. (C) As a positive control for CHX activity, flow-cytometric analysis 
of GPI expression on the PIGM-deficient cells YK, which were either co-treated or 
treated with one of the two drugs. One out of three experiments is shown. 
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Co-treatment of the wild type (P277) and G6PD deficient (P7) cell lines with 
CHX and NaBu during a time course of 4h, 8h, 16h, 24h and 36h (Figure 3-11A) 
showed a similar effect to that of the treatment with NaBu alone (Figure 3-11B). The 
fact that G6PD expression increase persists after incubation of the cells with CHX 
provides evidence that NaBu directly upregulates G6PD in a translation-independent 
manner. This finding is also supported by the observation in this experiment that 
G6PD upregulation happens as early as 4h post-treatment (Figure 3-11A), eliminating 
the window for secondary effects to take place. Control experiments were also 
conducted and involved treatment with NaBu and DMSO, instead of CHX and 
treatment with CHX and PBS, instead of NaBu, to show that NaBu was active and 
that CHX alone does not change the expression of G6PD, respectively (Figure 3-11B). 
To also establish active CHX, I co-treated the PIGM-deficient cell line YK with 
NaBu and CHX to show that FLAER expression on the cell surface is inhibited 
(Figure 3-11C). 
3.7 Conclusions 
Taken together, the evidence of this study shows that HDACIs can selectively 
upregulate G6PD expression among all the genes of the GPPP. Using wild type B 
cells and a cell line derived from a G6PD deficient individual (G6PD Brighton), I was 
able to show that HDACIs upregulate G6PD expression at the mRNA and protein 
levels and that most importantly they increase the G6PD enzymatic activity, which is 
restored to normal levels after 24h and 36h with NaBu and SAHA, respectively in the 
G6PD deficient cell line. The novel findings of this study have demonstrated that this 
upregulation takes place as early as 4h after treatment at the mRNA level and it is the 
result of a direct effect by the HDACIs. Contrary to my initial hypothesis, the other 
genes of the GPPP are not significantly affected by treatment with HDACIs, including 
NaBu and SAHA, in both normal and deficient cell lines.  
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4 Results II: Glycolytic enzyme gene expression 
in in vitro generated erythroid precursors 
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4.1 Introduction 
Erythropoiesis is the process that generates mature erythrocytes. HSCs 
differentiate through intermediary forms of progenitor and precursor cells that 
undergo terminal differentiation and maturation to give rise to RBCs (Ji et al., 2011; 
Lodish et al., 2010). As described in 1.3.2 in greater detail, the erythroid lineage is 
derived from the MEPs, which can further differentiate and commit to either the 
erythroid or megakaryocytic lineages. Downstream erythroid progenitors are the 
BFU-Es, which differentiate into CFU-Es (Hattangadi et al., 2011; Lodish et al., 
2010; Wu et al., 1995). In Figure 1-7, surface markers that can be used to identify 
BFU-E/CFU-E and the morphologically distinct erythroid precursors are shown. As 
erythroblasts mature, they pass through the precursor stages of proerythroblasts, 
basophilic normoblasts and early and late polychromatic normoblasts. These 
precursors decrease in size, undergo chromatin condensation, synthesise more 
haemoglobin and show altered gene expression patterns (Figure 1-7). To terminally 
differentiate, late polychromatic normoblasts lose their nucleus and give rise to 
mature RBCs. 
The main function of the RBCs is to carry haemoglobin in the bloodstream in 
high concentrations, facilitating gas exchange in the lungs and the tissue capillaries. 
For this purpose, the RBC needs a supply of energy and also a source of reducing 
power, which is generated by the GPPP (Castagnola et al., 2010). Consequently, 
mutations in most of the enzymes of the GPPP are associated with haemolytic 
anaemia. Since G6PD deficiency is associated with a clinical phenotype, i.e., 
haemolytic anaemia, which is restricted in the erythroid lineage it is important to 
investigate the effect of HDACIs in an erythroid system. 
4.1.1 Aim of the chapter 
The aim of this chapter is to further investigate the effect of HDACIs on the 
expression of GPPP enzyme genes and in particular of G6PD, using an in vitro 
erythroid differentiation system that recapitulates in vivo late erythroid differentiation. 
Furthermore, this system is used to assess the effect of HDACIs on in vitro- generated 
primary erythroid precursors from individuals with G6PD deficiency. 
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4.1.2 Experimental plan 
An in vitro two-phase liquid culture differentiation system was optimised to 
recapitulate the erythroid differentiation of mature erythrocytes starting from either 
PBMCs, CB-CD34+ cells or G-CSF-mobilised PB haematopoietic stem and 
progenitor CD34+ cells (GCSF-CD34+). The protocol used was modified from 
previous published protocols (Ohene-Abuakwa, 2005; Ronzoni et al., 2008) and is 
described in 2.3.  
Upon optimisation of the two-phase liquid culture erythroid differentiation 
system, I used it to treat purified proerythroblasts with HDACIs and determined their 
effects on GPPP expression. This system was used to determine the effects on both 
normal and G6PD deficient human cells obtained from patients. 
4.2 Characterisation of the in vitro erythroid differentiation system  
The results obtained from studying B cells, as described in Chapter 3, 
demonstrate that HDACIs increase G6PD mRNA and protein expression in WT and 
in G6PD deficient cell lines, resulting in restoration of the enzymatic activity of the 
G6PD Brighton B cell line to WT levels. However, since G6PD deficiency is 
associated with a haematological clinical phenotype, restricted to the erythroid lineage, 
it is important to show that the same effect can be achieved in erythroid cells. For this 
purpose, an in vitro two-phase liquid culture differentiation system was used to 
recapitulate erythroid development of mature erythrocytes from progenitor cells. The 
system was optimised for the use of either whole adult PBMCs, GCSF-CD34+ cells or 
CB-CD34+ cells. 
Erythroid differentiation of whole PBMCs (2x106/ml) or CD34+ cells (5x105 
cells/ml), as described in 2.3, was performed using serum-free medium supplemented 
with a cytokine cocktail of IL-3 (10ng/ml), SCF (100ng/ml) and EPO. This system 
allows the gradual differentiation from CD34+ progenitor cells (CD34+CD36-CD71-
GlyA-) to BFU-E/CFU-E (CD34+CD36+CD71lowGlyA-) and then sequentially to the 
precursors: proerythroblasts (CD34lowCD36+CD71+GlyA-), basophilic normoblasts 
(CD34-CD36+CD71+GlyAlow), polychromatic normoblasts (CD34-
CD36+CD71+GlyA+) and finally orthochromatic normoblasts (CD34-CD36+CD71- 
GlyA+). The system consists of two phases, each lasting for 7 days. Phase 1 uses a 
low EPO concentration (0.5U/mL) to allow initial erythroid cell expansion and 
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differentiation. At day 7 CD36+ cell selection is performed by immunomagnetic bead 
selection to isolate all erythroid progenitors. Cells are then replated into a high EPO 
(4U/mL) media to allow further differentiation. Cells are analysed by flow cytometry 
and cytospin staining at both day 7 and day 14.   
The system was first used with whole adult PBMCs. At baseline only a very 
small proportion of the whole PBMCs display erythroid specific cell surface markers 
(approximately 2.7% CD71+GlyA+; Figure 4-1A). However, by the end of phase 1, 
approximately 60% of the live cells are CD36+ erythroid cells. Of these, 33% are 
CD36+CD71+GlyA- corresponding to proerythroblasts and 62% are characterised as 
CD36+CD71+GlyAlow basophilic normoblasts (Figure 4-1). After phase 2, the CD36+ 
cells give rise to more mature erythroid stages; the majority are CD36+CD71+GlyA+ 
polychromatic normoblasts and only 20% achieve differentiation as late as the 
orthochromatic normoblast’s stage (Figure 4-1). During the erythroid differentiation 
of PBMCs only a very small minority of cells display myeloid or megakaryocytic 
characteristics as assessed by staining with anti-CD11b/CD14 and anti-CD61 
respectively (Figure 4-1A). 
In an attempt to produce greater numbers of erythroid cells, I used the culture 
system to differentiate GCSF-CD34+ cells, as this is an easily accessible source of 
CD34+ cells. Although I was able to induce erythroid differentiation on some 
occasions (Figure 4-2), most cultures led to the differentiation of myeloid cells (data 
not shown). Due to the lack of consistent erythroid differentiation I chose to not use 
the GCSF-CD34+ cells in further experiments.  
As an alternative to GCSF-CD34+cells, I next tried normal CB, as this also 
offers an easily obtainable source of CD34+ cells. The erythroid differentiation of 
CD34+ cells demonstrated differences to the differentiation of whole PBMCs. At day 
7, more than 80% of the live cells are CD36+ erythroid cells compared to only 60% in 
the PBMC culture, suggesting that the CD34+ cells have greater erythroid potential. 
Of note, as shown in Figure 4-2 and Figure 4-3, the GCSF-CD34+ cells show more 
rapid erythroid differentiation than the CB-CD34+ cells, with more rapid loss of CD34. 
After phase 2 of the CD34+ (both CB and GCSF) erythroid differentiation culture, the 
majority of cells are basophilic normoblasts, whilst the other cells are mainly 
pronormoblasts and polychromatic normoblasts. Compared to the PBMC cultures, the 
CD34+-differentiating cell cultures do not give rise to orthochromatic normoblasts by 
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day 14. This is likely to be because they represent a more immature starting 
population and therefore may require longer to achieve late-stage differentiation.   
Overall, the system allows effective erythroid differentiation of both PBMCs 
and CD34+ cells. In the case of the CD34+ cultures, either originating from CB 
(Figure 4-3) or from G-CSF mobilised PB (Figure 4-2), the cell types obtained at day 
7 and day 14 are at earlier stages than those obtained during the differentiation of 
PBMCs (Figure 4-1).  This may be explained by the fact that in the case of the 
PBMCs cultures the differentiating cells are already committed to the erythroid 
lineage and thus enter differentiation earlier. 
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Figure 4-1 Erythroid differentiation of PBMCs. (A) Flow cytometric analysis and 
(B) quantification of the cell types obtained during PBMC-erythroid differentiation at 
days 0, 7 and 14 (n=6). Day 0: PBMCs are plated at a concentration of 2x106 cells/ml 
and undergo the first phase of the erythroid differentiation, lasting for seven days. The 
erythroid progenitors present at day 0 constitute only 2.7% of the live gate. Day 7: At 
the end of Phase 1, approximately 60% of the live gate cells are erythroid (CD36+), of 
which 33% are CD36+CD71+GlyA-, i.e. proerythroblasts and 62% are 
CD36+CD71+GlyAlow, i.e. basophilic normoblasts. Upon CD36+ selection (cells 
boxed), they are placed back in culture for the second phase of differentiation. Day 
14: CD36+ cells have further differentiated into polychromatic and orthochromatic 
normoblasts. (C) MGG staining of cytospins confirms the stage of differentiation and 
determines the cells’ identity. 
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Figure 4-2 Erythroid differentiation of G-CSF mobilised PB CD34+ cells. (A) 
Flow cytometric analysis and (B) quantification of the different cell types obtained 
during G-CSF mobilised CD34+-erythroid differentiation at days 0, 7 and 14 (n=6). 
Day 0: The G-CSF mobilised CD34+ cells are plated at a concentration of 5x105 
cells/ml and undergo the first phase of erythroid differentiation, following the same 
protocol as the PBMC erythroid cultures. A high proportion (>90%) is CD34+CD36-, 
indicating the high purity and potential to differentiate. Day 7: At the end of Phase 1, 
approximately 80%-90% of the live gate cells are CD36+ erythroid cells. 
Approximately 5% of these CD36+ cells are CD34+CD36+ BFU-Es and CFU-Es, 80% 
and 15% represent more differentiated forms of proerythroblasts and basophilic 
normoblasts, respectively. CD36+ cells (boxed) are plated for Phase 2. Day 14: CD36+ 
cells have further differentiated until the stage of polychromatic normoblasts. (C) 
MGG staining of cytospins confirms the stage of differentiation and determines the 
cells’ identity. 
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Figure 4-3 Erythroid differentiation of CB-CD34+ cells. (A) Flow cytometric 
analysis and (B) quantification of the different cell types obtained during CB-CD34+ -
erythroid differentiation at days 0, 7 and 14 (n=6). Day 0: The CB-CD34+ cells are 
plated at a concentration of 5x105 cells/ml and undergo the first phase of erythroid 
differentiation, following the same protocol as the PBMCs. A high proportion (>80%) 
is CD34+CD36-, indicating the high purity and potential to differentiate. Day 7: At the 
end of Phase 1, 70%-90% of the live gate cells are CD36+ erythroid cells. 
Approximately 20% of these CD36+ cells are CD34+CD36+ BFU-Es and CFU-Es, 
whereas 70% represent more differentiated proerythroblasts and 10% are basophilic 
normoblasts. CD36+ cells (boxed) are plated for Phase 2. Day 14: CD36+ cells have 
further differentiated until the stage of polychromatic normoblasts. (C) MGG staining 
of cytospins confirms the stage of differentiation and determines the cells’ identity. 
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In terms of cell expansion, the number of erythroid cells obtained from the 
CD34+ cultures is higher than the PBMCs cultures, as a greater proportion of CD34+ 
cells have the potential for erythroid commitment. Overall, the expansion of CD34+ 
cells is 10-fold by day 7 and 100-fold expansion by day 14. In contrast, PBMC 
expansion is only 80-fold from day 7 to day 14. It should be noted that during the 
PBMC differentiation it is not feasible to measure expansion of PBMCs as the initial 
culture contains a large proportion of cells that are committed to other lineages and do 
not give rise to erythroid cells.  
 
Table 4-1 Cell numbers in two-phase liquid culture systems. a  
 Day 0 Day 7:  
pre-selection 
Day 7:  
post-selection 
Day 14 
PBMCs 
cultures 
1x 106 5x 105 ± 0.37x105 1x 105 ± 0.1x105 8x106±0.55x106 
CB-CD34 
cultures 
5x 105 5x 106 ± 0.45x106 4x 106± 0.28x106 4x108±0.13x108 
GCSFmob-
CD34 
cultures 
5x 105 7x 106 ± 0.23x106 6x 106 ± 0.16x106 5x108±0.19x108 
a The values represent the average of n=6 experiments. Mean±SD is shown. 
 
Further optimisation of the erythroid culture system involved comparison of 
fresh and frozen PBMCs (Figure 4-4). Frozen PBMCs maintained their ability to 
differentiate to erythroid cells. However differentiation proceeded more slowly in the 
frozen PBMCs; at day 7 approximately 55% of the CD36+ cells in the fresh PBMCs 
erythroid culture were CD71+GlyA+/low whilst only 6% of the CD36+ cells obtained 
from the frozen PBMCs erythroid cultures were CD71+GlyA+/low. It is possible that 
amongst the circulating erythroid progenitors and precursors those further 
differentiated are more sensitive to the freezing-thawing procedure. Nevertheless, 
these results show that it is feasible to use frozen PBMCs in the two-phase erythroid 
culture system. 
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Figure 4-4 Comparison between same-donor fresh and frozen PBMCs in 
erythroid differentiation cultures. After cultured for seven days, erythroid 
differentiation of PBMC was assessed by flow cytometry. Frozen PBMCs maintain 
their ability to differentiate to erythroid cells, although differentiation proceeds slower 
than in fresh cell cultures. 
 
Taken together, in this study I optimised an in vitro erythroid differentiation 
system, which allows differentiation of PBMCs and CD34+ cells of different origins. 
Using this system I can successfully obtain erythroid precursor cells by the end of the 
first phase of culture and differentiated erythroid cells after the second phase of 
culture. Although I found differences in differentiation between alternate cell sources, 
these differences can be effectively controlled using control cells from equivalent 
sources.   
This system is of great importance, as it allows me to establish the effect of 
HDACIs on primary human erythroid cells. In the subsequent studies in this thesis I 
have used adult PBMCs and CB-CD34+ cells, which were treated with HDACIs and 
then assessed for the GPPP expression. 
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4.3 Effect of NaBu on erythroid differentiation in vitro 
4.3.1 Effect of NaBu on cell number and differentiation of PBMCs 
Having established conditions for erythroid differentiation of PBMCs and CB-
CD34+ cells, I proceeded to study the effect of NaBu on erythroid differentiation 
starting with cell number. Two alternate treatment schedules were used, both of which 
lasted for 7 days. In both cases PBMCs were initially plated in media supplemented 
with cytokines. Cells were then either treated at 16h with 0.5mM, 1mM or 3mM 
NaBu followed by cytokine and NaBu supplementation every 3 days, or treated at day 
5 with 1mM or 3mM NaBu.  
Assessment on day 7 showed that treatment with NaBu decreased cell 
numbers (Figure 4-5) and delayed differentiation under both schedules (Figure 4-6). 
In the untreated control cultures, approximately 41% of the cells at day 7 are CD36+, 
of which 92% are CD36+CD71+. NaBu results in a decreasing proportion of 
CD36+CD71+ cells in a dose-dependent manner, consistent with delayed erythroid 
differentiation (Figure 4-6).  It should be noted that decreased cell number cannot be 
attributed to reduced viability or reduced proliferation, as due to limiting cell numbers, 
appropriate experiments could not be conducted for this purpose. 
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Figure 4-5 Cell count on day 0 and day 7 of PBMC-differentiating erythroid 
cultures upon NaBu treatment. Number of cells plated at day 0 and those harvested 
at day 7 before CD36+ cell selection. The 2 different NaBu treatment methods involve 
treatment with 0.5mM, 1mM and 3mM NaBu after plating the cells for 16h with 
cytokines alone or, with 1mM and 3mM NaBu at the fifth day of the cultures. Mean 
and S.E.M. are shown for n=3. 
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Figure 4-6 PBMC-differentiating cells treated with a series of different NaBu 
concentrations. Flow cytometric analysis of PBMC differentiating cells at day 7 of 
differentiation. The cultures are treated with 0.5mM, 1mM and 3mM NaBu after 
plating the cells for 16h with CA or, with 1mM and 3mM NaBu at day 5 of the 
cultures. 
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4.3.2 Effect of NaBu on cell number and differentiation of CD34+ 
Similar to the PBMC erythroid differentiation cultures, the CB-CD34+ 
erythroid differentiation cultures were used to generate CD36+ erythroid cells to be 
tested for their G6PD expression upon treatment with NaBu at variable concentrations. 
Before doing so, I tested the effect of HDACIs, including NaBu, on the erythroid 
differentiation of CB-CD34+ cells.  
Treatment with 1mM NaBu on day 5 of the culture for a total of 48h did not 
have any effect on cell number (Figure 4-7) and erythroid differentiation as assessed 
on day 7 of the phase 1 culture (Figure 4-8). Prolonged treatment with 1mM NaBu 
throughout the 7 days of the culture (added 16 hours after plating the cells with CA) 
resulted in decreased cell number, although this was less pronounced than in the 
PBMC cultures (Figure 4-7). NaBu also promoted erythroid differentiation towards 
more differentiated cells, i.e. approximately 44% proerythroblasts and 49% basophilic 
normoblasts (Figure 4-8).  
In addition, I treated the CB-CD34+ cultures with SAHA and TSA to establish 
the effect that these have compared to NaBu. I treated with 1µM SAHA and 1nM 
TSA after plating the cells for 16h with cytokines alone, as described by Chaurasia 
and colleagues (Chaurasia et al., 2011). Although prolonged treatment with SAHA 
and TSA in this culture system resulted in reduced cell number (Figure 4-7), it did not 
seem to affect erythroid differentiation (Figure 4-8). 
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Figure 4-7 Cell count on day 0 and day 7 of CB-CD34+ erythroid cultures upon 
HDACI treatment. Number of cells plated at day 0 and those harvested at day 7 
before CD36+ cell selection. The 2 different treatment methods involve treatment with 
1mM NaBu at the fifth day of the cultures for 48h, or 1mM NaBu, 1µM SAHA 
and1nM TSA after plating the cells for 16h with cytokines alone. Mean and S.E.M. 
are shown for n=3. 
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Figure 4-8 CB-CD34+-differentiating cells treated with different HDACI 
concentrations. Flow cytometric analysis of CD34+-differentiating cells at day 7 of 
differentiation. The cultures are treated with either 1mM NaBu at the fifth day of the 
cultures for 48h, or 1mM NaBu, 1µM SAHA and1nM TSA after plating the cells for 
16h with CA.  
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4.3.3 Gene expression during erythroid differentiation 
A recent RNA-sequencing study conducted by Wong and colleagues (Wong et 
al., 2011) on primary mouse fetal liver erythroid cells, gave insights into the baseline 
expression of genes during erythroid differentiation. In this study, researchers isolated 
erythroid cells from mice and then FACS-sorted different populations, representing 
the stages of erythroid cell differentiation. The populations were FACS-sorted based 
on their CD71 and Ter119 (equivalent of GlyA in mice) expression (Figure 4-9A); R1 
corresponds to BFU-E/CFU-E, R2 to proerythroblasts and basophilic normoblasts, R3 
to early polychromatic normoblasts, R4 to late polychromatic normoblasts and R5 
orthochromatic normoblasts. The sorted cells were then subjected to RNA sequencing 
to examine changes in gene expression during erythroid differentiation. Of the 6,929 
genes that were found to be differentially expressed between the R2 and R5 stage, the 
vast majority (6,455) were downregulated. This finding is consistent with the fact that 
during erythropoiesis erythroid cells undergo condensation of the nucleus, prior to 
enucleation.  
Taking advantage of these data, which have been deposited on the Gene 
Expression Omnibus (GEO) database under the accession number GSE27893, I 
assessed the expression of the GPPP genes. Figure 4-9B shows that the expression of 
5 GPPP genes (G6PD, TPI, GPI, RPIA and PGLS) decreases during erythroid 
differentiation, reaching a minimum level at the R4 late polychromatic normoblast 
differentiation stage and then marginally, yet consistently, increasing at the R5 
orthochromatic normoblast stage. It is also shown how the expression of β –actin, the 
housekeeping gene used as an RT-qPCR reference gene, changes in comparison to 
G6PD, TPI, GPI, RPIA and PGLS GPPP genes that are regularly tested in this thesis.  
Bioinformatic analysis of the available data therefore suggests that the gene 
expression of both the GPPP genes and also the reference gene β-actin changes during 
the different stages of differentiation. One of the issues that emerge from this finding 
is that comparison of gene expression upon treatment of erythroid cultures with 
HDACIs should be assessed only when cultures at the same-stage have been produced 
with and without HDACIs. As shown in Figure 4-6 and Figure 4-8, long exposures or 
high concentration treatment with NaBu results in altered erythroid differentiation 
patterns. For this reason, I decided to use short exposures (i.e. treatment with HDACI 
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on day 5 for 48h) and low concentrations (1mM of NaBu) to assess expression of 
G6PD and other GPPP genes in primary human erythroid cells. 
 
 
Figure 4-9 GPPP gene expression during erythroid differentiation in mice. (A) 
Flow cytometric analysis shows the five erythroid differentiation stages, as used by 
Wong et al (Wong et al., 2011) for further RNA sequencing analysis (GEO database 
accession number GSE27893). (B) Gene expression analysis during erythroid 
differentiation from stages R2 to R5 of the reference gene β-actin, in comparison to 5 
genes of the GPPP (G6PD, TPI, GPI, PGLS and RPIA). 
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4.4 GPPP gene expression in normal erythroid precursors upon 
NaBu treatment 
To test the effect of NaBu on normal primary erythroid cells, CD36+ cells 
were purified from CB-CD34+ erythroid differentiation cultures as shown in Figure 
4-10, ensuring that erythroid cells obtained from NaBu-treated and control untreated 
cultures were at the same stage of differentiation.  
CD36+ cells were selected (post-selection purity >95% as assessed by flow 
cytometry) and then tested for G6PD mRNA expression (Figure 4-11A). Similarly to 
the B cell line data (Figure 3-6), as compared to untreated control, of all 17 GPPP 
genes (including the erythroid-specific PKLR gene), treatment with NaBu selectively 
increased G6PD mRNA expression levels to as much as 3.2-fold. In addition to 
mRNA, G6PD protein and enzymatic activity levels also increased by 3-fold and 2.5-
fold, respectively (Figure 4-11B and C). 
 
Figure 4-10 Same-stage differentiation upon NaBu in CB-CD34+-differentiating 
cells.  Flow cytometric and MGG staining analysis on CB-CD34+ -differentiating cells 
at day 7 of the culture. Untreated and treated cells with 1mM NaBu for 48h are shown. 
Treatment with NaBu is shown not to affect the erythroid differentiation under these 
conditions. 
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Figure 4-11 NaBu increases G6PD gene expression and enzymatic activity in CB-
CD34+-derived erythroid precursors. (A) NaBu treatment of CB-CD34+-
differentiating cells for 48h selectively increases G6PD mRNA as assessed by RT-
qPCR at day 7 of the culture. (B) G6PD protein levels are assessed by Western blot 
and quantified by the ImageJ software. G6PD protein is shown to increase 3-fold 
upon NaBu treatment. (C) Treatment of the erythroid cells also increases G6PD 
enzymatic activity. Mean and S.E.M. are shown for n=3. Student’s t-test was 
performed to compare the untreated to the treated condition. 
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4.5 GPPP gene expression in patient erythroid cells upon NaBu 
treatment 
Having established that NaBu increases G6PD gene expression and enzymatic 
activity in normal erythroid cells derived from CB-CD34+ cells, I next aimed to 
evaluate the potential clinical significance of this finding. Consequently, I tested the 
effect of NaBu on erythroid precursors derived from PBMCs of individuals with 
G6PD deficiency.  
Firstly, I employed the erythroid differentiation assay using PBMCs from a 
patient with G6PD Brighton, a class I G6PD variant caused by an in-frame deletion 
on exon 13 and clinically characterised by CNSHA. As shown in Figure 4-12, G6PD 
Brighton PBMCs generate proerythroblasts and basophilic normoblasts by day 7 and 
polychromatic and orthochromatic normoblasts by day 14 as assessed by flow 
cytometry (Figure 4-12A) and MGG staining (Figure 4-12B). Overall, the 
differentiation of G6PD deficient samples is the similar to normal PBMCs as 
previously described in Figure 4-1.  
PBMC-differentiating cells from G6PD Brighton as well as a healthy donor 
were treated with NaBu for 48h and analysed at day 7 (Figure 4-13). NaBu treatment 
is shown here not to affect the erythroid differentiation irrespective of the origin of 
the PBMCs. This finding also implies that the pathogenic mutation on the G6PD 
promoter does not affect the differentiation of erythroid cells. In fact, it is known that 
the defect is associated with the mature RBCs, which haemolyse due to the low G6PD 
enzymatic activity and not with earlier erythroid progenitors (Beutler, 2007; 
Cappellini and Fiorelli, 2008). 
 
 
 
 
 
  139 
 
Figure 4-12 Erythroid differentiation of PBMCs isolated from G6PD Brighton. 
(A) Flow cytometric analysis during PBMC erythroid differentiation from a G6PD 
deficient patient (G6PD Brighton) at days 7 and 14. Day 7: At the end of Phase 1, 
approximately 60% -70% of the live gate cells are CD36+ erythroid differentiated at 
the stages of proerythroblasts and basophilic normoblasts. Day 14: CD36+ cells have 
further differentiated until the stage of polychromatic and orthochromatic normoblasts. 
(C) MGG staining of cytospins confirms the stage of differentiation and determines 
the cells’ identity. 
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Figure 4-13 NaBu treatment of WT and G6PD Brighton PBMC-differentiating 
erythroid cells. (A) Normal and (B) G6PD Brighton PBMC-differentiating erythroid 
cells were treated at day 5 of phase 1 for 48h. Flow cytometric analysis and MGG 
staining confirms the stage of differentiation (proerythroblasts and basophilic 
normoblasts). 
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Having established that PBMCs isolated from G6PD deficient individuals can 
be differentiated into erythroid progenitors (Figure 4-12) and that their differentiation 
is not affected by short (48h) and low concentration (1mM) incubations with NaBu 
(Figure 4-13), I next sought to investigate G6PD mRNA and protein expression and 
enzymatic activity levels after treatment of these cells. For this purpose, I obtained 
PBMC-derived erythroid precursors from 3 class I deficient patients (G6PD Brighton, 
G6PD Serres and G6PD Harilaou) and from individuals with class III G6PD 
deficiency (G6PD Med and G6PD A- mutations; Table 2-2).  
Figure 4-14, Figure 4-15 and Figure 4-16 show G6PD mRNA and protein 
levels and enzymatic activity results for G6PD Brighton, G6PD Serres and G6PD 
Harilaou, respectively, obtained by treating the erythroid cells for 48h (from day 5 to 
day 7) with 1mM NaBu. Although the healthy donor (n=4) sample results are 
summarised in each figure, the results from each class I patient are shown in 
individual figures as they represent different pathogenic mutations. Figure 4-17 
summarises the cumulative results of all 3 class I G6PD deficient patients. 
In G6PD Brighton cells (Figure 4-14), G6PD mRNA and protein expression 
increases by 3.4-fold and 4-fold in response to NaBu treatment, respectively. 
Importantly, G6PD enzymatic activity is also increased by 3.1-fold, consistent with 
the results from CB-CD34+ erythroid cultures (Figure 4-11) as well as B cell lines 
(Figure 3-9). It is also very interesting to note that the absolute expression of G6PD 
protein as shown in Figure 4-14B by western blotting is lower in G6PD Brighton in 
comparison to the healthy donor sample. This is consistent with my findings in cell 
lines, which were presented in Figure 3-8. Similarly, G6PD mRNA and protein 
expression, as well as enzymatic activity increased 6.8-fold, 5.7-fold and 2.5-fold in 
G6PD Serres erythroid progenitors upon NaBu treatment (Figure 4-15). Furthermore, 
treated erythroid cells from G6PD Harilaou showed 10-fold, 4.7-fold and 4.2-fold 
increases in the G6PD mRNA expression, protein expression and enzymatic activity, 
respectively (Figure 4-16). Altogether, class I G6PD deficient cells showed a 
statistically significant (p<0.05) 6.7-fold increase in G6PD mRNA expression and a 
4.8-fold increase in G6PD protein expression as well as a 3-fold increase in G6PD 
enzymatic activity in response to NaBu (Figure 4-17). 
It should be noted that during the in vitro erythroid differentiation culture 
baseline G6PD enzymatic activity in class I patients appears to around 50% that of 
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normal cells, as opposed to approximately 10% that it is in RBCs in vivo (See Table 
2-2 with patient characteristics). This reflects the fact that erythroid precursors are 
nucleated cells with preserved ability to continuously transcribe G6PD, while mature 
RBCs have lost this capacity because they are anuclear.  
 
 
Figure 4-14 G6PD expression in normal and G6PD Brighton PBMC-derived 
erythroid cells upon NaBu treatment. PBMC cells were differentiated into 
erythroid precursors from healthy donors and the class I G6PD Brighton patient. (A) 
G6PD mRNA expression, assessed by RT-qPCR, increased 4.4-fold and 3.4-fold in 
healthy donors and G6PD Brighton, respectively upon 1mM NaBu treatment for 48h. 
(B) Similarly, Western blot assessed G6PD protein expression, which is shown to 
increase 3-fold and 4-fold in healthy donors and G6PD Brighton, respectively. (C) 
G6PD enzymatic activity increases 2.8-fold and 3.1-fold in healthy donors and G6PD 
Brighton, respectively upon NaBu treatment. Mean and S.E.M. are shown for n=4 for 
healthy donors and n=1 for G6PD Brighton. Student’s t-test was performed to 
compare the untreated to the treated condition of the healthy donors. 
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Figure 4-15 G6PD expression in normal and G6PD Serres PBMC-derived 
erythroid cells upon NaBu treatment. PBMC cells were differentiated into 
erythroid precursors from healthy donors and the class I G6PD Serres patient. (A) 
G6PD mRNA expression, assessed by RT-qPCR, increased 4.4-fold and 6.8-fold in 
healthy donors and G6PD Serres, respectively upon 1mM NaBu treatment for 48h. 
(B) Similarly, Western blot assessed G6PD protein expression, which is shown to 
increase 3-fold and 5.7-fold in healthy donors and G6PD Serres, respectively. (C) 
G6PD enzymatic activity increases 2.8-fold and 2.5-fold in healthy donors and G6PD 
Serres, respectively. Mean and S.E.M. are shown for n=4 for healthy donors and n=1 
for G6PD Serres. Student’s t-test was performed to compare the untreated to the 
treated condition of the healthy donors. 
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Figure 4-16 G6PD expression in normal and G6PD Harilaou PBMC-derived 
erythroid cells upon NaBu treatment. PBMC cells were differentiated into 
erythroid precursors from healthy donors and the class I G6PD Harilaou patient. (A) 
G6PD mRNA expression, assessed by RT-qPCR, increased 4.4-fold and 10-fold in 
healthy donors and G6PD Harilaou, respectively upon 1mM NaBu treatment for 48h. 
(B) Similarly, Western blot assessed G6PD protein expression, which is shown to 
increase 3-fold and 4.7-fold in healthy donors and G6PD Harilaou, respectively. (C) 
G6PD enzymatic activity increases 2.8-fold and 4.2-fold in healthy donors and G6PD 
Harilaou, respectively. Mean and S.E.M. are shown for n=4 for healthy donors and 
n=1 for G6PD Harilaou. Student’s t-test was performed to compare the untreated to 
the treated condition of the healthy donors. 
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Figure 4-17 G6PD expression in primary human normal and class I G6PD 
deficient erythroid cells. PBMC cells were differentiated into proerythroblasts from 
normal and class I G6PD deficient individuals. (A) G6PD mRNA expression, 
assessed by RT-qPCR, increased 4.4-fold and 6.7-fold in normal and G6PD deficient 
samples, respectively upon 1mM NaBu treatment for 48h. (B) Similarly, Western blot 
assessed G6PD protein expression, which is shown to increase 3-fold and 4.8-fold in 
normal and G6PD deficient cells, respectively. (C) G6PD enzymatic activity 
increases 2.8-fold and 3.2-fold in normal and G6PD deficient cells, respectively upon 
NaBu treatment. Mean and S.E.M. are shown for n=4 for normal and n=3 for class I 
deficient samples (i.e. G6PD Brighton, G6PD Serres and G6PD Harilaou). Student’s 
t-test was performed to compare the untreated to the treated condition. 
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Figure 4-18 G6PD expression in normal and G6PD Mediterranean PBMC-
differentiating erythroid cells upon NaBu treatment. PBMC cells were 
differentiated into proerythroblasts from healthy donors and the class III G6PD Med. 
(A) G6PD mRNA expression, assessed by RT-qPCR, increased 4.4-fold and 2.5-fold 
in healthy donors and G6PD Med, respectively upon 1mM NaBu treatment for 48h. 
(B) Similarly, Western blot assessed G6PD protein expression, which is shown to 
increase 3-fold and 2.5-fold in healthy donors and G6PD Med, respectively. (C) 
G6PD enzymatic activity increases 2.8-fold and 3.5-fold in healthy donors and G6PD 
Med, respectively. Mean and S.E.M. are shown for n=4 for healthy donors and n=1 
for G6PD Med. Student’s t-test was performed to compare the untreated to the treated 
condition of the healthy donors. 
 
G6PD Mediterranean 
A. B. 
C. 
G6PD  
β-actin  
59 
42 
0mM 1mM 
G6PD Med 
kDa 
Med RNA
WT G6PD Med
0
2
4
6
Untreated
NaBu
*
Fo
ld
 c
ha
ng
e 
in
 
G
6P
D
 m
R
N
A
Med prot
WT G6PD Med
0
1
2
3
4
Untreated
NaBu*
Fo
ld
 c
ha
ng
e 
in
 
G
6P
D
 p
ro
te
in
Med enzym
WT G6PD Med
0
200
400
600
800
Untreated
NaBu
*
G
6P
D
 e
nz
ym
at
ic
 
ac
tiv
ity
 (U
/m
g)
  147 
 
Figure 4-19 G6PD expression in normal and G6PD African PBMC-derived 
erythroid cells upon NaBu treatment. PBMC cells were differentiated into 
proerythroblasts from healthy donors and the class III G6PD A-. (A) G6PD mRNA 
expression, assessed by RT-qPCR, increased 4.4-fold and 15-fold in healthy donors 
and G6PD A-, respectively upon 1mM NaBu treatment for 48h. (B) Similarly, 
Western blot assessed G6PD protein expression, which is shown to increase 3-fold 
and 3.5-fold in healthy donors and G6PD A-, respectively. (C) G6PD enzymatic 
activity increases 2.8-fold and 3.3-fold in healthy donors and G6PD A-, respectively. 
Mean and S.E.M. are shown for n=4 for healthy donors and n=1 for G6PD A-. 
Student’s t-test was performed to compare the untreated to the treated condition of the 
healthy donors. 
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4.6 Conclusions 
In this chapter, I aimed to test the effect of NaBu on the GPPP gene 
expression in primary human erythroid cells. Therefore, I set up a two-phase liquid 
culture system for erythroid differentiation starting from either PBMCs or CB-CD34+ 
cells, which recapitulates erythropoiesis in vitro and produces erythroid precursors in 
7 days. However, treatment of the generated erythroid precursors with NaBu (but not 
other HDACIs) is shown to affect erythroid differentiation and to reduce cell numbers. 
In fact, PBMC-derived erythroid cells display delayed erythroid maturation, whereas 
in the case of the CB-CD34+-derived cells erythropoiesis seems to be promoted. 
SAHA and TSA are shown to reduce the number of erythroid cells produced, without 
affecting the differentiation of CB-CD34+-differentiating cells. Acknowledging the 
importance of producing same-stage cells upon NaBu treatment in order to compare 
them with the untreated cells in the context of GPPP expression, I established the 
conditions required for NaBu: low concentration of 1mM NaBu and short exposure of 
48h from day 5 to day 7 of phase 1. 
The results show that G6PD expression is selectively upregulated in CB-
CD34+-derived erythroid cells amongst all the 17 genes of the GPPP. Further 
investigation showed that during erythroid differentiation, irrespective of the origin of 
the erythroid cells, i.e. PBMCs or CD34+ cells, G6PD mRNA and protein expression 
as well as G6PD enzymatic activity increase. Importantly, this study reveals that the 
expression and enzymatic activity of G6PD can be increased by NaBu in human 
primary erythroid G6PD deficient cells, which were isolated from 5 different G6PD 
deficient individuals, including 3 class I and 2 class II G6PD variants, representing 5 
distinct characterised mutations.  
Returning to my original hypothesis posed at the beginning of this study, it is 
now possible to state that NaBu selectively upregulates G6PD expression and 
enzymatic activity in normal and G6PD deficient cells, suggesting new therapeutic 
potential for individuals with G6PD deficiency.  
 
 
 
  149 
 
 
 
 
 
 
 
 
 
 
 
 
5 Results III: Epigenetic regulation of the 
GPPP genes 
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5.1 Introduction 
The dynamic balance of histone acetylation and deacetylation plays a critical 
role in transcriptional regulation and determines activation versus repression. HDACs 
have been traditionally regarded as co-repressors that bind to gene promoters, instead 
of HATs and consequently inhibit transcription through histone deacetylation (Berger, 
2007; Xu et al., 1998).  However, a recent detailed genome-wide study (Wang et al., 
2009) that involved ChIP-seq analysis of primary CD4+ T cells provided new insights 
into the role of histone acetylation and deacetylation of active, primed and inactive 
genes. Specifically high binding levels of both HATs and HDACs were found at the 
promoters and gene bodies of active, housekeeping genes, whilst at primed genes 
there are high binding levels of both HATs and HDACs only at the gene promoters. 
In the case of inactive genes, HATs and HDACs were not recruited. This finding has 
led to the speculation that HDAC activity is required to reset the chromatin status by 
removing the acetyl groups after the completion of each round of transcription so that 
the gene does not hyper-acetylate (Wang et al., 2009). 
HDACIs are a class of compounds that inhibit the activity of histone 
deacetylases (Marks, 2010). One of the commonest used HDACIs is butyric acid and 
its derivatives (including NaBu), which have been previously used for the treatment 
of haemoglobinopathies (Perrine et al., 2010), urea cycle disorders (Batshaw et al., 
2001), sickle cell anaemia (Dover et al., 1994) and IGD (Almeida et al., 2007).   
Butyrate responsive elements have been characterised within the promoters of 
the butyrate-responsive genes (Davie, 2003; Siavoshian et al., 1997) and can be 
categorised into two separate groups. The first group consists of genes that are either 
induced or repressed and have a common AGCCACCTCCA sequence, suggesting 
that they are bound by a common transcription factor. In the other group, there are 
genes, which share an Sp1/Sp3 binding site within the butyrate responsive elements. 
Sp1 and Sp3 are transcription factors that are ubiquitously expressed and act as both 
activators and repressors of gene expression and have the ability to interact with 
HATs and HDACs.  
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5.1.1 Aim of the chapter 
The aim of this chapter is to dissect the transcriptional and epigenetic basis of 
the selective responsiveness of G6PD to HDACIs amongst the genes of the GPPP. By 
comparing the epigenetic and transcriptional landscape of the G6PD promoter to 
other genes of the GPPP. 
5.1.2 Experimental plan 
To explore the epigenetic and transcriptional status of the G6PD promoter, I 
performed bioinformatic analysis of the ENCODE project genome-wide ChIP-Seq 
data provided by the UCSC genome browser (http://genome.ucsc.edu/ENCODE/). 
Following this, ChIP analysis was employed to assess the acetylation status as well as 
the binding of HATs, HDACs and the TF Sp1 on the G6PD promoter compared to 
other GPPP promoters at baseline and in response to NaBu. 
5.2 ENCODE analysis of GPPP promoters 
As described in 1.4.3.1, G6PD is a housekeeping gene, which as a result of 2 
alternative TSSs encodes two variants: a short variant that consists of exons 2-13 and 
a longer inactive variant consisting of exons 1-13. Human G6PD is arranged in a 
‘head to head’ configuration with NEMO, a gene that encodes a non-catalytic subunit 
of the cytokine-dependent IκB kinase, involved in the activation of the TF NFkB (Jin 
and Jeang, 1999). NEMO is transcribed under the influence of 2 promoters (promoter 
A and B). Promoter B (868bp; including a 192bp core promoter(Philippe et al., 1994)) 
is housekeeping and has strong bidirectional activity driving the transcription of both 
G6PD and NEMO genes. The bidirectional G6PD gene promoter (Figure 1-12) is 
embedded within a CpG island (1245bp; Fusco et al., 2006) and contains two GC-
boxes that drive its expression (Ursini et al., 1990). Furthermore, 12 binding sites for 
the transcription factor Sp1 are predicted within a region of 1327bp surrounding exon 
1 of the G6PD gene (Fusco et al., 2006; Galgoczy et al., 2001; Philippe et al., 1994).  
Analysis of ENCODE-derived data (Figure 5-1) confirmed expression of 
G6PD in 9 different human cell lines (B lymphoblastoid cell line GM12878, stem cell 
line H1-hESC, cervical cancer cell line HeLa, hepatic cell line HepG2, myoblastic 
cell line HSMM, umbilical vein endothelial cell line HUVEC, erythroleukaemia cell 
line K562, epidermal keratinocytes NHEK and lung fibroblasts NHLF) and showed a 
considerable enrichment of Sp1 covering the length of the shared, housekeeping 
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promoter.  Furthermore, consistent with the features of housekeeping gene promoters, 
H3 acetylation marks but not silencing marks such as H3K27me3 are readily 
identified. As well as HATs, HDACs are shown to bind to the promoter at low level, 
thus confirming the validity of the results obtained by Wang et al.(Wang et al., 2009) 
i.e., that HATs and HDACs are both present in housekeeping gene promoters. Taken 
together these results suggest that Sp1, HATs, HDACs and histone acetylation are 
important structural and functional components of the G6PD promoter. 
Further bioinfomatic analysis sought to compare the G6PD promoter with 
other promoters of the GPPP, such as those of TPI and GPI, which are genes that 
remain unaffected by NaBu. This was conducted using both the ENCODE browser 
and the transcription factor binding site prediction browsers TFSearch 
(http://www.cbrc.jp/research/db/TFSEARCH.html) and CONSITE 
(http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite). Similarly to G6PD, the 
promoters of TPI and GPI present a typical housekeeping gene structure. They are 
embedded within CpG islands, contain GC boxes and are enriched for acetylation, 
HDACs, HATs, Sp1 and other common TFs (Figure 5-2 and Figure 5-3). 
Taken together, bioinformatics analysis of the promoters of G6PD, TPI and 
GPI shows that the key features of these promoters are very similar and consistent to 
those of housekeeping gene promoters. The only difference evident from this abalysis 
between G6PD and all the other GPPP genes is the fact that G6PD shares a 
bidirectional promoter with another gene, i.e. NEMO. 
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Histone Modifications by ChIP-seq from ENCODE/Broad Institute
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GM12878 ln(x+1) 4 _
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1) 4 _
0 _
HSMM ln(x+1) 4 _
0 _
HUVEC ln(x+1) 4 _
0 _
K562 ln(x+1) 4 _
0 _
NHEK ln(x+1) 4 _
0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC CTCF
H1-hESC H3K4 1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36 3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me1
NT2-D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4M3 Sg 1
GM78 H3K4M3 Sg 2
GM78 H3K27M3 Sg 1
GM78 H3K27M3 Sg 2
GM78 H3K36M3 Sg 1
GM78 H3K36M3 Sg 2
GM78 In Sg 1
K562 H3K4M3 Sg 1
K562 H3K4M3 Sg 2
K562 H3K27M3 Sg 1
K562 H3K27M3 Sg 2
K562 H3K36M3 Sg 1
K562 H3K36M3 Sg 2
K562 In Sg 1
K562 CTCF Sig 1
30 _
0 _
K562 Pol2 Sig 1
30 _
0 _
HeLaS3 Pol2 Sig 1
30 _
0 _
GM12878 c yc DS
GM12878 c yc OS
GM12878 CTCF DS
GM12878 CTCF OS
GM12878 Pol2 DS
GM12878 Pol2 OS
GM12878 Input DS
H1-hESC cMyc DS
H1-hESC cMyc OS
H1-hESC CTCF DS
H1-hESC CTCF OS
H1-hESC Pol2 DS
H1-hESC Pol2 OS
K562 cMyc DS
K562 cMyc OS
K562 CTCF DS
K562 CTCF OS
K562 Pol2 DS
K562 Pol2 OS
K562 Input DS
GM12878 EZH
GM 2878 H3K4m3
GM12878 H3K9ac
GM12878 H3K9m3
GM12878 H3K27ac
GM12878 H3K27m3
GM 2878 H3K36m3
GM12878 H3K7 m
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9ac
H1-hESC H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
H1-hESC HDAC2
H1-hESC HDAC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
H1-hESC PHF8
H1-hESC RBBP5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ12
K562 EZH2
K562 H3K9ac
K562 H3K9m3
K562 H3K9m1
K562 H3K79m2
K562 H4K20m1
K562 HDAC1
K562 HDAC2
K562 HDAC6
K562 LSD1
K562 NCoR
K562 NSD2
K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
K562 Pol2
K562 RBBP5
K562 REST
K562 RNF2
K562 SAP30
K562 SETDB1
K562 SIRT6
K562 SUZ12
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4 1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
chrX:
TCF4
p300
FOSL2
TBP
MafK_(SC-477)
MafK_(ab50322)
HEY1
ERalpha_a
Pol2
c-Myc
c-Myc
Pol2
TCF4
HMGN3
CCNT2
GR
GATA-1
GATA-2
c-Fos
FOXA1_(C-20)
c-Jun
CEBPB
p300
AP-2gamma
eGFP-JunD
p300_(N-15)
JunD
SP1
MafF_(M8194)
ZBTB7A_(SC-345 8)
eGFP-JunB
FOXA2_(SC-6554)
IRF1
FOSL1_(SC-183)
MafK_(ab50322)
STAT2
FOSL2
FOXA1_(SC-101058)
NF-E2
eGFP-FOS
ELF1_(SC-631)
AP-2alpha
MafK_(SC-477)
Egr-1
PU.1
Max
USF-1
c-Myc
Pol
STAT1
GR
USF2
USF-1
Max
Mxi1_(bHLH)
NRSF
PU.1
CEBPB
YY
HA-E2F1
Pol2
AP-2gamma
E2F6
GABP
Pol2-4H8
TAF1
E2F6_(H-50)
TBP
HEY1
ZBTB7A_(SC-34508)
ELF1_(SC 631)
Egr-1
Pol2(phosphoS2)
ZNF263
Pol2
Sin3Ak-20
GABP
E2F6_(H-50)
ELF1_(SC-631)
CCNT
HMGN3
AP-2gamma
IR 1
Egr
c- yc
AP-2alpha
TBP
CHD2_(N-1250)
BRCA1_(C-1863)
ELF1_(SC-631)
Pol2(phosphoS2)
GABP
ZBTB33
Pol2- H8
T F1
TR4
NFKB
Sin3Ak-20
PAX5-C20
PAX5-N19
HEY1
Egr-1
Ini
ZNF263
CEBPB
ELF1_(SC-631)
GM12878 ChromHMM
H1-hESC Chrom MM
K562 ChromHMM
HepG2 ChromHMM
HUVEC ChromHMM
HMEC ChromHMM
HSMM ChromHMM
NHEK ChromHMM
NHLF ChromH M
H1-hESC C CF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me
NT2-D1 H3K4me
NT2-D1 H3K9
NT2-D1 H3K27me
NT2-D1 H3K36me
U2OS H3K9me3
U2OS H3K 6me3
GM78 H3K4M3 Ht 1
GM78 H3K4M3 Pk 1
GM78 H3K4M3 Ht 2
GM78 H3K4M3 Pk 2
GM78 H3K27M3 Ht 1
GM78 H3K27M3 Pk 1
GM78 H3K27M3 Ht 2
GM78 H3K27M3 Pk 2
GM78 H3K36M  Ht 1
GM78 H3K36M  Pk 1
GM78 H3K36M3 Ht 2
GM78 H3K36M3 Pk 2
K56  H3K4M3 Ht 1
K562 H3K4M  Pk 1
K562 H3K4M3 Ht 2
K562 H3K4M3 Pk 2
K56  H3K27M3 Ht 1
K562 H3K27M3 Pk 1
K56  H3K27M3 Ht 2
K562 H3K27M3 Pk 2
K562 H3K36  t 
K562 H3K36   
K562 H3K36  t 
K562 H3K36   
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chrX:153753804..153755757-chrX:153768976..153771861,2
chrX:153758025..153760730-chrX:153770356..153773007,2
chrX:153760070..153764716-chrX:153773233..153775153,4
chrX:153760244..153763093-chrX:153768256..153770323,2
chrX:153763292..153764840-chrX:153770147..153771705,2
chrX:153768724..153770816-chrX:153778156..153780016,2
chrX:153770257..153772733-chrX:153989355..153991758,2
chrX:153773014..153778101-chrX:153778456..153782500,6
chrX:153775179..153776742-chrX:153978011..153980734,2
chrX:153778920..153781753-chrX:153977081..153979595,2
chrX:153779711..153781942-chrX:154465936..154467690,2
chr6:20401925..20402638-chrX:153774705..153775616,2
chr7:108167082..108167658-chrX:153775065..153775574,2
chr22:42016623..42017672-chrX:153775639..153776427,3
chr11:62608880..62609445-chrX:153775815..153776345,2
GM12878 cMyc Pk
GM12878 CTCF Pk
GM12878 Pol2 Pk
H1-hESC cMyc Pk
H1-hESC CTCF Pk
H1-hESC Pol2 Pk
K562 cMyc Pk
K562 CTCF Pk
K562 Pol2 Pk
GM12878 EZH2
H3K4m3
GM12878 H3K9ac
GM12878 H3K9m3
GM12878 H3K 7ac
GM12878 H3K27m3
GM12878 H3K36m3
GM12878 H3K79m2
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9ac
H1-hESC H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
H1-hESC HDAC2
H1-hESC HDAC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
H1-hESC PHF8
H -hESC RBBP5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ1
K562 EZH2
K562 H3K9ac
K562 H3K9m3
K562 1
K562 
K562 
K562 1
K562 2
K562 HDAC6
K562 LSD1
K562 NCoR
K562 NSD2
K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
K562 Pol
K562 RBBP5
K56  REST
K56  RNF
K562 SAP30
K56  SETDB
K562 SIRT6
K562 SUZ1
DNase Clusters
GM12878 DNase
H1-hESC DNase
K562 DNase
HUVEC DNase
HeLa-S3 DNase
HepG2 DNase
A549 DNase
CD20+ DNase
MCF-7 DNase
Mcyte-CD14+ DNase
NHEK DNase
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG  H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
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5 kb hg19
153,775,000
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Transcription Levels Assayed by RNA-seq on 9 Cell Lines from ENCODE
H3K27Ac Mark (Often Found Near Active Regulatory Elements) on 7 cell lines from ENCODE
Transcription Factor ChIP-seq from ENCODE
Chromatin State Segmentation by HMM from ENCODE/Broad
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Histone Modifications by ChIP-seq from ENCODE/Stanford/Yale/USC/Harvard
Histone Modifications by ChIP-seq from ENCODE/University of Washington
CpG Islands (Islands < 300 Bases are Light Green)
K562 CTCF ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 CTCF ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
Open Chromatin TFBS by ChIP-seq from ENCODE/Open Chrom(UT Austin)
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
DNaseI Hypersensitivity Uniform Peaks from ENCODE/Analysis
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
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GM12878 ln(x+1) 4
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1) 4 _
0 _
HSMM ln(x+1) 4 _
0 _
HUVEC ln(x+1) 4 _
0 _
K562 ln(x+1) 4 _
0 _
NHEK ln(x+1) 4 _
0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m
K562 H3K4m
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me
NT2-D1 H3K4me
NT2-D1 H3K9
NT2-D1 H3K27me
NT2-D1 H3K36me
U2OS H3K9me3
U2OS H3K 6me3
GM78 H3K4M3 Sg 1
GM78 H3K4M3 Sg 2
GM78 H3K27M3 Sg 
GM78 H3K27M3 Sg 2
GM78 H3K36M3 Sg 1
GM78 H3K36M3 Sg 2
GM78 In Sg 1
K562 H3K4M  Sg 1
K562 H3K4M  Sg 2
K562 H3K27M3 Sg 1
K562 H3K27M3 Sg 2
K562 H3K36   
K562 H3K36   
K562 In Sg 
K562 CTCF Sig 1
30 _
0 _
K562 Pol2 Sig 1
3
0 _
HeLaS3 Pol2 Sig 1
30 _
0 _
GM12878 cMyc DS
GM12878 cMyc OS
GM12878 CTCF DS
GM12878 CTCF OS
GM12878 Pol2 DS
GM12878 Pol2 OS
GM12878 Input DS
H1-hESC cMyc DS
H1-hESC cMyc OS
H1-hESC CTCF DS
H1-hESC CTCF OS
H1-hESC Pol2 DS
H1-hESC Pol2 OS
K562 cMyc DS
K562 cMyc OS
K562 CTCF DS
K562 CTCF OS
K562 Pol2 DS
K562 Pol2 OS
K562 Input DS
GM12 78 EZH2
 H3K4m3
GM12878 H3K9ac
GM12878 H3K9m3
GM12878 H3K 7ac
GM 2878 H3K27m3
GM12878 H3K36m3
GM12878 H3K79m2
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9ac
H1-hESC H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
H1-hESC HDAC2
H1-hESC HDAC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
H1-hESC PHF8
H1-hESC RBBP5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ12
K562 
K562 
K562 
K562 H3K 1
K562 3 79 2
K562 H4K20m1
K562 1
K562 HDAC2
K562 HDAC6
K562 LSD1
K562 NCoR
K562 NSD2
K562 P30
K562 PCAF
K562 PHF8
 PLU1
K562 Pol2
K562 RBBP5
K56  REST
K562 RNF
K562 SAP30
K56  SETDB
K562 SIRT6
K562 SUZ12
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG  H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H K79m2
HepG2 H4K20m1
HepG2 Input
Scale
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TCF4
p300
FOSL2
TBP
MafK_(SC-477)
MafK_(ab50322)
HEY1
ERalpha_a
Pol2
c-Myc
c-Myc
Pol2
TCF4
HMGN3
CCNT2
GR
GATA-1
GATA-2
c-Fos
FOXA1_(C-20)
c-Jun
CEBPB
p300
AP-2gamma
eGFP-JunD
p300_(N-15)
JunD
SP1
MafF_(M8194)
ZBTB7A_(SC-34508)
eGFP-JunB
FOXA2_(SC-6554)
IRF1
FOSL1_(SC-183)
MafK_(ab50322)
STAT2
FOSL2
FOXA1_(SC-101058)
NF-E2
eGFP-FOS
ELF1_(SC-631)
AP-2alpha
MafK_(SC-477)
Egr-1
PU.1
Max
USF-1
c-Myc
Pol2
STAT1
GR
USF2
USF-1
Max
Mxi1_(bHLH)
NRSF
PU.1
CEBPB
YY1
HA-E2F1
Pol2
AP-2gamma
E2F6
GABP
Pol2-4H8
TAF1
E2F6_(H-50)
TBP
HEY1
ZBTB7A_(SC-34508)
ELF1_(SC-631)
Egr-1
Pol2(phosphoS2)
ZNF263
Pol2
Sin3Ak-20
GABP
E2F6_(H-50)
ELF1_(SC-631)
CCNT2
HMGN3
AP-2gamma
IRF1
Egr-1
c-Myc
AP-2alpha
TBP
CHD2_(N-1250)
BRCA1_(C-1863)
ELF1_(SC-631)
Pol2(phosphoS2)
GABP
ZBTB33
Pol2-4H8
TAF1
TR4
NFKB
Sin3Ak-20
PAX5-C20
PAX5-N19
HEY1
Egr-1
Ini1
ZNF263
CEBPB
ELF1_(SC-631)
GM12878 ChromHMM
H1-hESC ChromHMM
K562 ChromHMM
HepG2 ChromHMM
HUVEC ChromHMM
HMEC ChromHMM
HSMM ChromHMM
NHEK ChromHMM
NHLF ChromHMM
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4 e1
NT2-D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4M3 Ht 1
GM78 H3K4M3 Pk 1
GM78 H3K4M3 Ht 2
GM78 H3K4M3 Pk 2
GM78 H3K27M3 Ht
GM78 H3K27M3 Pk 1
GM78 H3K27M3 Ht 2
GM78 H3K27M3 k 
GM78 H3K36M3 Ht 1
GM78 H3K36M3 Pk 1
GM78 H3K36M3 Ht 2
GM78 H3K36M3 Pk 2
K562 H3K4M3 Ht 1
K562 H3K4M3 Pk 
K562 H3K4M3 Ht 
K562 H3K4M3 Pk 2
K562 H3K27M3 Ht 1
K562 H3K27M3 Pk 1
K562 H3K27M3 Ht 2
K562 H3K27M3 Pk 2
K562 H3K36M3 Ht 1
K562 H3K36M3 Pk 1
K562 H3K36M3 Ht 2
K562 H3K36M3 Pk 2
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chrX:153758025..153760730-chrX:153770356..153773007,2
chrX:153760070..153764716-chrX:153773233..153775153,4
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Egr-1
c-Myc
AP- alpha
TBP
CHD2_(N-1250)
BRCA1_(C-1863)
ELF1_(SC-631)
Pol2(phosphoS2)
GABP
ZBTB33
Pol2-4H8
TAF1
TR4
NFKB
Sin Ak-20
PAX5-C20
PAX5-N19
HEY1
Egr-1
Ini1
ZNF263
CEBPB
ELF1_(SC-631)
GM12878 ChromHMM
H1-hESC ChromHMM
K562 ChromHMM
Hep 2 ChromHMM
HUVEC ChromHMM
HMEC ChromHMM
HSMM ChromHMM
NHEK ChromHMM
NHLF ChromHMM
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K 62 H3K2 m3
K 62 H3K3 m3
K562 H3K4me1
K562 H3K4me3
K56  H3K9ac
K562 3K27me3
NT2-D1 H3K4me1
NT -D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me
NT2-D1 H3K36me3
U2O  H3K9me3
U2OS H K3 me3
GM78 H3K4M3 Ht 1
GM78 H3K4M3 Pk 1
GM78 H3K4M3 Ht 2
GM78 H3K4M3 Pk 2
GM78 H3K27M3 Ht 1
GM78 H3K27M3 Pk 1
GM78 H3K27M3 Ht 2
GM 8 H3K27M3 Pk 2
GM78 H3K36M3 Ht 1
GM78 H3K36M3 Pk 1
GM78 H3K36M3 Ht 2
GM78 H3K36M3 Pk 2
K562 H3K4M3 Ht 1
K562 H3K4M3 Pk 1
K562 H3K4M3 Ht 2
K562 H3K4M3 Pk 2
K562 H3K27M3 Ht 1
K562 H3K27M3 Pk 1
K562 3K27M3 Ht 2
K562 3K27M3 Pk 2
K562 H3K36M3 Ht 1
K562 H3K36M3 Pk 1
K562 H3K36M3 Ht 2
K562 H3K36M3 Pk 2
CpG: 138
chrX:153285470..153287043-chrX:153774547..153776771,
chrX:153595148..153597150-chrX:153772995..153774995,2
chrX:153595773..153597738-chrX:153780009..153782155,2
chrX:153597323..153599953-chrX:153767551.. 53771879,5
chrX:153597771..153599703-chrX:153989259.. 53992360,3
chrX:153598177..153599749-chrX:153774215..153776821,2
chrX:153624567..153628166-chrX:153772694..153776749,9
chrX:153625830..153633897-chrX:153767392.. 53772063,11
chrX:153626573..153628178-chrX:153978925..153981640,2
chrX:153629459..153632266-chrX:153773289..153775719,2
chrX:153636134..153637859-chrX:153779117..153782021,2
chrX:153686728..153689524-chrX:153775483..153777304,2
chrX:153706238..153709054-chrX:153774005..153776728,3
chrX:153708819..153710866-chrX:154067775..1540 9439,2
chrX:153713383..153715797-chrX:153769453..153771661,2
chrX:153714637..153717614-chrX:153774027..153776587,2
chrX:153718262..153719962-chrX:153988941..153990796,2
chrX:153743857..153745716-chrX:153768769..1 3770861,3
chrX:153753804..153755757-chrX:153768976..1 3771861,2
chrX:153758025..153760730-chrX:153770356..1 3773007,2
chrX:153760070..153764716-chrX:153773233..1 3775153,4
chrX:153760244..153763093-chrX:153768256..153770323,2
chrX:153763292..153764840-chrX:153770147..153771705,2
chrX:153768724..153770816-chrX:153778156..153780016,2
chrX:153770257..153772733-chrX:153989355..153991758,2
chrX:153773014..153778101-chrX:153778456..153782500,6
chrX:153775179..153776742-chrX:153978011..153980734,2
chrX:153778920..153781753-chrX:153977081..153979595,2
chrX:153779711..153781942-chrX:154465936..154467690,2
chr6:20401925..20402638-chrX:153774705..153775616,2
chr7:108167082..108167658-chrX:153775065..153775574,2
chr22:42016623..42017672-chrX:153775639..153776427,3
chr11:62608880..62609445-chrX:153775815..153776345,2
GM12878 cMyc Pk
GM12878 TCF Pk
GM12878 Pol2 Pk
H1-hESC cMyc Pk
H1-hESC CTCF Pk
1-h  Pol2 Pk
K562 cMyc Pk
K562 CTCF Pk
K562 Pol2 k
GM12878 EZH2
GM12878 H3K4m3
GM12878 3 9ac
GM12878 H3K9m3
GM12878 3 27ac
GM12878 H3K27m3
GM12878 H3K36m3
GM12878 H3K79m2
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9 c
H1-hESC H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
H1-hESC H AC2
H1-hESC H AC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
1-hESC PHF8
H1-hESC RBB 5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ12
K562 EZH2
K562 H3K9ac
K56 9m3
K56 9m1
K562 H3K79m2
K562 H4K 0m1
K562 H AC1
K562 HDAC2
K562 HDAC6
K562 LSD1
K562 NCoR
K562 NSD2
K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
K562 Pol2
K562 RBBP5
K562 REST
K562 RNF2
K562 SAP30
K562 SETDB1
K562 SIRT6
K562 SUZ12
DNase Clusters
GM12878 DNase
H1-hESC DNase
K562 DNase
HUVEC DNase
HeLa-S3 DNase
HepG2 DNase
A549 DNase
CD20+ DNase
MCF-7 DNase
Mcyte-CD14+ DNase
NHEK DNase
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
Sequences
SNPs
Genes
Bands
5 kb hg19
153,775,000
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Transcription Levels Assayed by RNA-seq on 9 Cell Lines from ENCODE
H3K27Ac Mark (Often Found Near Active Regulatory Elements) on 7 cell lines from ENCODE
Transcription Factor ChIP-seq from ENCODE
Chromatin State Segmentation by HMM from ENCODE/Broad
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Histone Modifications by ChI -seq from ENCODE/Stanford/Yale/USC/Harvard
Histone Modifications by ChIP-seq from ENCODE/University of Washington
CpG Islands (Islands < 300 Bases are Light Green)
K562 CTCF ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 CTCF ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
Open Chromatin TFBS by ChIP-seq from ENCODE/Open Chrom(UT Austin)
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
DNaseI Hypersensitivity Uniform Peaks from ENCODE/Analysis
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Publications: Sequences in scientific articles
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GM12878 ln(x+1) 4 _
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1)  _
0 _
HSMM ln(x+1) 4 _
0 _
HUVEC ln(x+1) 4 _
0 _
K562 ln(x+1) 4 _
 _
NHEK ln(x+1) 4 _
0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K 6m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K 62 H3K27m3
K 62 H3K36m3
K562 H3K4me1
K562 H3K4me3
K56  H3K9ac
K562 H K27me3
NT -D1 H3K4me1
NT2-D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H K36me3
GM78 H3K4M3 Sg 1
GM78 H3K4M3 Sg 2
GM78 H3K27M3 Sg 1
GM78 H3K27M3 Sg 2
GM78 H3K36M3 Sg 1
GM78 H3K36M3 Sg 2
GM78 In Sg 1
K562 H3K4M3 Sg 1
K562 H3K4M3 Sg 2
K562 H3K27M3 Sg 1
K562 H3K27M3 Sg 2
K562 H3 3 M3 Sg 1
K562 H3K36M3 Sg 2
K562 In Sg 1
K562 CTCF Sig 1
30 _
0 _
K562 Pol2 Sig 1
30 _
0 _
HeLaS3 Pol2 Sig 1
30 _
 _
GM12878 cMyc DS
GM12878 cMyc OS
GM12878 TCF DS
GM12878 TCF OS
GM12878 Pol2 DS
GM12878 Pol2 OS
GM12878 Input DS
H1-hESC cMyc DS
H1-hESC cMyc OS
H1-hESC CTCF S
H1-hESC TCF OS
H1-hESC Pol2 S
H1-hESC Pol2 OS
K562 cMyc DS
K562 cMyc OS
K562 CTCF DS
K562 CTCF OS
K562 Pol2 DS
K562 Pol2 OS
K562 Input DS
GM12878 EZH2
GM12878 H3K4m3
GM12878 3 9ac
GM12878 H3K9m3
GM12878 3 27ac
GM12878 H3K27m3
GM12878 H3K36m3
GM12878 H3K79m2
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9 c
H1-hESC H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
H1-hESC H AC2
H1-hESC HDAC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
1-hESC PHF8
H1-hESC RBB 5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ12
K562 EZH2
K562 H3K9 c
K56 9m3
K56 3 9m1
K562 H3K79m2
K562 H4K20m1
K562 H AC1
K562 HDAC2
K562 HDAC6
K562 LSD1
K562 NCoR
K562 NSD2
K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
K562 Pol2
K562 RBBP5
K562 REST
K562 RNF2
K562 SAP30
K562 SETDB1
K562 SIRT6
K562 SUZ12
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
chrX:
TCF4
p300
TBP
MafK_(SC-477)
MafK_(ab50322)
EY1
ERalpha_
Pol
c-Myc
c-Myc
Pol2
TCF4
HMGN3
CCNT
GR
GATA-1
GATA-
c- os
FOXA1_(C-20)
c-Jun
CEBPB
p300
AP-2gamma
eGFP-JunD
p300_( -15)
JunD
SP1
MafF_(M8194)
ZBTB7A_(SC-34508)
eGFP-JunB
FOXA2_(SC-6554)
IRF1
FOSL1_(SC-183)
MafK_(ab50322)
STAT2
FOSL2
FOXA1_(SC-101058)
NF-E2
eGFP-FOS
ELF1_(SC-631)
AP-2alpha
MafK_(SC-477)
Egr-1
PU.1
Max
USF-1
c-Myc
Pol2
STAT
GR
USF2
USF-1
Max
Mxi1_(bHLH)
NRSF
PU.1
CEBPB
YY1
HA-E2F1
Pol2
AP-2gamma
E2F6
GABP
Pol2-4H8
TAF1
E2F6_( -50)
TBP
HEY
ZBTB7A_(SC-34508)
ELF1_(SC-631)
Egr-1
Pol2(phosphoS2)
ZNF263
Pol2
Sin3Ak-20
GABP
E2F6_( -50)
LF1_ SC-631)
CCNT2
HMGN3
AP-2gamma
IRF1
Egr-1
c-Myc
AP-2alpha
TBP
CHD2_(N-1250)
BRCA1_(C-1863)
ELF1_(SC-631)
Pol2(phosphoS2)
GABP
ZBTB33
Pol2-4H8
TAF1
TR4
NFKB
Sin3Ak-20
PAX5-C20
PAX5-N19
HEY1
Egr-1
Ini1
ZNF263
CEBPB
ELF1_(SC-631)
GM12878 ChromHMM
H1-hESC ChromHMM
K562 ChromHMM
HepG2 ChromHMM
HUVEC ChromHMM
HMEC ChromHMM
HSMM ChromHMM
NHEK ChromHMM
NHLF ChromHMM
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC 3 36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me1
NT2-D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4  t 1
GM78 H3K4   1
GM78 H3K4M3 Ht 2
GM78 H3K4M3 Pk 2
GM78 H3K27M3 Ht 1
GM 8 H3K2 M3 Pk 1
GM78 H3K2 M3 Ht 2
GM78 H3K2 M3 Pk 
GM78 H3K 6M3 Ht 1
GM78 H3K 6M3 Pk 1
GM78 H3K 6M  Ht 2
GM78 H3K 6M3 Pk 
K562 H3K4M3 Ht 1
K562 H3K4M3 Pk 1
K562 H3K4M  Ht 
K562 H3K4M3 Pk 2
K562 H3K2 M3 Ht 1
K56  H3K2 M3 Pk 1
K562 H3 2 M3 Ht 2
K562 H3K2 M3 Pk 
K562 H3K 6M3 Ht 1
K562 H3K 6M3 Pk 1
K562 H3K 6M3 Ht 
K562 H3K 6M3 Pk 
CpG: 138
rX: 53285470.. 5328 043- r : 4547.. 67 1,
chrX:153595148..15359 150- r : 2995.. 4995,
chrX:153595773..153597738- r : 80009.. 8215 ,
chrX:153597323..153599953-chrX:153767551..153771879,5
chrX:153597771..153599703-chrX:153989259..153992360,3
chrX:153598177..153599749-chrX:153774215..153776821,2
chrX:153624567..153628166-chrX:153772694..153776749,9
chrX:153625830..153633897-chrX:153767392..153772063,11
chrX:153626573..153628178-chrX:153978925..15398164 ,2
chrX:153629459..153632266-chrX:153773289..153775719,2
chrX:153636134..153637859-chrX:15377911 ..153782021,2
chrX:153686728..153689524-chrX:153775483..153777304,2
chrX:153706238..153709054-chrX:153774005..153776728,3
chrX:153708819..153710866-chrX:154067775..154069439,2
chrX:153713383..153715797-chrX:153769453..153771661,2
chrX:153714637..153717614-chrX:153774027..153776587,
chrX:153718262..153719962-chrX:153988941..153990796,2
chrX:153743857..153745716-chrX:153768769..153770861,3
chrX:153753804..153755757-chrX:1537689 6..153771861,2
chrX:153758025..153760730-chrX:1537703 ..153773007,2
chrX:153760070..153764716-chrX:153773233..1537751 3,4
chrX:153760244..153763093-chrX:153768256..153770323,2
chrX:153763292..153764840-chrX:153770147.. 53771705,2
chrX:153768724..153770816-chrX:153778156..15378 016,2
chrX:153770257..153772733-chrX:153989355..153991758,2
chrX:153773014..153778101-chrX:153778456..153782500,6
chrX:153775179..153776742-chrX:1539780 1..153980734,2
chrX:153778920..153781753-chrX:153977081..153979595,2
chrX:153779711..153781942-chrX:154465936..154467690,2
chr6:20401925..20402638-chrX:153774705..153775616,2
chr7:108167082..108167658-chrX:153775065..153775574,2
chr22:42016623..42017672-chrX:153775639..153776 27,
chr11:62608880..62609445-chrX:153775815..153776345,2
12878 cMyc Pk
12878 CTCF Pk
GM12878 Pol2 Pk
H1-hESC cMyc Pk
H1-hESC CTCF Pk
H1-hESC Pol2 Pk
K562 cMyc Pk
K562 CTCF Pk
K562 Pol2 Pk
GM12878 EZH2
GM12878 H3K4m3
GM12878 H3K9ac
GM 2878 H3K9m3
GM12878 H3K27ac
GM12878 H3K27m3
GM12878 H3K36m3
GM12878 H3K79m
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9ac
H1-hESC H3K 3
H1-hESC 3 79 2
H1-hESC H4K20m
H1-hESC 
H1-hESC 
H1-hESC JARID1A
H1-hESC J JD2A
H1-hESC P300
H1-hESC HF8
H1-hESC RBBP5
H1-hES  SAP30
H1-hESC SIRT6
H1-hESC SUZ1
K562 EZH
K562 H3K9ac
K562 H3K9m3
K562 H3K9m1
K562 H3K79m2
K562 H4K20m1
K562 HDAC1
K562 HDAC2
K562 HDAC6
K562 LSD1
562 NCoR
562 N D2
K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
K562 Pol2
K562 RBBP5
562 REST
562 RNF2
562 SAP30
K562 SETDB1
K562 SIRT6
5 2 SUZ 2
DNase Clusters
GM12878 DNase
H1-hESC DNase
K562 DNase
HUVEC DNase
HeLa-S3 DNase
HepG2 DNase
A549 DNase
CD20+ DNase
MCF-7 DNase
Mcyte-CD14+ DNase
NHEK DNase
HepG2 CTCF
HepG2 EZH
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36 3
HepG2 H3K79 2
HepG2 H4K20 1
Sequences
SNPs
Genes
Bands
5 kb hg19
153,775,000
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Transcription Levels Assayed by RNA-seq on 9 Cell Lines from ENCODE
H3K27Ac Mark (Often Found Near Active Regulatory Elements) on 7 cell lines from ENCODE
Transcription Factor ChIP-seq from ENCODE
Chromatin State Segmentation by HMM from ENCODE/Broad
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Histone Modifications by ChIP-seq from ENCODE/Stanford/Yale/USC/Harvard
Histone Modifications by ChIP-seq from ENCODE/University of Washington
CpG Islands (Islands < 300 Bases are Light Green)
K562 CTCF ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 CTCF ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
Open Chromatin TFBS by ChIP-seq from ENCODE/Open Chrom(UT Austin)
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
DNaseI Hypersensitivity Uniform Peaks from ENCODE/Analysis
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Publications: Sequences in scientific articles
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GM12878 ln(x+1) 4 _
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1) 4 _
0 _
HSMM ln(x+1) 4 _
0 _
HUVEC ln(x+1) 4 _
0 _
K562 ln(x+1) 4 _
0 _
NHEK ln(x+1) 4 _
0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K2 ac
H1-hESC 3 27m3
H1-hE C H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4 e1
K562 H3K4me3
K562 H3K9ac
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Figure 5-1 Transcriptional and epigenetic landscape of the G6PD promoter 
based on the ENCODE project. Schema obtained from the ENCODE project via the 
UCSC genome browser, showing the G6PD and NEMO genes in a bidirectional 
promoter conformation. Boxed in red is the bidirectional promoter B. The expression 
of the housekeeping genes is shown in 9 different cell lines. The enrichment for 
positive and negative chromatin marks is shown, as well as the enrichment for HATs 
(p300, PCAF), HDACs (HDAC1, 2 and 6) and Sp1 at baseline. 
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UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Transcription Levels Assayed by RNA-seq on 9 Cell Lines from ENCODE
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Transcription Factor ChIP-seq from ENCODE
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K562 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
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Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
DNaseI Hypersensitivity Uniform Peaks from ENCODE/Analysis
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
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K562 H3K27me3
NT2-D1 H3K4me1
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NT2-D1 H3K9ac
NT2-D1 H3K27me
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U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4M3 Sg 1
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GM78 H3K36M3 Sg
GM78 H3K36M3 Sg 2
GM78 In Sg 
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GM12878 CTCF DS
GM12878 CTCF OS
GM12878 Pol2 DS
GM12878 Pol2 OS
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H1-hESC cMyc OS
H1-hESC CTCF DS
H1-hESC CTCF OS
H1-hESC Pol2 DS
H1-hESC Pol2 OS
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K562 CTCF DS
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K562 Pol2 DS
K562 Pol2 OS
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H1-hESC H3K9m3
H1-hESC H3K 9m
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K562 Pol2
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HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
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Scale
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CTCF
Rad21
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CTCF_(C-20)
CTCF_(SC-5916)
CTCF
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AP-2gamma
SMC3_(ab9263)
Rad21
RFX5_(N-494)
CTCF_(SC-5916)
HDAC2_(SC-6296)
NANOG_(SC-33759)
CTCFL_(SC-98982)
CTCF_(C-20)
FOXA1_(C-20)
Pol2
CTCF
EBF
GTF2F1_(RAP-74)
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Pol2-4H8
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Rad21
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TAF1
Sin3Ak-20
CTCFL_(SC-98982)
HA-E2F1
USF2
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Egr-1
CTCF_(C-20)
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HEY1
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E2F4
TBP
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GM12878 CTCF Pk
GM12878 Pol2 Pk
H1-hESC cMyc Pk
H1-hESC CTCF Pk
H1-hESC Pol  Pk
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K562 CTCF Pk
K562 Pol2 Pk
GM12878 EZH
GM1 87  H3K4m3
GM12878 H3K9ac
GM12878 H3K9m3
GM12878 H3K27ac
GM12878 H3K27m3
GM12 78 H3K36m3
GM 2878 H3K7 m
GM12878 H4K20m1
H1-hESC EZH
H1-hESC H3K9ac
H -hESC H K9m3
H -hESC H3K79m
H1-hESC H4K20m1
H1-hESC HDAC
H1-hESC HDAC6
H1-hESC JARID A
H1-hE C JMJD2A
1-hESC P300
H1-hESC P F8
H1-hESC RBBP5
H1-hESC SA 30
H1-hESC SIRT6
H1-hESC SUZ1
K562 EZH2
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K56  H3K9m3
K56  H3K9m1
K562 H3K79m
K562 H4K2 m
K 62 HDAC1
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K 62 HDAC6
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K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
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K562 RBBP5
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K562 RNF
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K562 SETDB1
K5 2 SIRT6
K562 SUZ1
DNase lusters
GM12878 DNase
H1-hESC DNase
K562 DNase
HUVEC DNase
HeLa-S3 DNase
HepG2 DNase
A549 DNase
CD20+ DNase
MCF-7 DNase
Mcyte-CD14+ DNase
NHEK DNase
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
Sequences
SNPs
Genes
Bands
20 kb hg19
34,840,000 34,850,000 34,860,000 34,870,000 34,880,000 34,890,000 34,900,000
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Transcription Levels Assayed by RNA-seq on 9 Cell Lines from ENCODE
H3K27Ac Mark (Often Found Near Active Regulatory Elements) on 7 cell lines from ENCODE
Transcription Factor ChIP-seq from ENCODE
Chromatin State Segmentation by HMM from ENCODE/Broad
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Histone Modifications by ChIP-seq from ENCODE/Stanford/Yale/USC/Harvard
Histone Modifications by ChIP-seq from ENCODE/University of Washington
CpG Islands (Islands < 300 Bases are Light Green)
K562 CTCF ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 CTCF ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
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Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
DNaseI Hypersensitivity Uniform Peaks from ENCODE/Analysis
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
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GM12878 ln(x+1) 4 _
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1) 4 _
0 _
HSMM ln(x+1) 4 _
0 _
HUVEC ln(x+1) 4 _
0 _
K562 ln(x+1) 4 _
0 _
NHEK ln(x+1) 4 _
0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me
NT2-D1 H3K4me3
NT2-D1 H3K9a
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4M3 Sg 1
GM78 H3K4M3 Sg 
GM78 H3K27M3 Sg 1
GM78 H3K27M3 Sg 
GM78 H3K36M3 Sg 1
GM78 H3K36M3 Sg 
GM78 In Sg 1
K562 H3K4M3 Sg 1
K562 H3K4M3 Sg 
K562 H3K27M3 Sg 1
K562 H3K27M3 Sg 
K562 H3K36M3 Sg 1
K562 H3K36M3 Sg 
K562 In Sg 1
K562 CTCF Sig 1
30 _
0 _
K562 Pol2 Sig 1
30 _
0 _
HeLaS3 Pol2 Sig 1
30 _
0 _
GM12878 cMyc DS
GM12878 cMyc OS
GM12878 CTCF DS
GM12878 CTCF OS
GM12878 Pol2 DS
GM12878 Pol2 OS
GM12878 Input DS
H1-hESC cMyc DS
H1-hESC cMyc OS
H1-hESC CTCF DS
H1-hESC CTCF OS
H1-hESC Pol2 DS
H1-hESC Pol2 OS
K562 cMyc DS
K562 cMyc OS
K562 CTCF DS
K562 CTCF OS
K562 Pol2 DS
K562 Pol2 OS
K562 Input DS
GM12878 EZH
GM1 87  H3K4m3
GM12878 H3K9ac
GM12878 H3K9m
GM12878 H3K27ac
GM12878 H3K m3
GM12878 H3K36m
GM12878 H3K79m
GM12 78 H K20m1
H -hESC EZH
H1-hESC H3K9ac
H1-hESC H3K9m3
H1-hESC H K 9m
H1-hESC H4K20m1
H1-hESC HDAC
H1-hESC HDAC
H1-hESC JARID1A
H1-hESC J JD2A
1-hESC P300
H1-hESC PHF8
H1-hESC RBBP5
H1-hESC SAP30
H1-hESC SIRT6
H -hESC SUZ1
K562 EZH2
K562 H3K9ac
K56  H3K9m3
K56  H3K9m1
K 62 H3K79m2
K562 H4K20m1
K 62 HD C1
562 HDAC
K 62 HDAC
K562 LSD1
K 62 NCoR
K56  NSD
K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
K562 l
K562 RBBP5
K562 REST
K5 2 RNF
K562 SA 30
K562 SETDB1
K56  SIRT6
K562 SUZ12
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
chr19:
CTCF
Rad21
Egr-1
SMC3_(ab9263)
CTCF_(C-20)
CTCF_(SC-5916)
CTCF
AP-2alpha
AP-2gamma
SMC3_(ab9263)
Rad21
RFX5_(N-494)
CTCF_(SC-5916)
HDAC2_(SC-6296)
NANOG_(SC-33759)
CTCFL_(SC-98982)
CTCF_(C-20)
FOXA1_(C-20)
Pol2
CTCF
EBF
GTF2F1_(RAP-74)
NFKB
Pol2-4H8
Pol2(phosphoS2)
Ini1
Znf143_(16618-1-AP)
Rad21
SMC3_(ab9263)
TAF1
Sin3Ak-20
CTCFL_(SC-98982)
HA-E2F1
USF2
Max
Egr-1
CTCF_(C-20)
USF-1
HEY1
ZBTB7A_(SC-34508)
c-Myc
SIRT6
E2F4
TBP
E2F6
Nrf1
E2F6_(H-50)
TCF12
CCNT2
PAX5-C20
YY1_(C-20)
SETDB1
GR
BHLHE40
PAX5-N19
HMGN3
HDAC2_(SC-6296)
Mxi1_(bHLH)
AP-2gamma
ELF1_(SC-631)
USF1_(SC-8983)
AP-2alpha
SP1
CEBPB
eGFP-JunD
Sin3Ak-20
c-Fos
JunD
IRF1
MafK_(SC-477)
MafK_(ab50322)
Egr-1
MafF_(M8194)
NF-E2
ZBTB7A_(SC-34508)
c-Myc
FOSL2
Pol2-4H8
TAF1
HEY1
Pol2
TCF4
CEBPB
Sin3Ak-20
TAF1
HEY1
HEY1
Sin3Ak-20
ELF1_(SC-631)
Pol2
EBF1_(C-8)
Nrf1
TBP
TAF1
Egr-1
ETS1
NFKB
Pol2(phosphoS2)
c-Myc
YY1_(C-20)
Pol2-4H8
Sin3Ak-20
HEY1
YY1
HA-E2F1
HMGN3
ELF1_(SC-631)
Pol2
Pol2
c-Myc
Pol2
Pol2
SRF
Pol2
STAT1
GR
Pol2
Pol2
Pol2
Pol2
Pol2
Pol2
Pol2
Pol2
Pol2-4H8
Pol2
Pol2
Pol2(b)
Pol2
Pol2
Pol2
Pol2
Pol2
Pol2
Pol2(b)
Pol2-4H8
BCL3
TR4
Pol2
Pol2(phosphoS2)
Pol2-4H8
Pol2-4H8
Pol2
ZNF263
Pol2
ZNF263
CTCF
FOXA1_(S -101058
FOXA1_(C-20
FOXA2_(SC-6554)
HA-E2F1
TFIIIC-110
Pol2
Max
HEY1
E2F6
ZNF263
E2F6_(H- 0
Pol2-4H8
KAP1
TBP
Egr-1
MEF2A
USF-1
Mxi1_(bHLH
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NANOG_(SC-33759)
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GTF2F1_(RAP-74
ELF1_(SC-631)
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GM12878 ChromHMM
H1-hESC Chrom MM
K562 ChromHMM
HepG2 ChromHMM
HUVEC ChromHMM
HMEC ChromHMM
HSMM ChromH M
NHEK ChromHMM
NHLF Chrom MM
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me1
NT2-D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me
U2OS H3K36me3
GM78 H3K4M3 Ht 
GM78 H3K4M3 Pk 1
GM78 H3K4M3 Ht 2
GM78 H3K4M3 Pk 2
GM78 H3K27M3 Ht 
GM78 H3K27M3 Pk 1
GM78 H3K27M3 Ht 2
GM78 H3K27M3 Pk 2
GM78 H3K36M3 Ht 
GM78 H3K36M3 Pk 1
GM78 H3K36M3 Ht 2
GM78 H3K36M3 Pk 2
K562 H3K4M3 Ht 
K562 H3K4M3 Pk 1
K562 H3K4M3 Ht 2
K562 H3K4M3 Pk 
K562 H3K27M3 Ht 
K562 H3K27M3 Pk 1
K562 H3K27M3 Ht 2
K562 H3K27M3 Pk 2
K562 H3K36M3 Ht 1
K562 H3K36M3 Pk 1
K562 H3K36M3 Ht 2
K562 H3K36M3 Pk 2
CpG: 56
CpG: 76
CpG: 67
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chr19:13263195..13263725-chr19:48972551..48973161,2
chr19:13263478..13264035-chr19:47217394..47217910,2
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Figure 5-2 Transcriptional and epigenetic landscape of the GPI promoter based 
on the ENCODE project. Schema obtained from the ENCODE project via the 
UCSC genome browser, showing the GPI gene. Its promoter region is boxed in red. 
The expression of the housekeeping gene is shown in 9 different cell lines. The 
enrichment for positive and negative chromatin marks is shown, as well as the 
enrichment for HATs (p300, PCAF), HDACs (HDAC1, 2 and 6) and Sp1 (indicated 
with arrow) at baseline. 
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0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me1
NT2-D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4M3 Sg 1
GM78 H3K4M3 Sg 2
GM78 H3K27M3 Sg 1
GM78 H3K27M3 Sg 2
GM78 H3K36M3 Sg 1
GM78 H3K36M3 Sg 2
GM78 In Sg 1
K562 H3K4M3 Sg 1
K562 H3K4M3 Sg 2
K562 H3K27M3 Sg 1
K562 H3K27M3 Sg 2
K562 H3K36M3 Sg 1
K562 H3K36M3 Sg 2
K562 In Sg 1
K562 CTCF Sig 1
30 _
0 _
K562 Pol2 Sig 1
30 _
0 _
HeLaS3 Pol2 Sig 1
30 _
0 _
GM12878 cMyc DS
GM12878 cMyc OS
GM12878 CTCF DS
GM12878 CTCF OS
GM12878 Pol2 DS
GM12878 Pol2 OS
GM12878 Input DS
H1-hESC cMyc DS
H1-hESC cMyc OS
H1-hESC CTCF DS
H1-hESC CTCF OS
H1-hESC Pol2 DS
H1-hESC Pol2 OS
K562 cMyc DS
K562 cMyc OS
K562 CTCF DS
K562 CTCF OS
K562 Pol2 DS
K562 Pol2 OS
K562 Input DS
GM12878 EZH2
GM12878 H3K4m3
GM12878 H3K9ac
GM12878 H3K9m3
GM12878 H3K27ac
GM12878 H3K27m3
GM12878 H3K36m3
GM12878 H3K79m2
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9ac
H1-hESC H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
H1-hESC HDAC2
H1-hESC HDAC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
H1-hESC PHF8
H1-hESC RBBP5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ12
K562 EZH2
K562 H3K9ac
K562 H3K9m3
K562 H3K9m1
K562 H3K79m2
K562 H4K20m1
K562 HDAC1
K562 HDAC2
K562 HDAC6
K562 LSD1
K562 NCoR
K562 NSD2
K562 P300
K562 PCAF
K562 PHF8
K562 PLU1
K562 Pol2
K562 RBBP5
K562 REST
K562 RNF2
K562 SAP30
K562 SETDB1
K562 SIRT6
K562 SUZ12
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
chr12:
ZBTB7A_(SC-34508)
Egr-1
Ini
EBF1_(C-8)
TS
GTF2F1_(RAP-74)
YY1
Nrf1
PAX5 N19
PAX5-C20
TBP
TR4
Pol
SP1
GT 2
HA-E2F1
TA 1
Pol2(b
YY1_(C-20)
Pol2-4H8
HEY1
ELF1_(SC-631)
TAL1_(SC-12984)
Oct-2
POU2F2
NFKB
NRSF
N LFe
Pol2(phosphoS2)
MEF2A
TAF7_(SQ-8)
BCL3
TCF12
c-Myc
HA-E2F1
HEY1
Pol2-4H8
C NT2
Egr-1
E2F6
E2F6_(H-50
Nrf1
Ini1
Pol2(b
ZNF263
CTCF
CTCF_(C-20)
Pol2
CTCF
SMC3_(ab9263)
Pol2-4H8
Znf143_(16618-1-AP)
CTCF_(SC-5916)
CTCF_(C-20)
CTCFL_(SC-98982)
Rad2
Pol2
SP1
CTCF_(SC-5916
Pol2
Pol
Pol (b)
Pol2-4H8
GR
Pol2-4H8
IRF
TAF1
Pol2(b)
ZNF263
Pol2(phosphoS2)
USF-
Oct-2
POU2F2
Pol2
Pol2-4H8
CTCF
Ini1
ZBTB7A_(SC-34508)
CCNT2
IRF1
BCL3
Rad21
SP1
GABP
TCF4
ETS1
CTCF_(SC-5916)
Oct-2
POU2F2
Egr-1
SMC3_(ab926
YY1_(C-20
NANOG_(SC-33759
Znf143_(16618-1-AP)
USF-1
CTCF_(C-2
Max
c-Myc
PAX5 C20
Sin3Ak-20
Mxi1_(bHLH)
USF1_(SC-8983)
CTCFL_(SC-98982)
HNF4A_(H-171
HEY1
Pol2
CHD2_(N-1250
Sin3Ak-20
HEY
Pol2-4H8
TAF
HA-E2F1
Oct-2
POU2F2
TAF7_(SQ-8)
ELF1_(SC-631)
GABP
THAP1_(SC-98174)
PU.1
IRF1
HMGN3
SP1
TBP
HDAC2_(SC-6296
PAX5-N19
Egr-1
CCNT2
NANOG_(SC-33759)
BCL3
ZBTB7A_(SC-34508)
AP-2alpha
Sin3Ak-20
AP-2gamma
JunD
EBF1_(C-8)
GM12878 ChromHMM
H1-hESC ChromHMM
K562 ChromHMM
HepG2 ChromHMM
HUVEC ChromHMM
MEC ChromHMM
SMM ChromHMM
NH K hromHMM
NHLF hromHMM
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC 3
H1-hESC 3K27ac
H1-hESC H3K27m3
H1-hESC 36
K562 CTCF
K562 H3K4m
K562 H3K4m
K562 H3K27
K562 H3K27m
K562 36m3
K562 1
K562 H3K4me3
K562 H3K9ac
K562 27
NT -D1 4 1
NT2-D1 H3K4
NT2-D1 H K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H3K 6me3
GM78 H3K4 3 Ht 1
GM78 H3K4  Pk
GM78 H3K4 3 Ht 2
GM78 H3K4  Pk
78 3K27 3 Ht 1
GM78 H3K27M3 Pk
GM78 H3K27  Ht 2
GM78 H3K27 Pk 2
GM78 H3K36  Ht 1
GM78 H3K36 Pk 1
GM78 36  Ht 2
GM78 36 Pk 2
K562 H3K4 3 Ht 1
K562 H3K4  Pk
K562 H3K4 3 Ht 2
K562 H3K4  Pk
K562 3K27 3 Ht 1
K562 H3K27M3 Pk
K562 H3K27M3 Ht 2
K562 H3K27M3 Pk 2
K562 H3K36M3 Ht 1
K562 H3K36M3 Pk 1
K562 H3K36M3 Ht 2
K562 H3K36M3 Pk 2
CpG: 89
CpG: 60
chr12:6771921..6772891-chr12:7000348..7000907,2
chr12:6962015..6962745-chr12:6979695..6980431,2
chr12:6981363..6982123-chr12:7070499..7071191,2
641483 643594 644 78439 2
642097 644714 9926 7000 31
chr12:6 42 65..6645243-chr12:705 576..7055882,
648337 6508 2 6975497 697 221
716723 7182 2 75300 6978143
720385 725343 98853 7001996 4
7212 5 723163 772 9 78872
7 1072 7735 6 6976490 6978699
3 817 37 61 69762 1 697892
850730 85371 6984815 6986381 2
85261 854936 7 187 6980879
85 800 864010 6975 37 6980764 8
8 9931 86242 81459 6983 57
chr12:6869632..6879107-chr12:7050110..705 62,17
873684 876029 046246 04877
87400 876784 638 35 2
874 40 87668 6983174 6985558
877751 880 01 6980177 69825 4
879737 88 441 52644 55552
884090 8866 51714 54307 2
369 4 40163 1 8 77 4
394 9 41575 6999930 01952
4 98 5 10 5278 54697
52 97 55 87 6998835 00 93 2
chr12:6958078..6960507-chr12:70 8798..7071590,3
chr12:6958839..69 0500-chr12:7265 5..72 7694,2
chr12:69 9334..6961375-chr12:6998812..70 0464,
chr12:69 9685..6962490-chr12:7029529..7 31 07,2
60042 620 9 46202 48615
chr12:6 60400.. 962739 7035 92 703 103
60454 63129 7 627 761 3
60515 670 7 5094 5469 7
63282 6493 5 828 5 32
68 93 1539 02935 031911
chr12:696 61..6972208-chr12:7052907..7055945 4
chr12:6974392..6985867-chr12:706 986..7084535,44
chr12:6974 74..6986387-chr12:7041 12..705 930,64
chr12:6975377..6984002-chr12:703129 ..7040431,2
chr12:697539 ..6984904-chr12:6995336..7005 85,28
chr12:6975558..6978174-chr12:7060698..7062544,2
chr1:46597413..46599611-chr12: 9762 9..6978931,2
chr12:6976300..6978608-chr12:7012256..7014363,5
chr12:6976466..6978990-chr12:7022593..7025120,2
chr12:6976640..6979328-chr12:7095331..7097408,2
chr12:6976659..6978784-chr12:7277808..7280440,2
chr12:6977978..6980643-chr6:31692087..31694537,2
chr12:6978371..6983032-chr12:7264183..7268791,5
chr12:6979160..6981764-chr12:7064239..7066977,3
chr12:6980234..6982504-chr12:7124501..7127721,3
chr12:6982810..6984579-chr12:7275043..7277464,2
chr12:1100037..1100656-chr12:51442773..5144 4 6
chr12:110056 ..1101509-chr12:13045545..13046207
176 631 177 98 3061 123 30611927
211 450 211 09 0729375 0730033
chr12:2986046..2986 77-chr12:105837647..105838612
2986233 29869 4 52445321 5244611
chr12:3067602..3068298-chr12:52448592..52449299
3067756 3068750 49524687 49525383
30679 9 306851 49760 28 49761230 2
3068022 3068656 5244 848 5244 4 4
chr12:4657883..4658 0 -chr12:2709 77 ..27091466
chr12:6437289..6 38191-chr12:7053075..7053905
chr12:6445350.. 446083-chr12:6976592..69773 1
chr12:64497 8..6450537-chr12:115121 89..115122116
chr12:6493661..6494494-chr12:122240808..1222 137
chr12:6579825..6580446-chr12:49 60124..49760909
chr12:6601869..6602478-chr12:46766269..4 76 080
chr12:6602062..6602710-chr12:109125071..109125824
chr12:664 0 6644022-chr12:32908375..32 08 95
chr12:6 43355..6 4438 -chr12 1492260 14923704 4
643615 644394 48214539 48215281
chr12:664 729..6644390-chr12:91019 9..9 0 49
chr12:664 935..6644608-chr12:31478666..31479590
chr12:6772065..677265 -chr12:12072 810..120729 29 2
chr12:6862397..6863139 7052529 7053409
chr12:6874875..6875 3 -chr12 706 9270 706 9969 2
chr12: 875174..6875957-chr12:7052816..7053616
chr12: 87552 ..6876463-chr12: 9 276..6977149
chr12:6960258..6961149-chr12:7052438..7053378
chr1 149223193..149223726-chr12:6 76 76..6976 5
r : 287.. 6947- rX 48815259 48815 79
2 976290..6977146-chr12:7205075 ..72051649 2
chr12:6976303..697 166-chr6:34191919..34192632
chr12:6976 52..6977196-chr7:116502411..11 502913
chr12:6976375..6977053-chr7:75987627..7598870 3
chr1:444403 2..44441088 64 2 193
chr 2:69764 4 6977445-chr5:3344080 ..33441840 3
chr12:6976489.. 977354-chr5:1542370 2..154237955
76521 77147 5 323617 1 32362281
76524 77040 20 60640685 60641621
chr12:6976553..6977445-chr12:1207 9222..12072988
2: 9766 9 6977 64-chr2:11484024..114 4907
chr1 :62609048 2609718-chr12:6976672..6 77575 3
chr12:6976691..6977203-chr12:7 5288 ..7053 86
chr1: 343794..2344714 76715 772 5
chr12:6976800..6977302-chr2:204103594..204104123,2
chr1:150533875..150534761-chr12:6977016..6977548,2
chr11:33182020..33182621-chr12:6977125..6977668,2
chr11:45201626..45202272-chr12:6978913..6979896,2
chr12:6980464..6981299-chr2:159825466..159826422,2
chr12:6980793..6981654-chr18:12376730..12377450,2
chr12:6980841..6981343-chr12:13254416..13255272,2
chr1:16532808..16533374-chr12:6981026..6981539,2
chr12:6981553..6982066-chr5:34929986..34930910,2
chr12:6981832..6982808-chr2:231280454..231281321,2
chr11:65270221..65271153-chr12:6982207..6982874,2
GM12878 c yc Pk
GM12878 T F Pk
GM12878 ol2 Pk
H1-hESC cMyc Pk
H1-hESC CTCF Pk
H1-hESC Pol2 Pk
K562 cMyc Pk
K562 CTCF Pk
K562 Pol2 Pk
GM12878 EZH2
GM12878 H3K4
GM12878 H3K9ac
GM12878 H3K9 3
GM12878 H3K27ac
GM 2878 H3K27m3
GM 2878 H3K36
GM12878
GM12878
H1-hESC EZH
-  3K9ac
1-h  H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
H1-hESC HDAC2
 HDAC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
H1-hESC PHF8
H1-hESC RBBP5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ1
K562 EZH2
 3K9ac
K562 H3K9m3
K562 H3K9m1
K562 H3K79m2
K562 H4K20m1
K562 HDAC1
K562 HDAC2
K562 HDAC6
LSD1
562 NCoR
K562 NSD
K562 P300
PCAF
PH 8
K562 PLU1
K562 Pol2
K562 RBBP5
K562 REST
K562 RNF2
K562 SAP30
K562 SETDB1
K562 SIRT6
K562 SUZ12
DNase Clusters
GM12878 DNase
H1-hESC DNase
K562 DNase
HUVEC DNase
HeLa-S3 DNase
ep 2 DNase
A549 DNase
CD20+ DNase
MCF-7 DNase
Mcyte-CD14+ DNase
NHEK DNase
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
ep 2 3K4m1
HepG2 H3K4 2
HepG2 H3K4
HepG2 H3K9ac
HepG2 H3K9 3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
Sequences
SNPs
Genes
Bands
5 kb hg19
6,974,000 6,975,000 6,976,000 6,977,000 6,978,000 6,979,000 6,980,000 6,981,000 6,982,000 6,983,000
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Transcription Levels Assayed by RNA-seq on 9 Cell Lines from ENCODE
H3K27Ac Mark (Often Found Near Active Regulatory Elements) on 7 cell lines from ENCODE
Transcription Factor ChIP-seq from ENCODE
Chromatin State Segmentation by HMM from ENCODE/Broad
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Histone Modifications by ChIP-seq from ENCODE/Stanford/Yale/USC/Harvard
Histone Modifications by ChIP-seq from ENCODE/University of Washington
CpG Islands (Islands < 300 Bases are Light Green)
K562 CTCF ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 CTCF ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
Open Chromatin TFBS by ChIP-seq from ENCODE/Open Chrom(UT Austin)
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
DNaseI Hypersensitivity Uniform Peaks from ENCODE/Analysis
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Publications: Sequences in scientific articles
USP5
USP5
TPI1
TPI1
SPSB2
SPSB2
RRPL13L
K
K
H
G
GK
HK
Kgn
G
G
Gg
1HLK
L
G1HLUaegghgmpgggggghmmnpr
G1
K
H
G1HKgg
K
G1gs
G1Kggh
LK
GLK
K
Gg
Gg
g
h
K
H
G
1
1
G
Gm
Hm
LK
gh
K
GK
K
K
G
H
K
t
G1hKnnnnos fgmmmpaaaaabgggggghhhhhhh
G
1Hag
G1HLhhhUKnnnnoaas fgmmmpaaaaabcggggggghhhhhhhhsw
GH
h
G
1 t
G
K
G1HLKs
a
1
t
a
1HLaeggmpggpr
K
1gg
a
G1Kggh
K
H
HK
t
H
a
g
g
Haegghgmpgggghmmnr
G1gh
G1HLhhhUKnnnnoaas fg
H
K
K
K
Ls
G1K
1
h
K
1 t
GK
H
G
1
G
1aa
G
Un
mmn
Gg
G1LK
HK
s
K
L
L
Laegggpgg
L
G
LK
GKh
1Kg
Hm
G
G
1
GLK
GHK
K
g
K
K
G1LK
K
L
G
GK
K
1
1K
K
H
K
H
1H
G
GM12878 ln(x+1) 4 _
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1) 4 _
0 _
HSMM ln(x+1) 4 _
0 _
HUVEC ln(x+1) 4 _
0 _
K562 ln(x+1) 4 _
0 _
NHEK ln(x+1) 4 _
0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC
H1-hESC
H1-hESC
H1-hESC
H1-hESC
H1-hESC
K562 CTCF
K562 H3K4m
K562 H3K4m
K562 H3K27
K562 H3K27m
K562 36m3
K562 H3K4me1
K562 H3K4
K562 H3K9ac
K562 H3K27
NT2-D1 H3K4 1
NT2-D1 H3K4me3
NT2-D1 H K9ac
NT2-D1 H3K27me3
NT2-D1 H3K 6me3
U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4 Sg
GM78 H3K4 Sg
GM78 H3K27 3 Sg
GM78 H3K27 3 Sg
GM78 3K36 3 Sg
GM78 3K36 3 Sg
GM78 In Sg 1
K562 H3K4 Sg
K562 H3K4 Sg
K562 H3K27M3 Sg 1
K562 H3K27M3 Sg 2
K562 H3K36M3 Sg 1
K562 H3K36M3 Sg 2
K562 In Sg 1
K5 2 CTCF Sig 1
30 _
0 _
K562 Pol2 Sig 1
30 _
0 _
HeLaS3 Pol2 Sig 1
30 _
0 _
GM12878 D
GM12878 cMyc OS
GM12878 D
GM12878 TCF OS
GM12878 D
GM12878 Pol2 OS
GM12878 Input
H1-hESC cMyc DS
H1-hESC cMyc O
H1-hESC CTCF DS
H1-hESC CTCF O
H1-hESC Pol2
H1-hESC Pol2 OS
K562 cMyc DS
K562 cMyc OS
K562 CTCF DS
K562 CTCF OS
K562 Pol2 DS
K562 Pol  OS
K562 Input DS
GM12878 EZH2
GM12878 H3K4 3
GM12878 H3K9ac
GM12878 H3K9m3
GM 2878 H3K27
GM 2878 H3K27
GM12878 36 3
GM12878 3 79 2
GM12878 H4K20m1
H1-hESC EZH2
H1-hESC H3K9ac
-  H3K9m3
H1-hESC H3K79m2
H1-hESC H4K20m1
 HDAC2
H1-hESC HDAC6
H1-hESC JAR D1A
H1-hESC JMJD2A
H1-hESC P300
H1-hESC PHF8
H1-hESC RBBP5
H1-hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ12
K562 EZH2
 3K9ac
K562 H3K9m3
K562 H3K9m
K562 H3K79m2
K562 H4K20m1
K562 HDAC1
K562 HDAC2
K562 HDAC6
LSD
K562 NC R
K562 NSD2
K562 P300
PCAF
K562 PHF8
K562 PLU
K562 Pol2
 RBBP5
K562 REST
K562 RNF2
K562 SAP30
K562 SETDB1
K562 SIRT6
K562 SUZ12
HepG2 CTCF
HepG2 EZH2
HepG2 H A.Z
HepG2 H3K4 1
HepG2 H3K4 2
HepG2 H3K4 3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
chr12:
ZBTB7A_(SC-34508)
Egr-1
Ini1
EBF1_(C-8)
ETS1
GTF2F1_(RAP-74)
YY1
Nrf1
PAX5-N19
PAX5-C20
TBP
TR4
Pol2
SP1
GTF2B
HA-E2F1
TAF1
Pol2(b)
YY1_(C-20)
Pol2-4H8
HEY1
ELF1_(SC-631)
TAL1_(SC-12984)
Oct-2
POU2F2
NFKB
NRSF
NELFe
Pol2(phosphoS2)
MEF2A
TAF7_(SQ-8)
BCL3
TCF12
c-Myc
HA-E2F1
HEY1
Pol2-4H8
CCNT2
Egr-1
E2F6
E2F6_(H-50)
Nrf1
Ini1
Pol2(b)
ZNF263
CTCF
CTCF_(C-20)
Pol2
CTCF
SMC3_(ab9263)
Pol2-4H8
Znf143_(16618-1-AP)
CTCF_(SC-5916)
CTCF_(C-20)
CTCFL_(SC-98982)
Rad21
Pol2
SP1
CTCF_(SC-5916)
Pol2
Pol2
Pol2(b)
Pol2-4H8
GR
Pol2-4H8
IRF1
TAF1
Pol2(b)
ZNF263
Pol2(phosphoS2)
USF-1
Oct-2
POU2F2
Pol2
Pol2-4H8
CTCF
Ini1
ZBTB7A_(SC-34508)
CCNT2
IRF1
BCL3
Rad21
SP1
GABP
TCF4
ETS1
CTCF_(SC-5916)
Oct-2
POU2F2
Egr-1
SMC3_(ab9263)
YY1_(C-20)
NANOG_(SC-33759)
Znf143_(16618-1-AP)
USF-1
CTCF_(C-20)
Max
c-Myc
PAX5-C20
Sin3Ak-20
Mxi1_(bHLH)
USF1_(SC-8983)
CTCFL_(SC-98982)
HNF4A_(H-171)
HEY1
Pol2
CHD2_(N-1250)
Sin3Ak-20
HEY1
Pol2-4H8
TAF1
HA-E2F1
Oct-2
POU2F2
TAF7_(SQ-8)
ELF1_(SC-631)
GABP
THAP1_(SC-98174)
PU.1
IRF1
HMGN3
SP1
TBP
HDAC2_(SC-6296)
PAX5-N19
Egr-1
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HepG2 ln(x+1) 4 _
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HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
chr12:
ZBTB7A_(SC-34508)
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GM78 H3K27M3 Pk 2
GM78 H3K36M3 Ht 1
GM78 H3K36M3 k 1
GM78 H3K36M3 Ht 2
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HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
Sequences
SNPs
Genes
Bands
5 kb hg19
6,974,000 6,975,000 6,976,000 6,977,000 6,978,000 6,979,000 6,980,000 6,981,000 6,982,000 6,983,000
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & C mparative Gen ics)
Transcription Levels Assayed by RNA-seq on 9 Cell Lines from ENCODE
H3K27Ac Mark (Often Found Near Active Regulatory Elements) on 7 cell lines from ENCODE
Transcription Factor ChIP-seq from ENCODE
Chromatin State Segmentati n by HMM from ENCODE/Broad
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Histone Modifications by ChIP-seq from ENCODE/Stanford/Yale/USC/Harvard
Histone Modifications by ChIP-seq from ENCODE/University of Washington
CpG Islands (Islands < 300 Bases are Light Green)
K562 CTCF ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 CTCF ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
K562 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Interactions Rep 1 from ENCODE/GIS-Ruan
HeLa-S3 Pol2 ChIA-PET Signal Rep 1 from ENCODE/GIS-Ruan
Open Chromatin TFBS by ChIP-seq from ENCODE/Open Chrom(UT Austin)
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
Digital DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE
DNaseI Hypersensitivity Uniform Peaks from ENCODE/Analysis
Histone Modifications by ChIP-seq from ENCODE/Broad Institute
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GM12878 ln(x+1) 4 _
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1) 4 _
0 _
HSMM ln(x+1) 4 _
0 _
HUVEC ln(x+1) 4 _
0 _
K562 ln(x+1) 4 _
0 _
NHEK ln(x+1) 4 _
0 _
NHLF ln(x+1) 4 _
0 _
Layered H3K27Ac
100 _
0 _
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H3K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
K562 H3K9ac
K562 H3K27me3
NT2-D1 H3K4me1
NT2-D1 H3K4me3
NT2-D1 H3K9ac
NT2-D1 H3K27me3
NT2-D1 H3K36me3
U2OS H3K9me3
U2OS H3K36me3
GM78 H3K4M3 g 1
GM78 H3K4M3 Sg 2
GM 8 H3K27M3 Sg 1
GM78 H3K27M3 Sg 2
GM78 H3K36M3 Sg 1
GM78 H3K36M3 Sg 2
GM78 In Sg 1
K562 H3K4M3 Sg 1
K562 H3K4M3 Sg 2
K562 H3K27M3 Sg 1
K562 H3K27M3 Sg 2
K562 H3K36M3 Sg 1
K562 H3K36M3 Sg 2
K562 In Sg 1
K562 CTCF ig 1
30 _
0 _
K562 Pol2 Sig 1
30 _
0 _
HeLaS3 Pol2 Sig 1
3  
0 _
12878 cMyc DS
12878 cMyc OS
12878 CTCF DS
12878 CTCF OS
GM12878 Pol2 DS
GM12878 Pol2 OS
GM12878 Input DS
H1-hESC cMyc DS
H1-hESC cMyc OS
H1-hESC CTCF DS
H1-hESC TCF OS
1-h  Pol2 DS
1-h  Pol2 OS
K562 cMyc DS
K562 cMyc OS
K562 TCF DS
K562 TCF OS
K562 Pol2 DS
K562 Pol2 OS
K562 Input DS
GM12878 EZH
GM 28 8 H3K4m3
GM12878 H3K9ac
GM12 78 H3K9m3
GM12878 H3K27ac
GM12878 H3K27m3
GM12878 H3K36m3
GM1 878 H K79m
GM12878 H K 0m1
H1-hESC EZH
H1-hESC H3K9ac
H1-hESC H3K9m3
H1-hESC H K79m
H1-hESC H K20m1
H1-hESC HDAC
H1-hESC HDAC6
H1-hESC JARID1A
H1-hESC JMJD2A
H1-hESC P300
H1-hESC PHF8
H1-hESC RBBP5
H -hESC SAP30
H1-hESC SIRT6
H1-hESC SUZ1
K562 EZH
K562 H3K9ac
K56  H3K9m
K 62 H3K9m1
K5 2 H3K7 m
K562 H4K20m1
K562 HDAC1
K5 2 HDAC
K56  HDAC6
K562 LSD1
K562 NCoR
K56  NSD
K562 P300
K562 PCAF
K56  PHF8
K56 PLU1
K562 Pol2
K562 RBBP5
K562 REST
K562 RNF2
K562 SAP30
K56 SETDB1
K562 SIRT6
K562 SUZ12
HepG2 CTCF
HepG2 EZH2
HepG2 H2A.Z
HepG2 H3K4m1
HepG2 H3K4m2
HepG2 H3K4m3
HepG2 H3K9ac
HepG2 H3K9m3
HepG2 H3K27ac
HepG2 H3K27m3
HepG2 H3K36m3
HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
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ZBTB7A_(SC-34508)
Egr-1
Ini1
EBF1_(C-8)
ETS1
GTF2F1_(RAP-74)
YY1
Nrf1
PAX5-N19
PAX5-C20
TBP
TR4
Pol2
SP1
GTF2B
HA-E2F1
TAF1
Pol2(b)
YY1_(C-20)
Pol2-4H8
HEY1
ELF1_(SC-631)
TAL1_(SC-12984)
Oct-2
POU2F2
NFKB
NRSF
NELFe
Pol2(phosphoS2)
MEF2A
TAF7_(SQ-8)
BCL3
TCF12
c-Myc
HA-E2F1
HEY1
Pol2-4H8
CCNT2
Egr-1
E2F6
E2F6_(H-50)
Nrf1
Ini1
Pol2(b)
ZNF263
CTCF
CTCF_(C-20)
Pol2
CTCF
SMC3_(ab9263)
Pol2-4H8
Znf143_(16618-1-AP)
CTCF_(SC-5916)
CTCF_(C-20)
CTCFL_(SC-98982)
Rad21
Pol2
SP1
CTCF_(SC-5916)
Pol2
Pol2
Pol2(b)
Pol2-4H8
GR
Pol2-4H8
IRF1
TAF1
Pol2(b)
ZNF263
Pol2(phosphoS2)
USF-1
Oct-2
POU2F2
Pol2
Pol2-4H8
CTCF
Ini1
ZBTB7A_(SC-34508)
CCNT2
IRF1
BCL3
Rad21
SP1
GABP
TCF4
ETS1
CTCF_(SC-5916)
Oct-2
POU2F2
Egr-1
SMC3_(ab9263)
YY1_(C-20)
NANOG_(SC-33759)
Znf143_(16618-1-AP)
USF-1
CTCF_(C-20)
Max
c-Myc
PAX5-C20
Sin3Ak-20
Mxi1_(bHLH)
USF1_(SC-8983)
CTCFL_(SC-98982)
HNF4A_(H-171)
HEY1
Pol2
CHD2_(N-1250)
Sin3Ak-20
HEY1
Pol2-4H8
TAF1
HA-E2F1
Oct-2
POU2F2
TAF7_(SQ-8)
ELF1_(SC-631)
GABP
THAP1_(SC-98174)
PU.1
IRF1
HMGN3
SP1
TBP
HDAC2_(SC-6296)
PAX5-N19
Egr-1
CCNT2
NANOG_(SC-33759)
BCL3
ZBTB7A_(SC-34508)
AP-2alpha
Sin3Ak-20
AP-2gamma
JunD
EBF1_(C-8)
GM12878 ChromHMM
H1-hESC ChromHMM
K562 ChromHMM
HepG2 ChromHMM
HUVEC ChromHMM
HMEC ChromHMM
HSMM ChromHMM
NHEK ChromHMM
NHLF ChromHMM
H1-hESC CTCF
H1-hESC H3K4m1
H1-hESC H K4m3
H1-hESC H3K27ac
H1-hESC H3K27m3
H1-hESC H3K36m3
K562 CTCF
K562 H3K4m1
K562 H3K4m3
K562 H3K27ac
K562 H3K27m3
K562 H3K36m3
K562 H3K4me1
K562 H3K4me3
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GM78 H3K4M3 Ht 1
GM78 H3K4M3 Pk 1
GM78 H3K4M3 Ht 
GM78 H3K4M3 Pk 2
GM78 H3K27M3 Ht 
GM78 H3K27M3 Pk 
GM78 H3K27M3 Ht 2
GM78 H3K27M3 Pk 2
GM78 H3K36M3 Ht 1
GM78 H3K36M3 Pk 1
GM78 H3K36M3 Ht 
GM78 H3K36M3 Pk 2
K562 H3K4M3 Ht 1
K562 H3K4M3 Pk 1
K562 H3K4M3 Ht 2
K562 H3K4M3 Pk 
K562 H3K27M3 Ht 
K562 H3K27M3 Pk 
K562 H3K27M3 Ht 
K562 H3K27M3 Pk 2
K562 H3K3 M3 Ht 1
K562 H3K36M3 Pk 
K562 H3K36M3 Ht 2
K562 H3K36M3 Pk 2
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UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
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GM12878 ln(x+1) 4 _
0 _
H1-hESC ln(x+1) 4 _
0 _
HeLa-S3 ln(x+1) 4 _
0 _
HepG2 ln(x+1) 4 _
0 _
HSMM ln(x+1) 4 _
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HUVEC ln(x+1) 4 _
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GM78 H3K4M3 Sg 2
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GM78 H3K27M3 Sg 2
GM78 H3K36M3 Sg 1
GM78 H3K36M3 Sg 2
GM78 In Sg 1
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K562 H3K4M3 Sg 2
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HepG2 H3K79m2
HepG2 H4K20m1
HepG2 Input
Scale
chr12:
ZBTB7A_(SC-34508)
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Figure 5-3 Transcriptional and epigenetic landscape of the TPI promoter based 
on the ENCODE project. Schema obtained from the ENCODE project via the 
UCSC genome browser, showing the TPI gene. Its promoter region is boxed in red. 
The expression of the housekeeping gene is shown in 9 different cell lines. The 
enrichment for positive and negative chromatin marks is shown, as well as the 
enrichment for HATs (p300, PCAF), HDACs (HDAC1, 2 and 6) and Sp1 (indicated 
with arrow) at baseline. 
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5.3 The role of NEMO in the G6PD selective upregulation 
Having established the G6PD-selective effect of HDACIs on the genes of the 
GPPP and taking into account the main structural difference between G6PD and the 
other genes is that it shares a bidirectional promoter with NEMO, I sought to 
understand the role NEMO might have in the upregulation of G6PD. I hypothesised 
that NEMO might be a target of NaBu and therefore might be upregulated whilst also 
driving the upregulation of G6PD. 
Normal and G6PD deficient cell lines were treated with NaBu at a time course 
of 8h, 16h, 24h and 36h and were tested for NEMO mRNA expression with RT-qPCR. 
Figure 5-4A shows that NEMO expression is not affected by NaBu in cell lines. 
Furthermore, CB-CD34+-differentiating erythroid cells were produced as described in 
4.2 and were treated with NaBu at the fifth day of the culture for 48h. In this case, 
RT-qPCR analysis (Figure 5-4B) confirmed that NEMO is stably expressed in the 
presence of NaBu. I therefore concluded that the G6PD-selective upregulation is not 
driven by NEMO. 
 
 
Figure 5-4 NEMO mRNA expression upon NaBu treatment. RT-qPCR was 
employed to assess NEMO mRNA expression in (A) WT and G6PD deficient cell 
lines at a time course of 3mM NaBu treatment as well as in (B) CB-CD34+-
differentiating erythroid cells after 1mM NaBu treatment for 48h. In both cases, 
NEMO expression remains unaffected. Mean and S.E.M. are shown for n=3. 
Student’s t-test was performed to compare the untreated to the treated conditions. 
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5.4 Epigenetic status of the GPPP promoters 
To gain insights into the transcriptional and epigenetic basis of the selective 
responsiveness of G6PD to HDACIs, I assessed the levels of histone acetylation, a 
modification that is associated with transcriptional activation at the promoters of 
genes of the GPPP. For this purpose I employed ChIP assays using four sets of G6PD 
ChIP primers (Table 2-11 and Figure 5-5), designed to span the full length of the 
G6PD promoter including a primer pair that amplifies part of the core promoter 
(primer set 2). Furthermore, these modifications were tested in other genes of the 
GPPP, particularly TPI, GPI, PGLS and RPIA for which I designed primers to 
amplify regions within their core promoters (Table 2-11). 
 
Figure 5-5 ChIP primers on the G6PD promoter. Schematic representation of the 4 
sets of the primers used for ChIP analysis of G6PD. 
 
Figure 5-6 shows that in WT B cell lines there are increased levels of H3 and 
H4 acetylation in the core promoters of all GPPP genes at baseline, consistent with 
their status as active, housekeeping genes. However, histone hyper-acetylation in 
response to NaBu is only observed in G6PD and in none of the other GPPP genes and 
was evident as early as 1 hr post NaBu treatment (Figure 5-6). Similarly, in G6PD 
deficient B cells (Figure 5-7), NaBu treatment leads to histone hyper-acetylation of 
G6PD but not of any other genes of the GPPP tested, i.e TPI, GPI, PGLS, RPIA and 
GAPDH. GAPDH is also used here as a positive control for acetylation at baseline. As 
a negative control I have used primers against an intergenic region (GW10). Figure 
5-8 shows acetylation levels at baseline for G6PD and other GPPP gene promoters. In 
this figure, since I am not showing the enrichment relative to the untreated, it is clear 
that the negative control GW10 is indeed negative. 
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Figure 5-6. Histone acetylation of GPPP gene promoters in WT cells. (A) Histone 
3 and (B) histone 4 acetylation assessed by ChIP in the WT B cell line P277 at a time 
course NaBu treatment of 1h, 5h and 24h. Enrichment on the promoters is calculated 
as % of input relative to the untreated for each primer set. GAPDH is used as a 
positive control for enrichment and GW10 is the negative control for acetylation at 
baseline. Immunoprecipitation against IgG is employed to set the enrichment 
background. Mean and S.E.M. are shown for n=3. Student’s t-test was performed to 
compare the untreated to the treated conditions. 
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Figure 5-7 Histone acetylation of GPPP gene promoters in G6PD deficient cells. 
(A) Histone 3 and (B) histone 4 acetylation assessed by ChIP in the G6PD deficient B 
cell line P7 at a time course NaBu treatment of 1h, 5h and 24h. Enrichment on the 
promoters is calculated as % of input relative to the untreated for each primer set. 
GAPDH is used as a positive control for enrichment and GW10 is the negative control 
for acetylation at baseline. Immunoprecipitation against IgG is employed to set the 
enrichment background. Mean and S.E.M. are shown for n=3. Student’s t-test was 
performed to compare the untreated to the treated conditions. 
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Figure 5-8 Acetylation levels on the GPPP gene promoters at baseline. H3 and H4 
acetylation assessed by ChIP on the promoters of G6PD and other GPPP genes (TPI, 
GPI, RPIA and PGLS). Baseline acetylation is shown in the (A) WT B cell line and 
(B) G6PD deficient cell line. Enrichment on the promoters is calculated as % of input. 
GAPDH is used as a positive control for enrichment and GW10 is the negative control 
for acetylation at baseline. Immunoprecipitation against IgG is employed to set the 
enrichment background. Mean and S.E.M. are shown for n=3. 
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activity of HATs and HDACs. Furthermore, baseline binding levels of HATs and 
HDACs on the G6PD promoter are similar to those of other GPPP genes. Therefore it 
cannot be suggested that higher HAT or HDAC binding on the G6PD promoter drives 
its selective transcriptional upregulation. 
Following this, I treated WT B cells with NaBu for 5h, in order to capture the 
early epigenetic events in response to NaBu and performed ChIP to assess the binding 
of HATs (Figure 5-10) and HDACs (Figure 5-11). It is apparent from this data that 
HDAC and HAT occupancy in response to HDAC inhibition was altered only at the 
promoter of G6PD, but not the other GPPP genes that were tested. Whilst HAT 
binding is significantly increased for all 3 HATs tested, HDAC binding increase is 
statistically significant only in the case of HDAC1 and HDAC6. 
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Figure 5-9 HAT and HDAC binding on GPPP gene promoters at baseline. (A) 
HAT and (B) HDAC binding assessed by ChIP in the WT B cell line P277 at baseline 
followed by RT-qPCR using primers amplifying the core promoters of the GPPP 
genes (In the case of G6PD, that is primer set 2 as shown in Figure 5-5). Enrichment 
on the promoters is calculated as % of input. p21 is used as a positive control for 
enrichment and GW10 is the negative control at baseline. Immunoprecipitation 
against IgG is employed to set the enrichment background. Mean and S.E.M. are 
shown for n=3.  
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Figure 5-10 HAT binding on the GPPP gene promoters in WT B cells in the 
presence of NaBu. p300, CBP and GCN5 binding assessed by ChIP in the WT B cell 
line P277 upon 5h NaBu treatment. Enrichment on the promoters is calculated as % of 
input relative to the untreated for each primer set. p21 is used as a positive control for 
enrichment and GW10 is the negative control for binding at baseline. 
Immunoprecipitation against IgG is employed to set the enrichment background. 
Mean and S.E.M. are shown for n=3. Student’s t-test was performed to compare the 
untreated to 5h treatment. 
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Figure 5-11 HDAC binding on the GPPP gene promoters in WT B cells in the 
presence of NaBu. HDAC1, 3, 4/5/7 and 6 binding assessed by ChIP in the WT B 
cell line P277 upon 5h NaBu treatment. Enrichment on the promoters is calculated 
as % of input relative to the untreated for each primer set. p21 is used as a positive 
control for enrichment and GW10 is the negative control for binding at baseline. 
Immunoprecipitation against IgG is employed to set the enrichment background. 
Mean and S.E.M. are shown for n=3. Student’s t-test was performed to compare the 
untreated to 5h treatment. 
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I next determined HAT and HDAC binding on the promoters of GPPP genes 
in G6PD deficient cells in response to NaBu. I therefore treated the G6PD Brighton 
deficient cell line for 5h with NaBu and then immunoprecipitated against the HATs 
p300, CBP and GCN5 as well as the HDACs 1, 3, 4/5/7 and 6. As shown in Figure 
5-12 and Figure 5-13, as with the normal cells, GPPP gene promoters are co-occupied 
by HATs and HDACs at baseline, which would be expected to dynamically regulate 
transcription. HAT binding is significantly upregulated on the G6PD promoter, but 
not any other GPPP gene promoters; HDAC1 and HDAC6 binding is also increased 
on the G6PD promoter, whereas the rest of the HDACs show the same degree of 
binding after treatment. Of note, p21 is a gene that is upregulated upon HDACI 
treatment (Gui et al., 2004) and here shows the same characteristics as G6PD in 
response to NaBu. 
It should be also noted here that because the sonication fragments obtained for 
the purposes of the ChIP assays are between 200-400bp, it is very challenging to 
distinguish binding in regions that are very close to each other; however, it still allows 
us to understand the general binding pattern in the promoter region. Consequently, the 
use of more than one primer pairs top cover the G6PD promoter and this aims at 
getting a better understanding of the features of the promoter as a whole, rather than 
to separately characterise fragments of it. 
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Figure 5-12 HAT binding on the GPPP gene promoters in G6PD deficient B cells 
in the presence of NaBu. p300, CBP and GCN5 binding assessed by ChIP in the 
G6PD deficient B cell line P7 upon 5h NaBu treatment. Enrichment on the promoters 
is calculated as % of input relative to the untreated for each primer set. p21 is used as 
a positive control for enrichment and GW10 is the negative control for binding at 
baseline. Immunoprecipitation against IgG is employed to set the enrichment 
background. Mean and S.E.M. are shown for n=3. Student’s t-test was performed to 
compare the untreated to 5h treatment. 
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Figure 5-13 HDAC binding on the GPPP gene promoters in G6PD deficient B 
cells in the presence of NaBu. HDAC1, 3, 4/5/7 and 6 binding assessed by ChIP in 
the G6PD deficient B cell line P7 upon 5h NaBu treatment. Enrichment on the 
promoters is calculated as % of input relative to the untreated for each primer set. p21 
is used as a positive control for enrichment and GW10 is the negative control for 
binding at baseline. Immunoprecipitation against IgG is employed to set the 
enrichment background. Mean and S.E.M. are shown for n=3. Student’s t-test was 
performed to compare the untreated to 5h treatment. 
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Linking these selective epigenetic events with the increased G6PD mRNA 
levels following HDACI treatment (described in Chapters 3 and 4), I decided to 
investigate polymerase II (PolII) binding. Hence, I employed ChIP analysis and used 
an antibody against the N-terminus of polymerase II in order to capture binding of 
both its transcription initiating and elongating forms.  
ChIP analysis revealed enhancement of PolII binding to the core and wider 
promoter of G6PD, as well as within the gene body (primers GB1 and GB2), an 
increase that was not observed in other GPPP genes (Figure 5-14). This finding 
indicates that amongst genes of the GPPP, the selective increase of G6PD 
transcription in response to HDACIs is underpinned by increased recruitment of 
HATs, HDACs, histone hyper-acetylation and increased PolII recruitment. Figure 
5-15 shows PolII recruitment at baseline for G6PD and other GPPP gene promoters as 
well as the G6PD gene body, which appears to be at similar levels in all genes tested 
in both cell lines. 
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Figure 5-14 Polymerase II binding on the GPPP genes in response to NaBu. 
Polymerase II binding assessed by ChIP in the (A) WT and (B) G6PD deficient B cell 
lines P277 and P7, respectively upon 5h NaBu treatment. Enrichment on the 
promoters is calculated as % of input relative to the untreated for each primer set. 
GAPDH is used as a positive control for enrichment and GW10 is the negative control 
for binding at baseline. Immunoprecipitation against IgG is employed to set the 
enrichment background. Mean and S.E.M. are shown for n=3. Student’s t-test was 
performed to compare the untreated to 5h treatment. 
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Figure 5-15 Polymerase II recruitment on the GPPP gene promoters and G6PD 
gene body at baseline. PolII recruitment assessed by ChIP on the promoters of G6PD 
and other GPPP genes (TPI, GPI, RPIA and PGLS) as well as the G6PD gene body. 
Baseline acetylation is shown in the (A) WT B cell line and (B) G6PD deficient cell 
line. Enrichment on the promoters is calculated as % of input. GAPDH is used as a 
positive control for enrichment and GW10 is the negative control for PolII at baseline. 
Immunoprecipitation against IgG is employed to set the enrichment background. 
Mean and S.E.M. are shown for n=3. 
 
5.5 Sp1 binding on the GPPP promoters 
To test my initial hypothesis that the Sp1-dependent control of histone 
acetylation and transcriptional activation characterised in IGD (Almeida et al., 2006; 
2007; Caputo et al., 2013) can be extended to the genes of the GPPP, I performed 
ChIP analysis to assess Sp1 binding on the GPPP gene promoters upon treatment with 
NaBu. Figure 5-16 shows that Sp1 promoter occupancy is similar amongst all 5 GPPP 
genes tested. However, Figure 5-17 shows that in response to NaBu, Sp1 binding 
increased only at the promoter of G6PD of both normal (Figure 5-17A) and G6PD 
deficient cells (Figure 5-17B). This upregulation in the Sp1 recruitment is G6PD-
specific. These findings suggest that the selective increase in Sp1 binding at the 
G6PD promoter in response to HDACIs is required for transcriptional upregulation of 
G6PD. 
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Figure 5-16 Sp1 recruitment on the GPPP gene promoters at baseline. Sp1 
recruitment assessed by ChIP on the promoters of G6PD and other GPPP genes (TPI, 
GPI, RPIA and PGLS). Baseline acetylation is shown in the (A) WT B cell line and 
(B) G6PD deficient cell line. Enrichment on the promoters is calculated as % of input. 
DHFR is used as a positive control for enrichment and GW10 is the negative control 
for Sp1 binding at baseline. Immunoprecipitation against IgG is employed to set the 
enrichment background. Mean and S.E.M. are shown for n=3. 
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Figure 5-17 Sp1 binding on the GPPP gene promoters in response to NaBu. Sp1 
binding assessed by ChIP in the (A) WT and (B) G6PD deficient B cell lines P277 
and P7, respectively upon 5h NaBu treatment. Enrichment on the promoters is 
calculated as % of input relative to the untreated for each primer set. DHFR is used as 
a positive control for enrichment and GW10 is the negative control for binding at 
baseline. Immunoprecipitation against IgG is employed to set the enrichment 
background. Mean and S.E.M. are shown for n=3. Student’s t-test was performed to 
compare the untreated to 5h treatment. 
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5.6 Conclusions 
In this chapter my aim was to dissect the transcriptional and epigenetic basis 
of the selective responsiveness of G6PD to HDACIs amongst the genes of the GPPP. 
Therefore, I compared the transcriptional and epigenetic status of the G6PD promoter 
to other genes of the GPPP. 
Bioinformatic analysis of the GPPP gene promoters using ENCODE, 
TFsearch and CONSITE databases showed that the G6PD and other GPPP gene 
promoters contain features characteristic of housekeeping genes. Specifically, they are 
highly acetylated on histones 3 and 4, they lack silencing chromatin marks and are co-
occupied by HATs and HDACs indicating that they are dynamically regulated. 
Additionally, all the genes tested showed considerable enrichment for Sp1 binding. 
However, even though Sp1 binding sites are normally abundant on butyrate-
responsive promoters, only G6PD out of the 17 GPPP genes responds to HDACIs by 
transcriptional upregulation. According to the bioinformatics analysis the most 
striking difference between G6PD and the other GPPP gene promoters is the fact that 
G6PD shares a bidirectional promoter with NEMO. Nevertheless, NEMO mRNA 
expression remains unaffected by NaBu treatment. 
ChIP analysis was also employed to determine the epigenetic status of the 
GPPP gene promoters at baseline and in response to NaBu. In agreement with the 
bioinformatics analysis, the ChIP experiments showed high levels of histone 
acetylation and PolII, HAT, HDAC and Sp1 binding at baseline. However, the 
epigenetic status of the G6PD promoter was the only one to change in response to 
HDAC inhibition. Consistent with increased transcription, the G6PD promoter was 
hyper-acetylated in response to NaBu treatment and increased PollII was recruited to 
the promoter and gene body of G6PD. Furthermore, binding of the HATs CBP, p300 
and GCN5 was increased as well as binding of HDAC1 and HDAC6. The selective 
increase of these features underpins the increased transcriptional activity on the G6PD 
promoter. It is interesting to note that HDAC inhibition led to a commensurate 
increase of both HATs and HDACs suggesting that, similar to baseline conditions, 
their dynamic balance is required to sustain increased transcription following HDACI 
treatment. Finally Sp1 binding is selectively increased on the G6PD promoter in 
response to NaBu, suggesting that Sp1 is central to transcriptional upregulation in 
response to HDACIs. This will be further examined in Chapter 6.  
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6.1 Introduction 
It is well known that HDAC inhibition causes widespread histone hyper-
acetylation, yet affects the transcription of only 2-20% of genes (Davie, 2003; 
Mitsiades et al., 2004; Sealy and Chalkley, 1978; Van Lint et al., 1996). Factors that 
determine the number of genes altered in transcription involve the length of exposure, 
the concentration, the type of HDACI and the type of cells used (Peart et al., 2005). 
For example, in one study, it was reported (Daly and Shirazi-Beechey, 2006) that 
butyrate upregulates and downregulates equal number of genes in colonic epithelial 
cells. In line with this observation, another study (Rada-Iglesias et al., 2007) showed 
that as opposed to the global increase in chromatin acetylation, a number of genomic 
regions close to transcription start sites corresponding to genes that were 
downregulated under butyrate exposure, were deacetylated.  
To date, very little is known about the global gene expression of erythroid 
cells upon HDACI treatment. In fact, almost all the genome-wide studies conducted 
so far to evaluate gene expression changes in response to HDACIs involved cell lines 
rather than primary human cells. The sole study that has been conducted in primary 
cells was published by Wang and colleagues (Wang et al., 2008, 2009; 1.1.3), in 
which primary human CD4+ T cells were treated with NaBu and TSA to evaluate 
global chromatin changes and gene expression in response to HDACIs. 
6.1.1 Aim of the chapter 
The aim of this chapter is to identify the genome-wide gene expression 
changes in response to NaBu in primary human erythroblasts. Analysis of the 
promoters of upregulated versus downregulated and stably expressed genes might 
allow identifying genetic and epigenetic features that are responsible for the selective 
upregulation of G6PD amongst all the 17 genes of the GPPP. Furthermore, 
identification of genes of medical interest that are upregulated by NaBu might offer 
new therapeutic opportunities.  
6.1.2 Experimental plan 
To study the impact of HDAC inhibition on global gene expression in primary 
human erythroid cells, I first generated proerythroblasts from CB-CD34+ cells, as 
described in 4.2. These were treated with NaBu and then subjected to gene expression 
profiling (GEP) analysis. The results were compared with other recent genome-wide 
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studies conducted in human primary CD4+ T cells (Wang et al., 2009) and mouse 
pancreatic cell lines (Kubicek et al., 2012) which, were treated with HDACIs. 
Subsequently, de novo motif discovery was performed on the promoters of the 
upregulated versus the downregulated and genes that do not change in order to 
identify the in cis DNA features driving the selective upregulation of specific genes, 
including G6PD. Upon identification of a candidate motif, further transactivation and 
mutagenesis assays were performed to establish its functional importance. 
6.2 Genome-wide implications of HDAC inhibition in primary 
proerythroblasts 
6.2.1 Preparation of samples 
To dissect the genome-wide implications of HDAC inhibition induced by 
NaBu in primary erythroid cells, I performed GEP analysis on CB-CD34+-
differentiating proerythroblasts. Specifically, three independent CB samples were 
processed and CD34+ cells were differentiated down the erythroid lineage as 
described in 4.3.2. At day 5 of the culture (Figure 6-1), flow cytometric analysis was 
employed to identify the stage of differentiation by gating the CD36+ cells and 
assessing CD71 and GlyA staining. For each sample 5x105 out of 10 x105 of the cells 
were treated for 6h with 1mM NaBu and the other half remained in culture untreated. 
Both the untreated and treated cells were then CD36-selected.  
RNA was extracted from the six samples and the RNA quality and integrity 
were assessed using the Nanodrop and the Agilent 2100 Bioanalyser. The Nanodrop 
is used to calculate RNA concentration and the 260/280 purity ratio. Nucleic acids 
and proteins absorb at 260nm and 280nm wavelengths, respectively. Traditionally, a 
ratio of ~2.0 is accepted as “pure” RNA. All six samples (Table 6-1) had acceptable 
260/280 ratios. Furthermore, the Agilent 2100 bioanalyser was used to calculate the 
RNA Integrity Number (RIN) algorithm, which is an additional quality control for 
eukaryotic total RNA. The RIN is calculated based on the fluorescence of the 18S and 
28S rRNA and values equal to 10 indicate intact RNA. As shown in Table 6-1 and 
Figure 6-2, all six samples used for gene expression profiling have RIN equal or 
above 8, which lies within the acceptable range. Importantly, in Figure 6-2B, which 
visualises the samples run in an acrylamide gel, it is shown clearly that all samples are 
of good quality and are not degraded. 
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Figure 6-1 Flow cytometric analysis of samples used for GEP. Three CB-CD34+ 
samples were used and subjected to erythroid differentiation. At day 5 flow cytometry 
assay was performed to assess the stage of differentiation by anti -CD34, -CD36, -
CD71 and -GlyA staining. Each sample was split in half; half of the cells were treated 
for 6h with 1mM NaBu and the other half remained in culture untreated. Both were 
then CD36-selected and the selection purity was again tested by flow cytometric 
analysis. 
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Table 6-1 Quality controls for microarray RNA samples. 
 Nanodrop Bioanalyser 
RNA concentration 
(ng/µl) 
RNA 260/280 
ratio 
RNA integrity 
number 
Sample 1 
untreated 
74.5 2.00 8.00 
Sample 1 
NaBu 
68.6 2.07 8.70 
Sample 2 
untreated 
112.8 1.94 9.60 
Sample 2 
NaBu 
96.7 1.99 9.90 
Sample 3 
untreated 
97 2.00 9.90 
Sample 3 
NaBu 
89 2.17 9.80 
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Figure 6-2 RNA quality controls using the bioanalyser. Plots as taken from the 
Agilent 2100 bioanalyser showing the quality of the RNA used for microarray 
analysis. (A) Graphs represent the fluorescence against time (in seconds) for the 
marker (1st peak), the 18S rRNA (2nd peak) and the 28S rRNA (3rd peak). (B) 
Visualisation of the ladder and samples run on an acrylamide gel.  
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Furthermore, expression of α- and β-globin was tested by RT-qPCR to decide 
whether it was necessary to eliminate the expressed globin before further processing 
the samples. It is common when conducting GEP in erythroid cells to eliminate the 
globin mRNA, as it might interfere with the accuracy of the results due to its very 
high expression at the later stages of erythropoiesis. However, in this set of 
experiments, the erythroid cells obtained at day 5 are early erythroblasts and therefore 
do not yet express high levels of haemoglobin. In Figure 6-3, the Ct values obtained 
by RT-qPCR for the adult α-globin and β-globin are shown in comparison to G6PD 
and GAPDH. Conventionally, the Ct value is the number of cycles for the fluorescent 
signal to cross the threshold cycle and therefore exceed the background levels. Higher 
Ct values correspond to lower expression. The Ct values of α-globin and β-globin 
shown in Figure 6-3 are higher than those of GAPDH indicating that the expression of 
the globin genes at this stage of erythroid differentiation is relatively low thus 
negating the need to remover globin gene mRNA.  
Once the RNA quality was established, 1µg total RNA per sample was used to 
hybridise onto Affymetrix GeneChIP 2.0 ST Arrays in collaboration with Dr. Robert 
Geffers at the Helmholtz Centre for Infection Research, Braunschweig, Germany. 
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Figure 6-3 RT-qPCR analysis of α-globin and β-globin expression in erythroid 
cells of day 5 and day 7. Ct values obtained by RT-qPCR for the expression of α- 
and β-globin in comparison to G6PD and GAPDH. The Ct values of α- and β-globin 
are comparable to G6PD and GAPDH and do not exhibit higher expression that them. 
Mean and S.E.M. are shown for n=3. 
 
6.2.2 Genome expression profiling 
GEP analysis of the microarray data revealed an equal number of upregulated 
versus downregulated genes (Table 6-2; Appendix A and B). Out of 19,137 annotated 
genes, only 607 and 528 genes were found to be significantly upregulated and 
downregulated, respectively. To estimate the number of upregulated and 
downregulated genes statistical significance was set to p≤0.05 and fold change of 
≥1.5 was used as a threshold. Similar to previously reported data (Daly and Shirazi-
Beechey, 2006; Rada-Iglesias et al., 2007; Wang et al., 2009) I found that 3.17% were 
upregulated and 2.76% of genes were downregulated, whereas the majority of genes 
did not show significantly altered expression after 6 hours of NaBu treatment of phase 
1 proerythroblasts. 
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Table 6-2 Number of genes upregulated and downregulated according to GEP 
analysis of microarray data. a 
 Number of genes P value and 
Fold Change 
Percentage 
Upregulated 
genes 
607 p≤0.05 
FC≥1.5 
3.17% 
Downregulated 
genes 
528 p≤0.05 
FC≥1.5 
2.76% 
Total genes 19,137   
a GEP analysis was conducted in human primary proerythroblasts derived from CD-CD34+ 
cells, which were treated for 6h with 1mM NaBu. Out of a total of 19,137 genes, 2,283 and 
2,039 genes were significantly upregulated and downregulated, respectively. 
 
I next utilised the microarray data to analyse the expression of the GPPP genes 
upon NaBu treatment. As I have already shown in 3.3 and 4.4, against my initial 
hypothesis, experiments employing RT-qPCR that were conducted in B cell lines and 
CB-CD34+ - differentiating cells revealed that amongst the 17 genes of the GPPP only 
mRNA levels of G6PD increased in a time-dependent fashion in response to NaBu. 
This finding was confirmed in GEP analysis of proerythroblasts generated from CB- 
CD34+ cells that were treated with 1mM NaBu for 6h (Figure 6-4A). Out of 17 genes 
of the GPPP, microarray analysis showed that only G6PD is significantly upregulated 
1.6-fold post-treatment. This finding was also confirmed by bioinfomatic analysis I 
conducted on previously published data by Wang and colleagues (Wang et al., 2009), 
who treated primary human CD4+ T cells with a combination of 100ng/ml TSA and 
2mM NaBu for 12 hours (Figure 6-4B).  These expression data sets can be found in 
the GEO database under the accession number GSE15735 (Wang et al., 2009). I next 
performed bioinfomatic analysis on data published by Kubicek and colleagues 
(Kubicek et al., 2012), who treated the mouse pancreatic cell line a-TC1 with either 
1.3µM SAHA, or 0.015µM panobinostat or 0.22µM TSA for 6h and then performed 
Affymetrix microarray gene expression analysis (Figure 6-4C). Figure 6-4C shows 
that even in mouse cells, G6pdx expression significantly is upregulated upon SAHA 
and panobinostat treatment. However, in mice the expression of Hk1, Bpgm, Pklr, 
Pgd and Taldo1 is also upregulated in the presence of certain HDACIs. 
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Figure 6-4 GEP analysis of the GPPP genes upon HDACI treatment. (A) Fold 
change in mRNA expression of GPPP genes shown by GEP analysis of microarray 
data generated from CB-CD34+-differentiating proerythroblasts after 6h treatment 
with 1mM NaBu. (B) Bioinformatic analysis on data published by Wang et al., 2008. 
CD4+ T cells were treated with 100ng/ml TSA and 2mM NaBu for 12h. Fold change 
in mRNA expression of GPPP genes is shown. (C) Bioinformatic analysis on data 
published by Kubicek et al., 2012. Mice pancreatic cell lines were treated with 1.3µM 
SAHA, 0.015µM Panobinostat and 0.22µM TSA for 6h. Fold change in mRNA 
expression of GPPP genes is shown. Mean and S.E.M. are shown for n=3 independent 
microarray experiments. One-way ANOVA has been performed to compare the pre- 
and the post- treatment values. 
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I next aimed to use the microarray data I generated from primary human 
proerythroblats to identify factors that selectively drive upregulation or 
downregulation of specific genes, such as G6PD amongst the GPPP genes. For this 
purpose, I first compared the baseline expression of the genes that were significantly 
upregulated and downregulated (as described in Table 6-2) as well as of 2,000 more 
stably expressed genes after the treatment with NaBu. As shown in Figure 6-5A, the 
baseline expression of genes that are upregulated by NaBu is lower than the baseline 
expression of the genes that are downregulated. This could explain why some genes 
have the potential to further increase their expression as opposed to other genes, albeit 
the genes that are unaffected display the lower baseline expression. This interesting 
finding is confirmed by also analyzing the baseline expression in CD4+ T cells 
(Figure 6-5B).  
 
 
Figure 6-5 Baseline mRNA expression of upregulated versus downregulated 
genes. Box and whisker plots of data obtained from GEP analysis of (A) CB-CD34+-
differentiating proerythroblasts (p<0.0001 for comparisons between UP vs DOWN, 
UP vs NO, UP vs MEDIAN, DOWN vs NO, DOWN vs MEDIAN and NO vs 
MEDIAN) and (B) CD4+ T cells (Wang et al., 2008; p<0.001 for comparisons 
between UP vs DOWN, UP vs NO, UP vs MEDIAN, DOWN vs NO, DOWN vs 
MEDIAN and NO vs MEDIAN). Boxes are shown for the upregulated (UP, 
n=14.25%; FC≥1.5, p≤0.05) and downregulated genes (DOWN, n=12.25%; FC≥1.5, 
p≤0.05), as well as 2,000 genes that remain the most unaffected (NO) by HDACI 
treatment. The median value represents the middle value. One-way ANOVA has been 
performed. 
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Furthermore, to search for in cis DNA elements that determine increased 
transcription in response to HDACIs, I performed de novo motif discovery using 
MEME Suite, a motif-based sequence analysis tool (http://meme.nbcr.net/meme/). 
For this purpose, I compared the promoter sequences of the 50 top ranked in fold 
change genes from my microarray data, i.e. those that were the most upregulated, 
including G6PD, the 50 lower ranked genes, i.e. those that were most dramatically 
dowregulated and finally 50 mid ranged genes that were identified to be the most 
stably expressed ones. This analysis identified two motifs that are highly enriched in 
the overexpressed but not in the other 2 groups of genes (Figure 6-6). Interestingly, 
one of the two motifs (Figure 6-6B) corresponds to a bona fide Sp1 binding sequence 
(Sp1 binding sequences are 5’-G/T-GGGCGG-G/A-G/A-C/T-3’ or 5’G/T-G/A-
GGCG-G/T-G/A-G/A-C/T-3’ as mentioned in 1.1.4.2). 
 
 
Figure 6-6 Motifs on the promoters of the genes that are responsive to HDAC 
inhibition. MEME Suite analysis was performed on the promoters of genes that are 
upregulated versus those that are downregulated or stably expressed upon NaBu 
treatment in primary human proerythroblasts. Motifs (A) and (B) are present on the 
promoter of genes that are upregulated with the latter corresponding to a bona fide 
Sp1 binding sequence. According to MEME instructions “the height of the motif 
block is proportional to –log(p value), truncated at the height for a motif with a p 
value of 1e-10 ”. Here, p= 8.72e-09 for motif A and p=3.17e-07 for motif B.  
 
The G6PD promoter has been shown to have 12 putative binding sites for the 
transcription factor Sp1 within its 1327bp-long wider promoter region, two of which 
have been previously validated (1.4.3.1 and Figure 1-12; Franzè et al., 1998; Fusco et 
al., 2006; Galgoczy et al., 2001; Philippe et al., 1994). In addition, I have already 
shown (6.3 and Figure 5-17) that NaBu selectively increases the binding of Sp1 on the 
G6PD promoter amongst other GPPP genes, which suggests a potential role of Sp1 in 
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the selective upregulation of G6PD expression. Taking this information along with 
the fact that Sp1 binding sites are key components of some butyrate-responsive 
elements, I decided to focus the next part of my research on defining the role of Sp1 
on the NaBu effect.  
6.3 The role of Sp1 in the regulation of G6PD transcription 
6.3.1 Transcriptional activity of G6PD promoter 
I next aimed to assess the importance of Sp1 in the selective effect of HDACIs 
on transcriptional upregulation of G6PD. To determine the significance of core, 
proximal and distal promoter in the transcriptional activity of G6PD, I performed 
reporter assays with amplified regions of the promoter. For this purpose, I amplified 
(Table 2-12 and Figure 2-3) promoter fragments of increasing length (Figure 6-7A), 
which were used to transfect 293T cells and measure luciferase activity of promoter 
regions using the approach described in 2.11. Prior to measurement, the cells were 
treated for 24h with 3mM NaBu or PBS. In a separate set of experiments I established 
that the treatment of 293T cells with 3mM NaBu for 24h is sufficient to significantly 
increase G6PD mRNA expression (Figure 6-8).  
Measurement of luciferase activity driven by the amplified G6PD promoter 
fragments revealed that both at baseline and post- NaBu treatment, G6PD promoter 
activity is dependent on a 562bp promoter fragment. As shown in Figure 6-7B, 
constructs 4 and 5 showed the highest activity both at baseline and after treatment. On 
the contrary, constructs 1, 2 and 3 did not show any activity implying the promoter 
sequences they contain are not important for G6PD transcription. Construct 6 showed 
similar activity to construct 5, which indicates that the additional upstream DNA 
sequence included in construct 6 is dispensable for transcriptional control of G6PD in 
vitro. The 562bp promoter region that appears to be crucial for G6PD promoter 
activity contains 7 potential Sp1 bindings sites, including the 2 previously validated 
Sp1 binding motifs (Figure 6-7A, B). 
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Figure 6-7 Reporter assay to determine the promoter activity potential of G6PD. 
(A) Representation of the wider G6PD promoter B, spanning between G6PD exon 2 
and NEMO exon 1B. The core promoter is also highlighted. In blue are the predicted 
Sp1 binding sites and marked with an asterisk are the two previously validated sites. 
The common reverse (R) and the different forward (F1-6) primers that were used to 
amplify six increasing in length parts of the promoter. (C) Plasmid constructs 
containing promoter fragments were transfected into 293T cells and luciferase activity 
driven by these promoter parts was measured at baseline and upon 3mM NaBu 
treatment for 24h. Activity is normalised against pGL3 basic (without insert) and is 
shown relative to the baseline levels of the long fragment (6). Boxed in red is the 
562bp fragment that appears to be responsible for baseline and upon HDACI activity.  
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Figure 6-8 G6PD mRNA expression in 293T cells.  RT-qPCR performed on 293T 
cells upon treatment with 1mM, 3mM and 5mM NaBu for 24h. Fold expression is 
shown. Mean and S.E.M. are shown for n=3 experiments. Student’s t-test has been 
performed to compare untreated with treated values normalised to β-actin. 
 
6.3.2 Dependence of the G6PD transcriptional activity on Sp1 
I next proceeded to confirm the functional importance of the Sp1 motifs that 
are contained in the 562bp promoter region in the regulation of baseline G6PD 
activity and its enhancement following NaBu treatment (Figure 6-9A). For this 
purpose, I mutagenized the Sp1 motifs on the G6PD promoter region of interest. 
For the mutagenesis assays, I utilised construct 5, which was generated for the 
reporter assay described above and also contains the 562bp responsive G6PD 
promoter region. Using pGL3-Fr5 as a template, I separately mutagenised each one of 
the 7 Sp1 binding sites (Figure 6-9A) as described in 2.12. After the mutated plasmid 
constructs were confirmed by DNA sequencing analysis, they were transfected into 
293T cells followed by luciferase activity measurement 48h later. Prior to 
measurement, the cells were treated for 24h with 3mM NaBu or PBS control. 
 
Untreated 1mM 3mM 5mM
0
1
2
3
4
NaBu treatment 
Fo
ld
 c
ha
ng
e 
in
G
6P
D
 m
R
N
A
 e
xp
re
ss
io
n
* *
  196 
 
Figure 6-9 Mutagenesis of Sp1 binding sites. (A) Schematic representation of the 
promoter region of G6PD. Boxed in red is the 562bp region responsible for baseline 
and post-treatment activity. R and F5 are the primers that were previously used to 
amplify and clone the promoter region containing the 562bp region into a pGL3-basic 
vector and create construct 5. Numbered 1-7 are the Sp1 binding sites that are 
included in the 562bp promoter region. (B) Luciferase assay conducted on 293T cells 
after transfection with the constructs containing the mutated Sp1 binding sites at 
baseline and upon 3mM NaBu treatment for 24h. Activity is normalised against pGL3 
basic (without insert) and is shown relative to the baseline levels of the WT pGL3-Fr5 
(construct 5). Mean and S.E.M. are shown for n=3 experiments. Student’s t-test has 
been performed to compare pGL3-Fr5 activity to the mutated construct activities at 
baseline. 
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Figure 6-9B shows luciferase activity relative to the WT pGL3-Fr5 activity 
(set as 100% activity) and normalised against the activity of pGL3-basic. Sp1 mutants 
1,2,3,4 and 5 significantly reduce the promoter activity to 18% (p≤0.0001), 39% 
(p≤0.05), 56% (p≤0.05), 34% (p≤0.0001) and 65% (p≤0.001), respectively at baseline 
(Figure 6-9 C and Table 6-3). Mutation of more than one site simultaneously might be 
needed to completely abrogate activity due to the transactivation ability of Sp1. It is 
very interesting to note that mutant 1, which corresponds to the Sp1 site with 100% 
homology to the motif identified to be unique amongst the upregulated genes by motif 
analysis, is the one that results in the most dramatic effect with only 18% promoter 
activity (Table 6-3). Furthermore, treatment with 3mM NaBu for 24h restores the 
promoter activity and exceeds the baseline activity of all mutant constructs. However, 
mutations that have resulted in a great reduction in the promoter activity are not able 
to reach activity levels after treatment as those reached by the WT promoter or 
mutations that do not affect the activity, i.e. Sp1 sites 6 and 7.  
 
Table 6-3 Sp1 binding sites within the 562bp G6PD promoter region. a 
Sp1 sites DNA sequence Similarity to  
-CCCCGCCCCC-
motif 
Promoter activity 
after mutagenesis 
(at baseline) 
 
Site 1 CCCCGCCCCC 100% 18% 
Site 2 GCCCCGCCCC 90% 39% 
Site 3 GAGGGGTGGT 40% 56% 
Site 4 GCCCCGCCCC 90% 34% 
Site 5 GGGGCGGGGC 90% 65% 
Site 6 CAGGCGGGGA 70% 97% 
Site 7 GCCCCGCCCA 80% 96% 
a The DNA sequence and the % of similarity to the –CCCCGCCCCC- motif identified by 
microarray analysis of the Sp1 sites within the 562bp G6PD promoter region are shown. 
 
 
  198 
To further highlight and confirm the importance of Sp1 in the transcriptional 
regulation of G6PD, the wild type (P277) and G6PD deficient (P7) B cell lines were 
co-treated with 3mM NaBu and 1mM mithramycin A (MTA) during a time course of 
4 - 36h (Figure 6-10A). MTA binds to GC-rich DNA and as such it inhibits binding of 
Sp family to their cognate motifs (Sleiman et al., 2011). Co-treatment of the two cell 
lines with MTA and NaBu prevented the increase in G6PD transcription confirming 
that the enhanced transcriptional activity upon NaBu treatment is Sp1-dependent.  
Furthermore, by adopting a genetic approach, I transfected a dominant 
negative (DN; contains the zinc finger but nor the transactivation domain) form of 
Sp1 (Al-Sarraj et al., 2004) into 293T cells and assessed G6PD mRNA expression As 
a control, the pEBGV plasmid without an insert is used, therefore allows for the 
endogenous Sp1 to bind to DNA. As shown in Figure 6-10B, the DN form of Sp1 
nearly abrogates transcription of G6PD 48h post-transfection. Interestingly, NaBu 
treatment is not able to increase G6PD transcription in the presence of the DN Sp1. 
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Figure 6-10 Chemical and functional elimination of Sp1 binding. (A) The wild 
type (P277) and G6PD deficient (P7) cell lines were co-treated with 3mM NaBu 
together with 1mM MTA and the mRNA levels of G6PD were assessed by RT-qPCR. 
Control experiments treating with NaBu and DMSO or MTA and PBS are shown. 
Mean and S.E.M. are shown for n=3. (B) 293T cells were transfected with a plasmid 
containing a gene expressing a dominant negative form of Sp1, which lacks the 
transactivation domain, or with a control plasmid that does not contain any insert. 48h 
after the tranfection the cells were collected and RT-qPCR was conducted to evaluate 
the G6PD mRNA expression. Mean and S.E.M. are shown for n=3. 
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6.4 Conclusions 
In this final chapter I aimed to describe the genome-wide gene expression 
changes in response to NaBu in primary human proerythroblasts generated from CB-
CD34+ cells.  Microarray analysis showed that 3.17% and 2.76% of genes are 
upregulated and downregulated, respectively. Analysis of the expression of the GPPP 
genes, confirmed the selective increase of G6PD amongst the 17 genes of the GPPP. 
This result was also confirmed by bioinformatic analysis I performed on published 
data by Wang and colleagues (Wang et al., 2009) on CD4+ T cells, although in this set 
of data ALDOA, another PPP gene, appears to be marginally upregulated by a 
combination of NaBu and TSA. Bioinformatic analysis of microarray data obtained 
on mouse cells lines by Kubicek and colleagues (Kubicek et al., 2012) also showed 
increased expression of G6pdx, upon treatment with SAHA or panobinostat.  
De novo DNA motif analysis on the data I obtained from the microarray 
assays on CB-CD34+-differentiating proerythroblasts, identified a unique Sp1 motif (-
CCCCGCCCCC-) amongst the upregulated genes. Reporter assays on the G6PD 
promoter revealed a small 562bp-long promoter region that is responsible for basal 
and in response to NaBu activity. This region contains 7 Sp1 binding sites, out of 
which one is the CCCCGCCCCC- motif site. Mutation of the CCCCGCCCCC- motif 
and other 4 Sp1 binding sites significantly reduces the promoter activity, with the 
CCCCGCCCCC-motif mutation resulting in the most dramatic decrease down to 18% 
activity. It was further confirmed that the G6PD upregulation is Sp1-dependent by the 
overexpression of a dominant negative form of Sp1 into 293T cells, which almost 
completely abrogated G6PD expression. Co-treatment of B cell lines with NaBu and 
MTA, an Sp1 binding inhibitor, also prevented the G6PD upregulation. Taken 
together, these findings clearly show that G6PD upregulation is Sp1-dependent. 
Furthermore, the CCCCGCCCCC- motif appears to be essential for upregulation, 
although it does not appear to be the only Sp1 motif needed on a given promoter. This 
is indicated by the fact that mutation of other Sp1 motifs is also shown to reduce 
promoter activity. However, the presence of the CCCCGCCCCC- motif only on the 
G6PD promoter and not on the other 17 GPPP enzyme genes could be the reason for 
the selective responsiveness of G6PD to NaBu. 
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HATs and HDACs antagonistically regulate transcription through acetylation 
and deacetylation of the histone tails (Brownell and Allis, 2001). Active genes are 
associated with high binding levels of both HATs and HDACs to the promoters and 
gene bodies, which dynamically regulate transcription of genes (Wang et al., 2009).  
HDAC inhibition, using drugs such as NaBu, dysregulates this process resulting in 
altered expression of a large number of genes. Both HATs and HDACs are recruited 
to butyrate-responsive genes by Sp1 (Davie, 2003; Wierstra, 2008). Disruption of Sp1 
binding in IGD, a rare inherited disease caused by a mutation in the Sp1 binding site 
of the promoter of the housekeeping gene PIGM, results in reduced PIGM expression 
(Almeida et al., 2006; 2007; Caputo et al., 2013). The finding that HDACIs restore 
Sp1 binding and histone acetylation in IGD led to the main hypothesis of my research, 
that Sp1-dependent control of histone acetylation and transcriptional activation might 
also apply for genes that are part of other enzymatic biosynthetic pathways with 
housekeeping function. Therefore, characterisation of Sp1-dependent epigenetic 
control of genes with these characteristics could offer new therapeutic opportunities 
for inherited disorders of ubiquitous biosynthetic pathways such as that of glycolysis.  
In summary, the work I have presented in this thesis provides direct evidence 
that G6PD is selectively upregulated by NaBu in primary erythroid cells and B cell 
lines derived from normal and G6PD deficient individuals. The upregulation of G6PD 
mRNA expression leads to the increased protein expression and enzymatic activity. In 
fact, G6PD enzymatic activity is restored to normal levels in G6PD deficient cells, 
indicating the therapeutic potential of phenylbutyrate in the treatment of G6PD 
deficiency. Epigenetic analysis has shown that the upregulation of G6PD is associated 
with increased acetylation of the gene promoter, recruitment of HATs, HDACs and 
the TF Sp1. De novo motif analysis identified a specific Sp1 binding motif that is 
present only in genes that are upregulated by NaBu in primary erythroid cells. Further 
work presented in this thesis shows that this motif is crucial for the upregulation of a 
gene due to the action of HDACIs.   
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7.1 G6PD selectively responds to HDACIs  
My work provides evidence for the first time that, within the GPPP, HDAC 
inhibition selectively upregulates G6PD expression. The use of wild type B cells, as 
well as a cell line derived from a patient with G6PD Brighton (class I G6PD 
deficiency), enabled me to demonstrate that HDACIs (NaBu and SAHA) upregulate 
G6PD mRNA, protein expression and enzymatic activity. Importantly, enzymatic 
activity in the deficient cells was restored to normal levels after 24h and 36h with 
NaBu and SAHA, respectively (3.3 and 3.5).  
The selective upregulation of G6PD over the other GPPP genes was 
confirmed using bioinformatic analysis of the published data by Wang and colleagues 
(Figure 6-4; Wang et al., 2009). Although Wang et al did find upregulation of one 
other GPPP gene (ALDOA) on HDACI treatment, the increase was considerably 
lower than the upregulation of G6PD. I did not find any effect of HDACI treatment 
on ALDOA levels in my experiments, which suggests this may be a cell type-specific 
effect.  
Contrary to my expectations, the other 16 genes of the GPPP were not 
significantly affected by treatment with HDACIs in either normal or deficient cell 
lines (3.3). My results therefore demonstrate that active genes sharing the same 
pathway or other common mechanism, such as regulation by a particular TF, are not 
necessarily regulated in the same manner. This is contrary to the notion that they 
would share the same specialised transcription factory, as suggested by Schoenfelder 
and colleagues who showed that globin genes regulated by the common TF Klf1, are 
transcribed in the same factory (Schoenfelder et al., 2009). Transcription factories are 
considered to be “ever-changing and self-organising structures that contain DNA or 
chromatin loops tethered to active transcription units through the transcription 
machinery” (Xu and Cook, 2008), i.e. a polymerase (active or inactive) and/or its 
transcription factors (activators or repressors; Dillon, 2008; Osborne et al., 2004; 
Papantonis et al., 2010; Schoenfelder et al., 2009; Sexton et al., 2007; Xu and Cook, 
2008). This occurs in order to achieve more efficient transcription by concentrating 
relevant machinery and raw materials in one location. Therefore, I had initially 
hypothesised that transcription of the genes of the GPPP at baseline and in response to 
NaBu would be co-regulated and be part of a transcription factory structurally and 
functionally organised by a TF, such as Sp1, as all GPPP genes are bound by Sp1 
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based on ENCODE analysis (Figure 5-1, Figure 5-2 and Figure 5-3). However, the 
results of this study clearly demonstrate that, at least in the case of the GPPP, genes 
that share a common pathway are not necessarily regulated by a common epigenetic 
mechanism, as has previously been suggested (Schoenfelder et al., 2009). 
From an evolutionary perspective, the selective upregulation of G6PD might 
reflect its critical and indispensible role as the main source of reductive potential in 
the form of NADPH (Castagnola et al., 2010; Metallo and Vander Heiden, 2013). A 
rapid increase in G6PD transcription in response to oxidative stress challenges would 
result in increased NADPH production and protection of the cell from oxidative 
damage and death.  
The cell line results shown in this thesis suggested that HDACI treatment 
could be used to overcome G6PD deficiency. However, it was important to confirm 
that NaBu produced a similar increase in G6PD levels in erythroid cells. To address 
this, I optimised a two-phase liquid culture system that allows the production of large 
numbers of erythroblasts starting from either PBMCs or CD34+ cells (4.2). Although 
PBMCs showed more rapid differentiation by day 7 than CD34+- cells (Figure 4-1, 
Figure 4-2 and Figure 4-3), both cell sources exhibited efficient erythroid 
differentiation. The differences are likely due to the fact that PBMCs contain cells 
that are already committed to the erythroid lineage and therefore enter differentiation 
earlier. Interestingly, this result has not previously been described. I used this system 
to assess the effect of HDACI on in vitro generated erythroblasts produced from 
either normal CB-CD34+ cells (4.4), or PBMCs from normal and G6PD deficient 
individuals (4.4, 4.5) carrying various mutations. Consistent with the cell line results, 
G6PD mRNA and protein expression, as well as G6PD enzymatic activity, were 
selectively upregulated, whilst all other genes of the GPPP remained unaffected by 
HDACI treatment. This confirmed that G6PD upregulation is neither cell type nor 
HDACI specific, as it occurs in human B, T, erythroid and embryonic kidney cells 
and mouse pancreatic cells, using either NaBu, SAHA or panobinostat (Figure 3-6, 
Figure 3-9, Figure 3-10 and Figure 6-4). Importantly, these results strongly suggest 
that NaBu could be effective in the treatment of G6PD deficiency.  
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7.2 HDAC inhibition in erythropoiesis 
HDAC inhibitors have been used since the 1970s, when they were first 
discovered, for the treatment of cancer, haemoglobinopathies, sickle cell anaemia and 
most recently IGD. Compared to chemotherapeutics, short-chain fatty acids, including 
sodium phenylbutyrate, are not mutagenic and therefore do not carry carcinogenic 
risk long-term. However, they do have limitations, including their rapid metabolism, 
which requires administration of large doses and the inhibition of cell proliferation, 
which limits the pool of early erythroid progenitors (Perrine, 2008).  
In view of my results showing that HDACIs can restore G6PD enzymatic 
activity to normal levels, I wanted to further explore the effect of HDACIs on cell 
viability and differentiation. To investigate the effect of HDAC inhibition on cell 
viability and differentiation, I conducted experiments on cell lines and primary cells. I 
demonstrated that NaBu induces apoptosis in B lymphoblastoid cell lines, assessed by 
annexinV staining (Figure 3-1) and reduced cell numbers of primary erythroid cells 
generated by either PBMC (Figure 4-5) or CD34+ (Figure 4-7) erythroid 
differentiation cultures, in a dose-dependent manner. Annexin V staining was not 
performed in primary erythroid cultures, due to cell number limitations, and it was 
therefore not possible to confirm that the reduced cell numbers were due to increased 
apoptotic rates. My findings are consistent with other studies conducted on human 
cervix tumour cell lines (Dyson et al., 1992) and on a multilineage haematopoietic 
cell line (Ikuta et al., 1998) that were treated with butyrate. In fact, concentrations 
below 0.5mM were shown to decrease cell proliferation without inducing cell death 
for up to 5 days. In concentrations above 0.5mM cell growth was arrested and 
apoptosis was accelerated in a dose-dependent manner (Dyson et al., 1992). In 
contrast, a more recent study (Chaurasia et al., 2011) in which cord blood CD34+ cells 
were expanded to differentiate down the erythroid lineage, treatment with other 
chromatin modifying agents, i.e. SAHA, TSA and VPA, showed that these HDACIs 
could actually promote expansion of erythroid cells. This finding led the authors to 
suggest that HDACIs could be used to enhance in vitro generation of erythroid cells 
for the production of red cell concentrates for use in transfusion. However, the results 
of this study could not be confirmed by my work in which I have shown that, as with 
NaBu, both SAHA and TSA, decrease erythroid cell numbers at day 7 of the primary 
cell cultures (Figure 4-7). A possible explanation for this might be the fact that, 
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although the concentration and time of exposure to the HDACIs are the same, the 
culture system is different. Chaurasia et al are using a serum-containing two-phase 
liquid culture system consisting of IMDM implemented with 30% FBS, 100ng/ml 
SCF, 100ng/ml Flt3, 100ng/ml Tpo and 50ng/ml IL-3, whereas I am using a serum-
free system.   
Together, the data presented in this thesis show that treatment of the generated 
erythroid precursors with NaBu (but not other HDACIs) not only reduces cell number 
but also alters erythroid differentiation. In fact, PBMC-derived erythroid cells display 
delayed erythropoiesis (Figure 4-6), whereas in CB-CD34+-derived cells, 
erythropoiesis appears to be promoted after long exposure (treatment after 16h CA) to 
NaBu, whereas short-term exposures of 48h do not alter differentiation (Figure 4-8). 
On the other hand, although SAHA and TSA are shown to reduce the number of 
erythroid cells produced (Figure 4-7), they do not seem to affect the differentiation of 
CB-CD34+-differentiating cells even after long periods of treatment (treatment after 
16h CA; Figure 4-8). Other groups have conducted studies that have also shown 
variable results. Effects similar to those that I have observed for PBMC-derived 
erythroblasts have been characterised by Yamamura and colleagues (Yamamura et al., 
2006) who showed that the HDACI, romidepsin, inhibited the generation and 
proliferation of CD36+GlyAhigh mature erythroblasts, which were expanded from 
CD34+ cells. In agreement with the pleiotropic effect of HDACIs, and in contrast to 
romidepsin, TSA and VPA are shown to block enucleation at later stages of 
differentiation, but do not affect early differentiation and proliferation of erythroblasts 
(Ji et al., 2010; Migliaccio, 2010). In addition, two newly characterised HDACIs are 
shown to restore the impaired in vitro maturation of β-thalassaemic erythroblasts, by 
producing terminally differentiated erythroid cells with restored β-globin levels (Mai 
et al., 2007). On the other hand and in agreement with my findings in CB-CD34+ cells, 
studies in the erythroid J2E cell line show that treatment with NaBu induces erythroid 
differentiation, coupled with increased haemoglobin expression, but blocks cell 
proliferation (Busfield et al., 1993; Jaster et al., 1996). My findings may be explained 
by the fact that cells originating from different tissues respond differently to HDACIs 
and in particular NaBu. Irrespective of which cell type is used, altered erythroid 
differentiation in response to HDACIs underpins the importance of HDACs in the 
progression of every stage of erythoid differentiation (Migliaccio, 2010). 
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The rapid metabolism of NaBu and phenylbutyrate (serum half-life in humans 
is 0.8h; Kramer et al., 2001) and the fact that I have found that they inhibit cell 
proliferation and alter differentiation in vitro may set limitations regarding their 
potential clinical usefulness in the treatment of anaemias associated with glycolytic 
enzyme deficiencies. However, in vivo studies using HDACIs in mice and primates 
(baboons) with thalassaemia have not shown worsening of anaemia (Cao et al., 2005; 
Pace, 2002). In fact, short-chain fatty acid derivatives, including butyrate, stimulate γ 
globin gene expression and erythropoiesis by increasing the BFU-E and reticulocyte 
counts. Furthermore, sickle cell anaemia patients treated with butyrate experienced 
increased reticulocyte levels (no differentiation block), showing that this is a safe drug 
to use in patients with haematological disease (Dover et al., 1994).  Another 
advantage of butyrate is that it is a naturally occurring substance and has little or no 
toxic effect (Daniel et al., 1989; Fraczek et al., 2013; Miller, 2004a). In contrast to 
butyrate, other HDAC inhibitors have a wider spectrum of side effects. For instance, 
panobinostat, romidepsin and SAHA have been shown to block platelet production 
and cause thrombocytopenia (Bishton et al., 2011). More importantly, their long-term 
safety profile has not yet been established, placing limitations on their clinical use. 
Therefore, I suggest sodium phenylbutyrate would be the most suitable for the 
treatment of severe G6PD deficiency and other inherited diseases that might be 
caused by enzyme defects and respond to butyrate treatment, as shown by our 
genome-wide studies. However, it is important to note that given the potential 
therapeutic effects of sodium phenylbutyrate on G6PD deficiency, shown in this study, 
and other diseases, such as sickle cell anaemia, there is need for the production of a 
more patient-friendly form of sodium phenylbutyrate, which requires less frequent 
dosage.   
7.3 Genome-wide implications of HDAC inhibition 
To further investigate the effects of NaBu, I used microarray to assess global 
gene expression. GPPP enzyme deficiencies are manifest in the erythroid lineage; 
therefore, I chose to assess the genome-wide implications of HDAC inhibition in 
primary erythroblasts. Almost all prior studies conducted to evaluate gene expression 
in response to HDACIs, including butyrate, involved cell lines rather than primary 
human cells. Wang and colleagues (Wang et al., 2008) were the first to conduct gene 
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expression profiling in human primary cells, specifically primary human CD4+ T cells, 
which were treated with a combination of NaBu and TSA.  
The gene expression profiling data on primary human proerythroblasts 
generated by the in vitro erythroid differentiation system from CB-CD34+ cells, 
which I presented in this thesis, showed that only 5.93% of the genes tested are 
significantly affected (FC≥1.5, p≤0.05) by NaBu treatment with 3.17% and 2.76% of 
genes being upregulated and downregulated, respectively. These findings are in line 
with studies conducted by other researchers in various cell lines, using different 
HDACIs, which came to the general conclusion that only 2-25% of genes are affected 
by HDAC inhibition (Davie, 2003; Delcuve et al., 2012; Mitsiades et al., 2004; Sealy 
and Chalkley, 1978; Sekhavat et al., 2007; Van Lint et al., 1996). The time in culture, 
the concentration, the specific HDACI used and also the type of cells determine the 
number of genes altered in transcription. The number of affected genes increases as 
time and concentration increase likely as a result of secondary rather than direct 
effects (Peart et al., 2005). For example, treatment of a colonic epithelial cell line 
(SW620) with 5mM NaBu for 48h showed that 7% of the genes showed altered gene 
expression, with 3% upregulated and 4% downregulated (Mariadason et al., 2000). 
Similarly, treatment of a non-small lung carcinoma cell line (H460) with 1mM of 
NaBu for 24h, provided evidence that 4% of the tested genes were upregulated and 
8% were downregulated (Joseph et al., 2004). Gene-specific studies have also 
confirmed that HDACIs can decrease the expression of genes, such as that of the 
Epidermal Growth Factor Receptor (EGFR) in colorectal cell lines treated with TSA 
and SAHA independently (Chou et al., 2011) and that of cholesterol biosynthesis in 
enterocyte cell lines treated with NaBu (Alvaro et al., 2008). The results arising from 
these studies are in line with my results, showing a similar number of upregulated 
versus downregulated genes, the exact numbers of which appears to depend on the 
cell type, type of HDACI used and the HDACI concentration.  
Genome-wide experiments that have assessed the effect of HDACIs at 
different time points have provided further information. Peart and colleagues (Peart et 
al., 2005) treated T cell leukaemia cell lines (CEM) with either 2.5µM SAHA or 
1ng/ml depsipeptide and showed that the number of HDAC-regulated genes increased 
over time (SAHA: from 1.29% after 1h to 22% after 16h. Depsipeptide: from 0.27% 
after 1h to 24.8% after 16h.). Similarly, Tabuchi and collegues(Tabuchi et al., 2006) 
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treated colonic epithelial cells (MCE301) with 2mM NaBu over a 6, 12, 24h time 
course and showed that 2.7% (out of which 70% upregulated and 30% 
downregulated), 6.3% (out of which 53% upregulated and 47% downregulated) and 
11.5% (out of which 41% upregulated and 59% downregulated) of genes showed 
altered levels of expression, respectively. This dynamic change in gene expression 
during HDAC inhibition emphasises the fact that longer treatments may result in 
downstream rather than direct effects (although some genes might simply respond 
faster than others). It is also interesting to note that this information suggests that 
shorter HDACI treatment increases the number of genes upregulated rather than 
downregulated, whereas longer incubations with HDACIs result in a larger number of 
dowregulated genes, which is possibly the result of secondary effects. 
7.4 Epigenetic mechanism of action of NaBu 
As discussed previously, HDACIs restore Sp1 binding and histone acetylation 
in IGD, which led to the main hypothesis of my work, i.e., that Sp1-dependent control 
of histone acetylation and transcriptional activation could also apply for genes that are 
part of other enzymatic biosynthetic pathways with housekeeping function. Therefore, 
characterisation of Sp1-dependent epigenetic control of genes with these 
characteristics could offer new therapeutic opportunities for inherited disorders of 
ubiquitous biosynthetic pathways such as glycolysis. 
However, my finding that HDAC inhibition selectively upregulates G6PD led 
me to explore the mechanism behind this selective upregulation and therefore 
determine why G6PD differs from the other non-responsive genes. During the initial 
stages of this project, I showed that G6PD responsiveness is seen with a range of 
HDACIs, including NaBu, TSA and SAHA (Figure 3-7). Furthermore, this effect is 
cell type-independent, as it is present in human B cells (Figure 3-6), erythroid (Figure 
4-6, Figure 4-8 and Figure 6-4), T cells (Figure 6-4) and embryonic kidney cells 
(Figure 6-8), as well as mouse pancreatic cells (Figure 6-4). Importantly, this meant 
that I was able to study the epigenetic changes in cell lines, overcoming the potential 
limitations with cell number that I may have encountered had I needed to use primary 
cells. 
In this thesis, I have established that the epigenetic landscapes of G6PD and 
the other genes of the GPPP at baseline are that of typical housekeeping genes. 
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ENCODE analysis of the G6PD, TPI and GPI promoters (Figure 5-1, Figure 5-2 and 
Figure 5-3) and ChIP assays that assessed the G6PD, TPI, GPI, PGLS and RPIA 
promoters at baseline (Figure 5-8, Figure 5-9, Figure 5-15 and Figure 5-16) showed 
that they are all highly acetylated and enriched for positive chromatin marks, HATs, 
HDACs and Sp1. Binding of Polymerase II on the promoters and gene bodies of these 
genes is in line with their housekeeping expression pattern. A notable structural 
difference between G6PD and the other genes of the GPPP is the presence of a 
bidirectional promoter shared with NEMO. However, the hypothesis that the G6PD 
upregulation is NEMO-driven was disproved, as NEMO is not upregulated by NaBu 
(Figure 5-4). Having established all the information discussed above and based on 
evidence from CHX treatment (Figure 3-11) that G6PD is directly upregulated by 
NaBu in a translation-independent manner, I next sought to understand the epigenetic 
changes that occur as a result of the NaBu treatment.  
7.4.1 NaBu increases histone acetylation 
Prior studies have shown that HDAC inhibition causes widespread histone 
hyper-acetylation (Davie, 2003; Delcuve et al., 2012; Mitsiades et al., 2004; Sealy and 
Chalkley, 1978; Sekhavat et al., 2007; Van Lint et al., 1996). An extremely well 
studied gene-specific model of this is the p21 gene, which encodes the cyclin-
dependent kinase inhibitor p21 and mediates cell cycle arrest and thus apoptosis.  
HDACIs have been shown to upregulate the expression of p21 whilst causing hyper-
acetylation of both the proximal and distal promoter regions (Gui et al., 2004; also 
shown in Appendix A in primary proerythroblasts upon NaBu treatment). In line with 
those studies, ChIP analysis of the G6PD promoter showed increased acetylation on 
H3 and H4 in both normal and G6PD deficient cells (Figure 5-8). My findings are in 
disagreement with a study conducted by Halsall and colleagues (Halsall et al., 2012) 
who compared the genome-wide histone hyper-acetylation caused by VPA in the 
promyelocytic leukaemia cell line HL60 and transcriptional responses of selected 
genes. The main observation arising from this study was that promoter acetylation of 
individual genes was not increased in response to VPA, even at genes showing 
enhanced transcription. However, Halsall et al might have failed to identify an 
increase in acetylation due to the use of antibodies against only three acetylation 
marks (H3K9Ac, H4K8Ac and H4K16Ac), whereas I have used antibodies against 
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total H3 and H4 acetylation, which allows me to capture changes of all acetylation 
marks.  
Interestingly, the H4 acetylation increase is significantly stronger than the H3 
acetylation increase in both cell lines. In fact, H3 and H4 acetylation enrichment of 
the core promoter (G6PD.2) increased 4.2% and 12% in WT cells, respectively, and 
3% and 8% in G6PD deficient cells, respectively. A possible explanation might be 
that H4 acetylation is favoured due to the lower acetylation on H4 rather than H3 at 
baseline (2-fold; Figure 5-8). Another explanation may be that H4 acetylation is not 
regulated in the same manner as H3 acetylation and it might rely on some HDACs 
more than others. Although NaBu is a pan-HDAC inhibitor, it has been shown to have 
different levels of efficiency against target HDACs, which may influence acetylation 
of specific histones. Blackwell et al (Blackwell et al., 2008) have previously shown 
that butyrate is most potent against HDACs 1, 2, 3 and 6. More recently, 
chemoproteomic profiling of HDACIs (Bantscheff et al., 2011; Bradner et al., 2010) 
revealed different degrees of efficiency of a variety of HDACIs, including SAHA, 
TSA and VPA, against each HDAC examined. To test this assumption I could inhibit 
each HDAC separately either chemically or with the use of shRNAs. However, it 
should be noted that in this study I have only focused on general H3 and H4 
acetylation and haven’t examined specific acetylation marks that might be specifically 
increased on the G6PD promoter. Further studies looking at specific acetylation 
marks might provide more evidence to describe a detailed mechanism of action of 
NaBu. 
The most interesting finding was that NaBu did not hyper-acetylate other 
genes of the GPPP. Specifically, H3 and H4 acetylation of the TPI, GPI, RPIA and 
PGLS gene core promoters did not change significantly in either of the two cell lines 
used (Figure 5-6 and Figure 5-7). The fact that mRNA expression of these genes was 
not significantly altered in response to NaBu, suggests that histone acetylation may be 
required for upregulation of G6PD expression. This complements the findings of 
Rada-Iglesias’ study (Rada-Iglesias et al., 2007) in HepG2 and HT-29 cell lines. 
Rada-Iglesias has shown that treatment with HDACIs, including butyrate, in these 
cells caused deacetylation of a number of promoter regions, as opposed to the global 
acetylation increase that was observed. These promoter regions corresponded to genes 
that are downregulated under butyrate exposure, as opposed to unaffected genes like 
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those of the GPPP. It should be noted that in Rada-Iglesias’ study, upregulated genes 
display increased acetylation on their promoters, a finding, which is in agreement 
with the increased acetylation I observed on the G6PD promoter. 
7.4.2 NaBu increases the recruitment of chromatin regulators 
In this study, ChIP analysis of HAT and HDAC binding on the core promoters 
of G6PD and other genes of the GPPP at baseline demonstrated co-occupancy of 
those two classes of chromatin regulators for these genes. As shown in Figure 5-10 
and Figure 5-12 for HATs (CBP, p300 and GCN5) as well as Figure 5-11 and Figure 
5-13 for HDACs (HDAC1, 3, 4/5/7 and 6), recruitment of both these two classes of 
enzymes on the GPPP gene promoters is enriched.  
This finding supports previous research that has given further complexity to 
the general model of transcription, providing evidence for a dynamic cycle of 
acetylation and deacetylation by the simultaneous binding of HATs and HDACs. For 
instance, the genome-wide study by Wang (Wang et al., 2009) showed that active 
genes are associated with high binding levels of both HATs and HDACs. This 
suggested that HDACs are required to reset the chromatin status by removing the 
acetyl groups after the completion of each round of transcription so that the gene does 
not hyper-acetylate. Furthermore, Ram and colleagues (Ram et al., 2011) developed a 
novel ChIP method (ChIP-string) to map the genome-wide binding of 29 chromatin 
regulators, including several HATs and HDACs in K562 cells and H1 ESCs. Among 
other findings in this study, it was confirmed that HATs and HDACs dynamically 
regulate the expression of active genes. A further genome-wide study (Johnsson et al., 
2009) conducted in Schizosaccharomyces pombe, mapped the recruitment of the HAT 
Gcn5 to gene promoters and the distribution of H3K14ac. Gcn5 was found to localise 
in high concentration on coding regions of highly transcribed genes and to collaborate 
antagonistically with Clr3, a class II HDAC. This interplay between Gcn5 and Clr3 
was shown to be crucial for the regulation of stress-response genes. Several gene-
specific studies have also confirmed the co-occupancy of active gene promoters by 
both HATs and HDACs (Huang, 2005; Huang et al., 2007; Park, 2001). Confirmation 
of the co-recruitment of HATs and HDACs to the promoters of GPPP genes at 
baseline, through my work, is of great importance as it underpins the dynamic 
regulation of their transcription. Therefore, looking closer at the epigenetic status of 
the dynamically regulated GPPP gene promoters before and after NaBu treatment will 
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provide insights into the mechanism of action of NaBu and importantly the selective 
upregulation of G6PD. 
One of the most important findings of the present study was that HAT and 
HDAC recruitment on G6PD is enriched upon NaBu treatment. In fact, in both 
normal and G6PD deficient cell lines, 5h treatment with NaBu increased the 
recruitment of all HATs tested, i.e. p300, CBP and GCN5, as well as selected HDACs, 
i.e. HDAC1 and HDAC6. HDAC 3, 4, 5 and 7 binding is not significantly affected by 
NaBu, thus these HDACs remain bound - or constantly present through rapid cycles 
of recruitment - to the G6PD promoter. The fact that only the recruitment of HDAC1 
and 6 is upregulated might be related to the differential potency of NaBu against 
different HDACs. It should be noted that HAT and HDAC binding in all the other 
GPPP gene promoters is not significantly altered. Although there are few studies in 
the literature showing what happens to the recruited HDACs upon HDAC inhibition, 
the limited results that are available are controversial. Specifically, Huang and 
colleagues (Huang, 2005) have previously shown that TSA increased the recruitment 
of the HATs CBP and p300, as well as the TF Sp1 on the promoter of TSA-
responsive TGFβ type II receptor in human pancreatic cancer cell lines (BxPC-3, 
PANC-1, CFPAC-1, and MIA PaCa-2). Moreover, the same study provided evidence 
that HDAC1 recruitment on the promoter of those genes decreases after TSA 
treatment. Similarly, Nunes and colleagues (Nunes et al., 2010) treated the human 
neuroblastoma cell line SH-SY5Y and looked at the promoter status of the Sp1-
dependent HDAC-responsive CYP46A1. Although in this publication the authors are 
examining the recruitment of a small number of HATs (CBP and p300) and HDACs 
(HDAC1 and HDAC2), they show that TSA treatment induces a slight yet significant 
decrease in HDAC2 occupancy whereas it increases p300 occupancy. This was also 
followed by an increase in Sp1 binding. In contrast to these findings, Sekhavat and 
colleagues (Sekhavat et al., 2007) performed a combination of immunoprecipitation 
and immunoblotting in the human breast cancer cell line MCF-7 and showed that 
inhibition of HDAC1 and HDAC2 by TSA does not disturb their binding to the 
chromatin, without however investigating specific TSA-responsive genes. The same 
study showed that the association of HDAC2 with Sp1 is also not affected by TSA. 
These studies show the variability of the limited results available in the literature. 
However, the limitation of these studies is that they only investigate the binding of 
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some HDACs, whereas my work explores the binding of almost all HDACs and 
therefore provides a clear picture of the GPPP gene promoters upon HDAC inhibition. 
My data shed light on the controversy regarding the binding of HDACs after 
HDACI treatment and suggest a method of regulation of NaBu-responsive genes 
through the dynamic recruitment of both HATs and HDACs. My results suggest that 
NaBu treatment encourages the preferential action of HATs over the inhibited 
HDACs. This leads to further recruitment of additional HATs, which result in the 
increase of H3 and H4 acetylation and thus PolII binding resulting in the increased 
expression of G6PD. Furthermore, the inhibited HDACs do not dissociate from the 
transcription complex. In fact, more HDACs are recruited with the aim of balancing 
the increased HATs and keeping the system under control.  
7.4.3 Sp1 is vital for the upregulation of G6PD 
As a final step for this thesis I sought to understand what factor(s) determine 
the increased recruitment of HATs and HDACs on the G6PD promoter and also why 
G6PD is selectively upregulated by NaBu.  Reporter assays of fragments of the G6PD 
promoter indicated that a 562bp region of the promoter is responsible for basal 
activity as well as responsiveness of G6PD to NaBu. This indicates that this region 
must contain key binding sites for whichever factor is responsible for the upregulation 
of G6PD upregulation. Importance of this particular fragment for basal activity has 
also been previously shown by Philippe and colleagues (Philippe et al., 1994) who 
conducted reporter assays in HepG2 and K562 cells.  
Since Sp1 has previously been associated with HDACI-responsive genes, I 
studied the importance of Sp1 within this region. Specifically, as discussed in the 
introduction it is known that a group of butyrate-responsive genes contain Sp1 sites 
within their promoters (Davie, 2003; Majumdar et al., 2012; Siavoshian et al., 1997). 
Additionally, Sp1 has been shown to interact with HATs and HDACs (Hou et al., 
2002; Kundu et al., 2000; Nunes et al., 2010; Wierstra, 2008). Furthermore, Franze 
and colleagues (Franzè et al., 1998) have previously conducted transactivation assays 
in HeLa cells using co-transfection with an Sp1-expression plasmid and reporter 
plasmids containing different fragments of the -126 to +16 core promoter region, 
which is included in the 562-long region that I identified using transactivation assays. 
In this study, they showed that Sp1 is able to activate all Sp1 binding site-containing 
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fragments and lead to induction of promoter activity. This study showed the important 
role of Sp1 in the regulation of the G6PD core promoter at baseline. 
So far various studies have shown increased recruitment of Sp1 on the 
promoters of HDACI-responsive genes that are upregulated (Huang, 2005; Nunes et 
al., 2010; Zhang et al., 2006). Importantly, more recent studies have proven that gene 
expression upregulation through HDAC inhibition is dependent on Sp1. Specifically, 
a study that employed mutant construct transfections and MTA treatment of the 
human colon adenocarcinoma cell line BCS-TC2 proved that Sp1 is essential for the 
upregulation of the metalloprotein-expressing MMP11 gene upon NaBu or TSA 
treatment (Barrasa et al., 2012). In a similar approach, it was demonstrated by Yang et 
al (Yang et al., 2012) that MTA blocked the TSA- and SAHA- induced CD1d mRNA 
expression in human alveolar epithelial A549 cells and mouse melanoma B16/F0 cells. 
In the same study, co-transfection assays using Gal4-Sp1 and Fc-luciferase reporters 
shown that both TSA and SAHA induced CD1d promoter luciferase activity by 
enhanced Sp1 transactivation activity, which results in increased recruitment of Sp1 
on the CD1d promoter. Interestingly, a study by Law and colleagues(Law et al., 2011) 
demonstrated through the knockdown of Sp1 expression in human colon 
adenocarcinoma HT-29 cells that Sp1 is also responsible for the downregulation of 
stanniocalcin-1 (STC-1) upon TSA treatment. This latter study underpins the diverse 
yet crucial role of Sp1 during HDAC inhibition.  
In this study, I aimed to not only determine the importance of Sp1 in G6PD 
upregulation, but also to understand why G6PD amongst all GPPP genes is 
upregulated. ENCODE (Figure 5-1, Figure 5-2 and Figure 5-3) and ChIP (Figure 
5-16) analysis at baseline showed that all the genes of the GPPP are bound by Sp1, 
yet Sp1 recruitment is increased only on the promoter of G6PD (Figure 5-17) in 
response to NaBu. De novo DNA motif discovery analysis on the data obtained from 
the microarray assays on CB-CD34+-differentiating proerythroblasts, identified a 
unique Sp1 motif (-CCCCGCCCCC-) amongst the upregulated genes, thus providing 
independent evidence supporting the critical role of Sp1 in regulating transcription of 
G6PD in response to NaBu. Interestingly, this Sp1 binding motif is one of the 7 Sp1 
sites that fall within the 562bp region, which is responsible for basal and in response 
to NaBu activity.  
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Although it has been previously shown that Sp1 is able to transactivate genes 
through its binding to multiple Sp1 binding sites on a given promoter (Davie et al., 
2008), it might be possible that a specific Sp1 binding site is responsible for the 
preferential responsiveness upon HDAC inhibition. In fact, mutation of the 
CCCCGCCCCC- motif and other 4 Sp1 binding sites significantly reduces the 
promoter activity, with the CCCCGCCCCC-motif mutation resulting in the most 
dramatic decrease down to 18% activity. Similarly, Kim and colleagues (Kim et al., 
2008) have previously shown in gastric cancer cell lines the dependence of Deleted in 
Liver Cancer-1 (DLC-1) upregulation on Sp1 occupancy. In this study, luciferase 
reporter assays with mutant Sp1 sites were conducted to show the abrogation of TSA-
induced upregulation through the mutation of specific Sp1 sites.  Indeed, mutation of 
2 out of 8 Sp1 binding sites had the most dramatic effect in the prevention of the 
DLC-1 upregulation. However, in this study the researchers did not further investigate 
the functional difference in these 2 sites in comparison to the other Sp1 sites. In my 
study, it was further confirmed that G6PD transcriptional upregulation is Sp1-
dependent by the overexpression of a dominant negative form of Sp1 into 293T cells, 
which almost completely abrogated G6PD expression. Co-treatment of B cell lines 
with NaBu and MTA also prevented G6PD upregulation. Taken together, these 
findings clearly show that G6PD upregulation is Sp1-dependent and for the first time 
it is proven that the CCCCGCCCCC sequence is the essential motif for upregulation. 
Further proof of the importance of this motif could be given if reporter assays were 
conducted using a synthetic basic promoter with and without the Sp1 binding motif in 
order to show its importance for basal and in response to NaBu promoter activity. 
Although in this study I have focused on the role of Sp1, further research 
could determine the importance of other factors in the responsiveness to HDACIs. A 
potential approach would be the combination of immunoprecipitation of specific parts 
of the genome (e.g. G6PD versus other genes of the GPPP) with mass spectrometry 
assays to determine what other factors bind on these genes. This approach has been 
used previously for the analysis of factors bound on telomeric DNA (Sperry et al., 
2008). 
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7.4.4 Epigenetic model for selective upregulation by NaBu 
In this study, I suggest a novel mechanism for the selective upregulation of 
genes by HDAC inhibition. Although my studies focused on the GPPP in response to 
NaBu, I suggest that this mechanism might apply globally in response to HDAC 
inhibition. Specifically, I suggest that HDACIs increase the recruitment of Sp1 in 
promoters containing the CCCCGCCCCC- motif. Furthermore, our lab (unpublished 
data) and others (Yang et al., 2012) have confirmed that HDACIs upregulate Sp1 
expression, which is likely to further enhance Sp1 binding. Increased Sp1 binding in 
the promoters containing the CCCCGCCCCC- motif leads to increased recruitment of 
HATs and thus H3 and H4 hyper-acetylation. Hyper-acetylation of these promoters 
leads to increased binding of PolII and therefore increased mRNA expression. At the 
same time, the inhibited HDACs do not dissociate from the transcription complex; 
more HDACs are in fact recruited with the aim of balancing the increased HATs and 
keeping the system under control.  
7.5 Directions for future work 
This work strongly suggests that the use of butyrate could be of therapeutic 
use for the treatment of severe G6PD deficiency. This has been suggested based on 
findings in G6PD deficient and normal cell lines and primary erythroblasts. In these 
cell types, treatment with NaBu increased G6PD mRNA and protein expression and 
most importantly restored G6PD enzymatic activity to normal levels in the G6PD 
deficient cells. However, a question that remains unanswered is whether the same 
effect could be observed in vivo. 
To confirm the in vivo upregulation of G6PD expression and activity, a G6PD 
deficient mouse model could be used. In fact, Pretsch and colleagues (Pretsch et al., 
1988) first described a G6PD deficient mouse strain that results in severely reduced 
G6PD levels (15% of WT) in hemizygous male or homozygous female mice. The 
genetic defect in these mice is an in-frame deletion on exon 1 that causes lower 
expression of the G6PD protein. The G6pdx-m1Neu strain is available to order on the 
EMMA database (http://www.emmanet.org/) under the code EM:00073. 
Phenylbutyrate injections could be administered to this mildly deficient mouse to 
assess the effect on G6PD enzymatic activity. Additionally, to test the effect of 
phenylbutyrate in severely deficient mice, naphthalene injections could be 
administered to the mice prior to phenylbutyrate treatment, as naphthalene is known 
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to cause acute haemolysis and mimic drug-incuded haemolytic anaemia in Class II/III 
G6PD deficient individuals. Such an experiment is likely to succeed as it has been 
previously shown (Kubicek et al., 2012) that G6pdx responds in the same manner as 
G6PD to NaBu (Figure 6-4). 
Alternatively, in vivo studies could be conducted in G6PD deficient patients, 
particularly those with severe chronic haemolytic anaemia. Confirmation of the 
effectiveness of NaBu in humans in vivo may be crucial for class I G6PD deficient 
patients who currently rely on regular blood transfusion.  
The overlap between the geographical distribution of G6PD deficiency and 
malaria infection presents a further potential use of NaBu. As mentioned in 1.4.3.2, 
amongst the drugs that have been shown to cause drug-induced haemolytic anaemia 
in G6PD deficiency are the anti-malarials primaquine and pamaquine. This places 
limitations on the treatment of malaria in patients with G6PD deficiency as treatment 
can induce severe haemolysis. However, co-treatment with phenylbutyrate could 
potentially increase expression and enzymatic activity of G6PD and prevent 
occurrence of acute haemolysis allowing the use of a wider range of anti-malarial 
drugs. 
Phenylbutyrate could also be of therapeutic use in other diseases that are 
caused by mutations that lead to reduced enzymatic activity. Appendix A shows the 
list of genes that were significantly upregulated (FC≥1.5, p≤0.05) and Appendix B 
those that are significantly downregulated (FC≥1.5, p≤0.05). Amongst the 
upregulated genes is coagulation factor VIII (FVIII) that shows a 1.77-fold increase 
on NaBu treatment (p≤0.001). Mutations in the FVIII gene promoter cause 
haemophilia A, a hereditary X-linked recessive disorder, associated with low levels of 
FVIII protein(Bolton-Maggs and Pasi, 2003; Mannucci and Tuddenham, 2001). 
Depending on the FVIII activity in patient plasma, haemophilia A is classified as 
severe (<1%), moderate (1–5%) or mild (>5% to <40%; Franchini and Mannucci, 
2013; Kulkarni and Soucie, 2011).  To test this hypothesis, FVIII expression upon 
NaBu treatment could be measured in WT hepatic cell lines, such as HepG2, FVIII 
deficient cell lines and in primary cells in vitro. As a next step, FVIII promoter – 
containing plasmids that also contain a luciferase gene could be transfected into 
HepG2 cells in order to measure the promoter activity upon NaBu treatment. 
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Zimmermann and colleagues (Zimmerman et al., 2012) have cloned the WT and 
several patient mutant variations of the FVIII core promoter into a luciferase gene-
containing plasmid construct, which they then used to transfect into HepG2 cells. 
These constructs could also be used to transfect HepG2 cells whilst treating them with 
NaBu in order to measure the changes in the FVIII promoter activity. Finally, if these 
experiments confirm our hypothesis, we would suggest conducting clinical trials in 
haemophilia A patients to test the administration of phenylbutyrate as an alternative to 
the current treatment methods. 
The future work suggested here underpins the therapeutic potential of 
phenylbutyrate beyond its current use. Despite its therapeutic potential, the form of 
sodium phenylbutyrate currently marketed and used for the treatment of diseases has 
a short half-life and is subjected to first pass hepatic clearance, explaining the 
milligram doses the patients are required to take in order to achieve therapeutic 
concentrations in vivo (Yoo and Jones, 2006). This often causes mild yet unpleasant 
side affects, such as muscle pain, swelling of the legs and tiredness. However, as 
mentioned in 7.2, the advantage of butyrate is that it is a naturally occurring substance 
and has little or no toxic effect (Daniel et al., 1989; Fraczek et al., 2013; Miller, 
2004a). In contrast to butyrate, other HDAC inhibitors have many side effects, for 
instance panobinostat, romidepsin and SAHA were shown to block platelet 
production and cause thrombocytopenia (Bishton et al., 2011); thus, their long-term 
safety profile has not been established as yet. To conclude, a more patient-friendly 
form of butyrate should be developed for the treatment of G6PD deficiency and 
possibly other enzymatic deficiencies.  
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Appendix A. List of significantly upregulated genes upon NaBu in CB-CD34+ -
differentiating erythroblasts. 
Gene Fold Change P value 
HIST1H1T 5.95 0.01 
DENND2C 5.90 0.00 
SERPINI1 5.83 0.01 
ENPP5 5.47 0.00 
MAPRE3 5.20 0.01 
PFN2 4.71 0.01 
TMOD2 4.33 4.73E-04 
KIF5A 3.97 0.02 
ROPN1L 3.82 0.00 
PLEKHH2 3.69 0.00 
ETNK2 3.61 0.01 
MYBL1 3.49 0.01 
KIF5A 3.49 0.03 
TUBB4A 3.47 0.00 
SERPINB9 3.46 6.72E-04 
PEG10 3.37 2.98E-04 
KIF5C 3.33 0.00 
GBP5 3.20 0.00 
CCDC68 3.08 0.00 
RBM11 3.02 3.14E-04 
IRF6 3.02 0.03 
TCP11L2 2.98 1.78E-04 
BMP6 2.98 0.01 
OCLN 2.89 0.01 
MAP1B 2.87 0.00 
FAM49A 2.84 0.00 
HSPA2 2.80 4.50E-05 
EFNA4 2.78 4.06E-04 
ZNF204P 2.68 0.00 
FBXO16 2.66 0.01 
SESN3 2.64 0.02 
TUFT1 2.61 0.02 
MERTK 2.60 0.01 
SLC7A8 2.58 0.00 
STXBP1 2.55 0.01 
STAT4 2.55 0.00 
KIAA1161 2.54 5.34E-04 
SV2A 2.54 0.05 
PTCH1 2.53 0.05 
H1FX 2.52 7.53E-04 
C5orf4 2.51 0.00 
ABCB9 2.51 0.00 
IER3 2.49 0.00 
AHNAK2 2.47 0.02 
HIST1H1A 2.44 0.00 
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HDAC11 2.44 0.00 
HIST2H4A  // 
HIST2H4B 2.42 0.04 
HIST2H4A  // 
HIST2H4B 2.42 0.04 
RAB3A 2.42 0.00 
LPPR2 2.40 0.01 
TSPAN13 2.40 0.05 
VCL 2.40 0.00 
ENDOD1 2.40 0.03 
RAB30 2.40 6.10E-04 
TESK2 2.38 0.00 
IER3 2.37 8.99E-04 
IER3 2.37 8.99E-04 
GALM 2.37 0.01 
CLDN10 2.36 0.01 
ABCB1 2.34 0.01 
FAM171A2 2.33 0.01 
ST3GAL5 2.32 0.01 
SCAMP5 2.31 0.00 
PBX1 2.27 0.00 
CCR7 2.26 7.42E-04 
C17orf104 2.26 0.01 
TPST1 2.25 0.04 
DPF1 2.25 1.10E-04 
TSPAN15 2.24 0.02 
ZC2HC1A 2.24 0.02 
SORT1 2.23 0.02 
PPM1J 2.22 6.17E-04 
FAM69A 2.22 0.00 
KIF3A 2.21 0.01 
SPATA6 2.20 0.01 
UBE2H 2.19 9.89E-05 
ETS1 2.18 0.03 
ALDH1A1 2.18 0.01 
REEP6 2.17 0.04 
DHRS1 2.16 1.36E-04 
TNFAIP6 2.16 0.05 
SMARCA1 2.16 0.02 
MOSPD1 2.16 0.03 
AKTIP 2.16 0.02 
DOK4 2.15 3.27E-04 
ABHD4 2.15 0.00 
SCD5 2.15 0.01 
SMOX 2.14 0.00 
HPSE 2.13 0.00 
ETV5 2.13 8.21E-04 
CDKL5 2.13 0.00 
TMEM63C 2.12 0.03 
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ZNF774 2.12 0.01 
CXADR 2.11 0.05 
KHK 2.11 0.01 
GABARAPL1 2.11 4.25E-05 
WDR31 2.11 0.03 
CAPN5 2.10 0.01 
C16orf45 2.09 4.15E-04 
EXPH5 2.09 0.03 
ENPP2 2.08 0.01 
C11orf67 2.08 0.01 
DNAJC28 2.08 0.01 
P2RX7 2.08 0.00 
CPEB4 2.08 6.21E-04 
ASMTL 2.08 0.00 
IFT80 2.06 0.00 
SORBS1 2.06 0.04 
MAST3 2.05 0.00 
FGD6 2.05 0.00 
ARHGEF26 2.05 0.00 
NBEAL1 2.05 3.82E-04 
TBC1D2 2.04 0.01 
RECK 2.04 0.00 
GLCE 2.03 0.01 
TSPAN2 2.03 0.03 
PLXNA3 2.03 5.54E-04 
AGPHD1 2.03 0.02 
ASPHD2 2.02 0.01 
C1orf116 2.02 3.73E-04 
NBEAL1 2.01 0.01 
EFHC1 2.01 0.02 
ATL1 2.00 0.00 
BIRC3 2.00 0.00 
SGTB 2.00 0.00 
RND2 2.00 0.00 
BACE1 2.00 1.13E-04 
ATP6V1G2 1.99 0.01 
ATP6V1G2 1.99 0.01 
CREB3 1.99 6.10E-06 
TIPARP 1.99 0.02 
RBMS2 1.99 0.01 
SPIRE1 1.98 0.01 
KIAA0513 1.98 0.00 
KIAA1324L 1.98 0.01 
NCOA3 1.98 0.00 
DNM3 1.98 0.00 
JUP 1.98 0.02 
ATP1A3 1.97 0.01 
GUCY1B3 1.97 4.77E-04 
ARL4D 1.97 0.00 
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OSBPL6 1.96 0.00 
PRKACA 1.96 5.83E-06 
LRCH2 1.96 0.00 
LPHN1 1.95 0.03 
SH3PXD2B 1.95 0.01 
STARD9 1.95 0.00 
CD22 1.94 0.00 
FBXO48 1.94 0.04 
CTTNBP2NL 1.94 6.36E-04 
PLA2G15 1.93 0.01 
RCOR2 1.93 0.01 
SLC25A37 1.93 0.03 
PCYOX1 1.93 9.17E-04 
WBP5 1.92 0.00 
RRAS 1.92 0.01 
GNA11 1.92 0.01 
MARK4 1.92 7.43E-04 
KRTAP6-1 1.92 0.01 
TRIP10 1.92 0.00 
GNG12 1.92 0.01 
CDC42EP3 1.92 0.00 
RASGEF1B 1.92 0.01 
DZIP3 1.91 0.01 
PGM2L1 1.91 0.02 
PAIP2B 1.91 0.01 
MT1G 1.91 0.05 
AGPAT4 1.90 6.73E-04 
POLB 1.90 0.01 
CYB5R1 1.90 0.00 
RHPN2 1.90 0.01 
SEMA4D 1.90 0.02 
PCGF2 1.90 0.00 
NXN 1.89 0.02 
CEP19 1.89 0.01 
EMP2 1.89 0.01 
ADD3 1.89 0.01 
TTLL7 1.88 0.02 
HIST3H2BB 1.88 0.01 
RAP1GAP 1.88 0.01 
RAB3D 1.88 0.02 
FAM102A 1.87 0.00 
SEMA4G 1.87 5.17E-05 
KIF3C 1.87 0.01 
GATSL3 1.87 8.50E-04 
CDC42BPB 1.87 0.01 
IQCK 1.87 0.01 
MAMLD1 1.86 0.01 
EPB41L5 1.86 9.31E-04 
TJP2 1.86 0.01 
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PITPNM1 1.86 0.02 
CTNS 1.86 0.01 
IL6ST 1.86 0.01 
FAM89B 1.86 0.01 
ABCD1 1.85 0.00 
BMPR1A 1.85 0.03 
FGFR1 1.85 2.22E-04 
HERC1 1.84 0.00 
FAM126B 1.84 0.01 
IFT57 1.84 0.00 
ANKRD6 1.83 0.00 
CHRM4 1.83 1.35E-04 
TCTEX1D1 1.83 0.02 
RBKS 1.83 0.05 
PFKM 1.83 5.39E-04 
YPEL2 1.83 0.00 
FMNL2 1.82 0.00 
SIAE 1.82 0.05 
ITGA6 1.82 0.03 
ARL3 1.82 0.01 
RFX2 1.82 3.70E-04 
NFKB2 1.82 6.01E-04 
CASP10 1.82 0.00 
FAM190B 1.82 0.00 
MAST1 1.81 0.03 
FAM171B 1.81 0.00 
TPMT 1.81 0.01 
CACNB3 1.80 0.03 
ARRDC4 1.80 0.03 
PPP1R21 1.80 0.01 
SCML1 1.80 0.01 
RTN4RL2 1.80 0.00 
SLC29A4 1.80 0.02 
CAMSAP2 1.80 0.00 
SCPEP1 1.80 0.01 
SEMA4D 1.79 0.00 
SMAD3 1.79 0.01 
NKIRAS1 1.79 0.00 
TSC22D3 1.79 0.02 
RNF122 1.78 0.02 
SRGAP2 1.78 0.01 
KIAA0895 1.78 0.03 
DYRK3 1.78 0.03 
MT1P1 1.78 0.02 
DNAJB5 1.78 0.00 
SALL2 1.77 5.40E-05 
GPR160 1.77 0.01 
SBF2 1.77 0.01 
SAT1 1.77 0.01 
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MCTP1 1.77 0.03 
PKP2 1.77 0.01 
DNMT3B 1.77 0.00 
F8 1.77 0.00 
ACSF2 1.76 0.01 
RWDD2A 1.76 0.00 
MT1E 1.76 0.02 
GOLGB1 1.76 0.00 
TEAD3 1.75 3.51E-04 
CYTH3 1.75 0.05 
CYTH1 1.75 3.90E-04 
STK17B 1.75 0.01 
CCDC92 1.75 6.42E-04 
SWAP70 1.75 0.00 
PRKD2 1.75 8.25E-04 
KDELC1 1.75 0.01 
TTLL1 1.75 0.01 
LGR4 1.75 0.03 
EXTL2 1.75 0.02 
MKNK1 1.75 0.00 
ACOX1 1.75 0.00 
ITSN1 1.74 0.01 
PTPN13 1.74 0.01 
MAP3K12 1.74 5.44E-04 
ACSL1 1.74 0.01 
TTYH2 1.74 0.00 
SERPINE1 1.74 0.01 
ANG 1.73 4.02E-04 
CYP2U1 1.73 0.01 
GRK5 1.73 0.05 
MKNK2 1.73 5.97E-05 
ATP8B1 1.73 0.02 
CEP70 1.73 5.04E-04 
RHOC 1.73 0.01 
C9orf89 1.73 1.69E-05 
KCTD21 1.73 0.02 
FOXO4 1.73 1.15E-04 
TTC26 1.73 0.03 
IFT81 1.72 0.01 
PGAP1 1.72 0.01 
AFMID 1.72 0.00 
IGSF3 1.72 0.00 
COQ10A 1.72 0.01 
TXK 1.72 0.03 
ATP8B2 1.72 0.02 
ZNF483 1.72 0.00 
FAM43A 1.71 0.01 
RPP25 1.71 0.01 
NMT2 1.71 0.00 
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NEU1 1.71 0.02 
NEU1 1.71 0.02 
GATSL2 1.71 0.04 
GATSL2 1.71 0.04 
C7orf23 1.71 0.00 
RCN3 1.71 0.01 
TOM1L2 1.71 0.03 
AK1 1.71 0.03 
FAM220A 1.71 0.01 
TMEM241 1.71 0.00 
NEU1 1.70 0.02 
FAM117A 1.70 0.01 
TMEFF1 1.70 0.03 
XRRA1 1.70 0.00 
TNFRSF11A 1.70 0.00 
GMCL1 1.70 6.62E-04 
ATP6V1G2 1.70 0.01 
APLF 1.70 0.03 
POLN 1.70 0.01 
NEK3 1.70 0.03 
MGAT5 1.70 0.04 
BMPR2 1.69 0.01 
SDE2 1.69 0.02 
WASF3 1.69 0.01 
ARID3B 1.69 0.03 
DNAJC18 1.69 0.03 
BACH2 1.68 0.05 
TRERF1 1.68 0.04 
MITF 1.68 0.01 
BMF 1.68 0.00 
SLC45A4 1.68 0.01 
CBX7 1.68 0.03 
DYNC2H1 1.68 0.03 
UBTD2 1.68 0.03 
ADHFE1 1.68 0.05 
AGTPBP1 1.68 3.42E-04 
CHRNA5 1.67 0.01 
MFSD12 1.67 0.01 
SLC25A30 1.67 0.00 
TMEM198B 1.67 0.02 
KIAA0040 1.67 0.01 
BBS7 1.67 0.01 
INPP5K 1.67 0.00 
PNPLA8 1.67 3.07E-04 
KLHL24 1.67 0.00 
MLLT4 1.67 0.01 
ZSCAN16 1.67 0.03 
REEP2 1.67 4.09E-04 
KSR1 1.67 0.02 
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USP2 1.66 0.01 
TMEM205 1.66 0.00 
USP44 1.66 0.02 
ENAH 1.66 0.01 
FAM220BP 1.66 0.01 
PLCG1 1.66 0.02 
HIBCH 1.66 0.01 
HABP4 1.66 0.00 
ARG2 1.66 0.03 
IL1A 1.66 0.04 
KCND1 1.66 0.01 
CYP2R1 1.66 0.01 
TC2N 1.65 0.03 
BAMBI 1.65 0.00 
DDAH2 1.65 0.02 
DDAH2 1.65 0.02 
C15orf39 1.65 0.02 
C14orf37 1.65 0.00 
ATG2A 1.65 0.02 
TMEM169 1.64 0.02 
TAC3 1.64 0.00 
RHOF 1.64 0.03 
ARHGAP18 1.64 0.00 
KIF1B 1.64 9.73E-04 
KATNB1 1.64 8.93E-04 
ST6GALNAC4 1.64 0.00 
MEGF9 1.63 0.00 
ATP6V1D 1.63 0.03 
CCDC113 1.63 0.03 
DMXL1 1.63 0.00 
FAM122C 1.63 0.02 
C17orf65 1.63 0.01 
CBL 1.63 0.05 
DYNLT3 1.63 1.84E-04 
PLCB3 1.63 4.58E-04 
KCNN1 1.63 0.01 
MPZL1 1.63 0.01 
ATP8A1 1.62 0.01 
PPP2R5B 1.62 0.01 
TMEM180 1.62 0.00 
MAP3K3 1.62 0.01 
TMEM25 1.62 0.03 
CMTM8 1.62 0.01 
ZNF555 1.62 0.04 
FGFR3 1.61 0.02 
FZD5 1.61 0.02 
PSMB9 1.61 0.02 
PSMB9 1.61 0.02 
PSMB9 1.61 0.02 
  250 
NIT1 1.61 2.94E-04 
PLS1 1.61 0.00 
IFT88 1.61 0.02 
KBTBD8 1.61 0.03 
NRGN 1.61 0.01 
UBE2S 1.61 0.00 
MAP2K3 1.61 0.03 
TSNAX 1.61 0.02 
SYP 1.61 0.01 
LLGL2 1.61 0.00 
PKIA 1.61 0.00 
DHTKD1 1.61 0.01 
SAMD15 1.61 0.03 
BCOR 1.60 0.01 
RAB3IP 1.60 0.01 
TCEA3 1.60 0.04 
C14orf129 1.60 0.02 
SLC45A4 1.60 0.03 
PI4K2A 1.60 0.01 
PRRG1 1.60 0.00 
WWTR1 1.60 0.05 
SLC2A4 1.60 0.03 
ANO10 1.60 0.01 
RABL5 1.60 0.05 
PPP2R3A 1.60 0.02 
PORCN 1.60 0.05 
PARD6B 1.59 0.03 
PELI1 1.59 0.03 
AAK1 1.59 0.01 
CASZ1 1.59 0.01 
PPARD 1.59 0.00 
SNAI1 1.59 0.01 
STAT2 1.59 0.01 
IGF2R 1.59 0.01 
SYAP1 1.59 0.01 
MYO10 1.59 0.02 
CYP2S1 1.59 0.00 
CNNM4 1.59 0.00 
MICA 1.59 0.01 
RTKN2 1.59 0.01 
SLC4A11 1.59 0.01 
PLCD1 1.59 0.01 
CTSL2 1.59 0.02 
WDR26 1.59 4.45E-04 
EPG5 1.59 0.02 
DDAH2 1.59 0.02 
AHI1 1.58 0.00 
G6PD 1.58 0.02 
RCBTB1 1.58 0.01 
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ZNF396 1.58 0.03 
TMEM232 1.58 0.05 
PGBD1 1.58 0.02 
MED20 1.58 0.00 
PPP1R13B 1.58 0.02 
STIM1 1.58 2.70E-06 
C4orf34 1.58 0.01 
ECE1 1.58 0.01 
WDR47 1.58 0.00 
CABLES2 1.58 0.00 
WASF1 1.58 0.02 
CD86 1.58 0.04 
PLEKHM1 1.58 0.01 
PRAF2 1.57 0.00 
NR6A1 1.57 0.01 
AJUBA 1.57 0.02 
RPS6KA2 1.57 0.01 
RYBP 1.57 0.01 
ANXA4 1.57 0.01 
HEXIM1 1.57 0.00 
ERBB3 1.57 0.03 
IRAK2 1.57 5.19E-04 
ZNF117 1.57 0.01 
KDM8 1.57 0.01 
MAGI3 1.57 0.05 
PLAT 1.57 0.05 
HDHD3 1.57 0.02 
RAP1GAP2 1.57 0.02 
BCORL1 1.57 0.00 
RABGAP1 1.57 0.01 
RALGAPA2 1.57 3.90E-04 
TNNI3 1.57 9.02E-04 
DZIP1 1.57 0.00 
FAM107B 1.57 0.04 
MT2A 1.57 0.02 
HOXA1 1.56 0.01 
TRIM26 1.56 0.00 
MT2A 1.56 0.02 
CRYZ 1.56 0.00 
FKBP7 1.56 0.02 
KLHL5 1.56 0.01 
ALS2 1.56 0.04 
EPB41L2 1.56 0.03 
APLP1 1.56 0.00 
BCL2L11 1.56 0.00 
MICB 1.56 0.00 
NR4A1 1.56 0.02 
MAP4K2 1.56 0.01 
HOOK2 1.56 0.03 
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CGRRF1 1.56 0.02 
NEK1 1.56 0.01 
EHD3 1.56 0.05 
CELSR2 1.56 0.01 
ATP6V1A 1.56 2.78E-04 
RASGEF1A 1.55 0.02 
SNAI3 1.55 0.00 
STX5 1.55 0.00 
UBE2S 1.55 0.00 
SEC61A2 1.55 0.01 
TRGV3 1.55 0.00 
KBTBD3 1.55 0.01 
GRHL1 1.55 0.01 
CLEC16A 1.55 2.36E-04 
TRIM62 1.55 0.00 
CNPY4 1.55 0.01 
ASAP2 1.55 0.02 
ARL13B 1.55 0.01 
APBB2 1.55 0.05 
TCEA2 1.55 0.01 
TPT1-AS1 1.55 0.00 
TMEM184B 1.55 0.00 
TMCC3 1.55 0.00 
ZNF217 1.55 0.00 
C5orf45 1.55 0.04 
PRRT3 1.54 0.01 
SLC9A9 1.54 0.03 
SP4 1.54 2.53E-04 
GSTA4 1.54 0.00 
SOAT1 1.54 8.95E-05 
MYLIP 1.54 0.00 
GNAZ 1.54 0.00 
AVPI1 1.54 0.01 
ICK 1.54 0.01 
MDM1 1.54 0.03 
LIMA1 1.54 0.02 
ZER1 1.54 0.03 
PRCP 1.54 0.01 
PAQR3 1.54 6.73E-04 
GTF2IRD1 1.54 7.53E-04 
LMBRD2 1.54 0.01 
GCC2 1.54 0.00 
FAM108A3P 1.54 8.67E-05 
FAM108A3P 1.54 8.67E-05 
PFKFB2 1.54 0.01 
LYST 1.54 0.05 
INPP5F 1.54 0.01 
P4HA2 1.54 0.01 
PQLC1 1.53 0.01 
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ENTHD1 1.53 0.02 
MT1X 1.53 0.05 
PITPNC1 1.53 7.63E-04 
KANK2 1.53 0.03 
DCUN1D3 1.53 0.04 
CRIP2 1.53 0.01 
LRFN3 1.53 0.02 
SNAP29 1.53 0.01 
FHL1 1.53 0.05 
HES1 1.53 0.00 
ZDHHC8 1.53 0.01 
RGS9 1.53 0.00 
MAP2 1.53 0.02 
GGCX 1.53 8.99E-05 
ANKRD13A 1.53 0.00 
U2AF1L4 1.53 0.03 
GNAI1 1.53 0.01 
GNG7 1.53 0.02 
USP28 1.53 0.01 
MLF1 1.53 0.01 
WIPI1 1.53 4.57E-04 
TRIM26 1.53 0.00 
STK38L 1.53 0.01 
SEZ6L2 1.52 0.00 
MPRIP 1.52 0.00 
LPCAT3 1.52 0.01 
MAP3K9 1.52 0.00 
HSD17B6 1.52 0.05 
PRKAR2B 1.52 0.03 
MICB 1.52 0.00 
BET1L 1.52 0.00 
CPNE3 1.52 0.01 
BST2 1.52 1.74E-04 
FADS3 1.52 0.01 
ARMC9 1.52 0.01 
FYN 1.52 0.02 
ZNF608 1.52 0.02 
ZNF277 1.52 0.01 
GLS 1.52 0.02 
PIGX 1.52 3.92E-04 
PLXNA2 1.52 0.01 
ATXN1 1.51 0.02 
KIAA1467 1.51 0.00 
ARL6IP6 1.51 0.01 
TOR1AIP2 1.51 0.00 
AMOT 1.51 0.01 
TBC1D7 1.51 0.05 
TNRC6B 1.51 9.33E-04 
CAMLG 1.51 0.01 
  254 
SLFN14 1.51 0.04 
NRARP 1.51 0.01 
SSBP3 1.51 6.14E-04 
GDI1 1.51 0.02 
SUFU 1.51 0.00 
SLC25A23 1.51 0.01 
CALCOCO2 1.51 0.00 
NFAT5 1.51 0.04 
ARL6 1.51 0.02 
AHR 1.51 0.04 
FNBP1L 1.50 0.01 
TUBB2B 1.50 0.02 
EFNB2 1.50 0.01 
PPM1N 1.50 0.03 
FRRS1 1.50 0.01 
ATP6V0A1 1.50 0.00 
CALCOCO1 1.50 0.01 
LRRC1 1.50 0.00 
SNRNP48 1.50 2.89E-04 
C12orf51 1.50 0.01 
FAM108A4P 1.50 3.60E-05 
SLC27A1 1.50 0.01 
ITPR2 1.50 0.02 
RHOQP2 1.50 0.01 
ACER3 1.50 0.01 
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Appendix B. List of significantly downregulated genes upon NaBu in CB-
CD34+ -differentiating erythroblasts. 
Genes Fold Change P value 
LANCL2 3.82 0.00 
PLA2G7 3.36 0.03 
ANGPT1 3.35 0.03 
IGSF6 3.32 0.01 
SLC7A11 3.32 0.01 
KMO 3.15 0.05 
UTP20 3.11 0.01 
IL7R 3.05 0.04 
C3orf14 3.03 0.04 
NAIP 3.01 0.04 
NAIP 2.99 0.03 
KCNQ5 2.97 0.00 
FGL2 2.92 0.04 
GPR141 2.90 0.01 
AVEN 2.84 0.00 
SNORD77 2.83 0.03 
RCN1 2.80 0.04 
CD84 2.79 0.03 
NIPAL2 2.75 0.01 
FPR3 2.75 0.04 
ZMYND11 2.75 0.01 
GTF2IRD2B 2.74 0.00 
MS4A6A 2.74 0.00 
SLAMF8 2.73 0.01 
CARD6 2.71 0.02 
PHF19 2.65 0.00 
MS4A2 2.65 0.01 
CLEC5A 2.61 0.05 
C15orf41 2.57 0.00 
LOC100128816 2.56 0.00 
ZBTB2 2.56 0.02 
GTF2IRD2B 2.55 0.00 
KDELC2 2.49 0.00 
CD1E 2.47 0.02 
PHF15 2.46 0.00 
GPR171 2.42 0.02 
CXorf26 2.42 0.02 
DIS3L 2.42 0.00 
TMEM117 2.40 0.02 
PARM1 2.40 0.02 
ZFP64 2.38 0.00 
NRP1 2.37 0.01 
IL12RB2 2.36 0.02 
LOC339524  // 
HS2ST1 2.35 0.02 
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EPC1 2.34 0.01 
USP13 2.33 0.00 
FAM57A 2.33 0.04 
SNORD34 2.33 0.03 
TMCO7 2.32 0.00 
PHF17 2.32 0.01 
METAP1D 2.30 0.02 
GINS3 2.29 0.02 
STAG1 2.29 0.00 
MTHFS 2.27 0.03 
PTPN7 2.27 0.05 
MRTO4 2.27 0.00 
STS 2.26 0.00 
FDXACB1 2.25 0.01 
CTPS1 2.25 0.00 
MRM1 2.25 0.02 
NETO2 2.24 0.04 
CLEC4A 2.24 0.01 
FAIM 2.23 0.03 
ARSB 2.21 0.01 
GALNT14 2.21 0.03 
UBXN8 2.19 0.00 
GTF2I 2.18 0.01 
IL27RA 2.18 0.02 
CABLES1 2.18 0.05 
BEND3 2.17 0.00 
HPDL 2.17 0.00 
NMI 2.16 0.00 
TFAP4 2.16 0.01 
ARMC6 2.16 0.00 
SLTM 2.15 0.02 
CASD1 2.15 0.04 
ADAMTS3 2.15 0.00 
ADAT2 2.13 0.01 
GPR34 2.13 0.01 
CD1A 2.13 0.04 
NSMAF 2.12 0.02 
LRMP 2.12 0.01 
EPC2 2.11 0.01 
BDH1 2.10 0.01 
AMICA1 2.10 0.04 
STAT5A 2.10 0.00 
HCFC1 2.09 0.01 
SMYD5 2.08 0.01 
ZBTB1 2.08 0.04 
ALG14 2.08 0.01 
UBTF 2.07 0.00 
FAM136A 2.07 0.05 
ADI1 2.06 0.01 
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FAS 2.05 0.02 
SNTB1 2.04 0.00 
ZNF804A 2.04 0.04 
CCL1 2.04 0.04 
PRDM10 2.04 0.01 
TOE1 2.03 0.02 
PHF2 2.03 0.00 
NOP16 2.03 0.02 
NFKB1 2.03 0.00 
MCM9 2.03 0.01 
ING5 2.02 0.00 
PATZ1 2.02 0.01 
CCR6 2.02 0.01 
GPATCH4 2.01 0.01 
HERC6 2.01 0.02 
CYP7B1 2.01 0.03 
CD1C 2.00 0.05 
ALDH5A1 2.00 0.03 
RPP40 1.99 0.00 
ING5 1.98 0.00 
GPR125 1.98 0.01 
KCTD15 1.98 0.00 
MTHFD1L 1.97 0.00 
ANAPC13 1.97 0.03 
TMEM87A 1.97 0.01 
DUS3L 1.96 0.00 
CSF1 1.95 0.03 
FAM217B 1.95 0.01 
GRAP2 1.94 0.04 
GGTA1P 1.94 0.01 
PDCL3 1.94 0.01 
NBN 1.94 0.02 
U2AF2 1.93 0.02 
PPRC1 1.93 0.02 
MSL1 1.93 0.02 
CD93 1.93 0.02 
FERMT3 1.92 0.03 
ATF5 1.91 0.01 
SNORA24 1.91 0.01 
KIAA0368 1.91 0.00 
PON2 1.90 0.01 
NAGPA 1.90 0.00 
C14orf102 1.90 0.00 
BANK1 1.90 0.00 
C10orf57 1.89 0.00 
INO80D 1.89 0.01 
EOGT 1.89 0.02 
C1QTNF9B-AS1 1.89 0.03 
VPS52 1.88 0.01 
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VPS52 1.88 0.01 
NLRC4 1.88 0.01 
PRKCQ 1.87 0.01 
ZNF366 1.87 0.01 
ACPP 1.87 0.03 
SNORA4 1.87 0.02 
RNASE6 1.87 0.05 
WT1 1.86 0.01 
NOL6 1.86 0.00 
VPS52 1.86 0.01 
P2RY14 1.86 0.02 
SLC39A10 1.85 0.02 
ANKLE1 1.85 0.02 
SUSD1 1.85 0.02 
METTL8 1.84 0.00 
PUS7 1.84 0.02 
NCOA2 1.84 0.00 
EFCAB4B 1.84 0.01 
LIF 1.84 0.04 
MINA 1.83 0.02 
FJX1 1.83 0.01 
IL9R 1.83 0.01 
IL9R 1.83 0.01 
FMNL1 1.83 0.00 
TYW3 1.83 0.01 
CLEC10A 1.83 0.04 
PMF1 1.83 0.00 
SLC38A5 1.83 0.02 
C8orf33 1.83 0.01 
PRKAR1B 1.83 0.01 
SNAPC5 1.82 0.05 
TMEM192 1.82 0.00 
CAB39L 1.82 0.01 
WARS2 1.81 0.02 
STAMBPL1 1.81 0.01 
RRS1 1.81 0.01 
LARP7 1.81 0.00 
GCFC2 1.81 0.02 
RABL3 1.81 0.01 
KEAP1 1.81 0.00 
SPR 1.81 0.00 
DTX3L 1.81 0.00 
FABP5 1.80 0.02 
PEF1 1.80 0.01 
ZNF114 1.80 0.05 
FBXO4 1.80 0.02 
SPRYD4 1.79 0.01 
CCDC94 1.79 0.03 
DDX26B 1.79 0.00 
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SPAG7 1.79 0.00 
KAT5 1.79 0.01 
ZFAT 1.79 0.01 
FST 1.79 0.01 
CWF19L2 1.79 0.01 
S1PR4 1.78 0.01 
SPATS2L 1.78 0.05 
LRP8 1.78 0.01 
SELRC1 1.78 0.03 
TSR1 1.78 0.00 
FABP5 1.78 0.02 
ITFG2 1.78 0.01 
TMPO 1.78 0.00 
PRMT6 1.77 0.01 
SLC5A6 1.77 0.01 
N6AMT2 1.77 0.01 
QRSL1 1.77 0.00 
GTPBP6 1.77 0.00 
LACE1 1.77 0.04 
GTF3C6 1.77 0.00 
PPIL1 1.77 0.00 
ZBTB38 1.76 0.00 
ASTE1 1.76 0.03 
SLC25A13 1.76 0.01 
SMARCB1 1.76 0.00 
C12orf26 1.76 0.00 
KAT2A 1.76 0.01 
FAM124B 1.76 0.02 
KCNH2 1.75 0.01 
ZFP161 1.75 0.00 
MTX3 1.75 0.03 
B3GALTL 1.75 0.01 
KAT6B 1.75 0.00 
ZC3HC1 1.75 0.01 
ACSL5 1.75 0.02 
HAVCR2 1.75 0.05 
E2F8 1.74 0.00 
CAD 1.74 0.00 
SMYD2 1.74 0.00 
MEPCE 1.74 0.00 
GPR125 1.74 0.00 
PILRA 1.74 0.02 
CUL1 1.73 0.03 
APOBR 1.73 0.00 
POLE4 1.73 0.01 
RPRD2 1.73 0.02 
HSD17B7P2 1.73 0.01 
EPM2A 1.73 0.01 
ZNF827 1.73 0.01 
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C6orf223 1.72 0.02 
SLC6A9 1.72 0.03 
TMBIM4 1.72 0.00 
ALG13 1.72 0.04 
WDFY4 1.72 0.05 
TMX4 1.72 0.00 
LRRC41 1.72 0.00 
C9orf91 1.72 0.04 
NSD1 1.72 0.01 
LHFPL2 1.71 0.01 
USP41 1.71 0.03 
ZNF692 1.71 0.00 
MANEA 1.71 0.00 
PCBD2 1.71 0.00 
LMNB1 1.71 0.04 
ZNF362 1.71 0.01 
MB21D1 1.70 0.05 
URGCP 1.70 0.01 
ZNF573 1.70 0.01 
BLNK 1.70 0.02 
CHST10 1.70 0.01 
UTP15 1.70 0.02 
BRPF3 1.69 0.01 
PBLD 1.69 0.03 
YDJC 1.69 0.01 
SNUPN 1.69 0.05 
SLC16A7 1.68 0.02 
HUS1 1.68 0.01 
RRP12 1.68 0.01 
MPDU1 1.68 0.01 
SDC2 1.68 0.01 
ADRBK1 1.68 0.02 
ZAK 1.67 0.05 
ZNF33A 1.67 0.00 
RN5S242 1.67 0.02 
SNORA74A 1.67 0.03 
DCPS 1.67 0.04 
ZC3HAV1L 1.67 0.03 
HSD17B7 1.67 0.01 
ALKBH8 1.67 0.00 
ARHGAP9 1.67 0.05 
GNE 1.67 0.01 
STEAP3 1.66 0.01 
LOC100131190 1.66 0.02 
SMG9 1.66 0.00 
MYBBP1A 1.66 0.01 
CHRAC1 1.66 0.05 
NUP205 1.66 0.00 
COQ7 1.66 0.00 
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FAM216A 1.66 0.03 
PTS 1.66 0.02 
CHCHD4 1.66 0.02 
TIMM21 1.66 0.01 
DHX33 1.66 0.00 
THRB 1.66 0.03 
TNFAIP8L2 1.66 0.00 
ZNF383 1.66 0.02 
TRMT2B 1.65 0.00 
GNA15 1.65 0.00 
ZNF407 1.65 0.02 
TTC27 1.65 0.01 
THOC6 1.65 0.00 
UCK2 1.65 0.01 
COMMD10 1.65 0.03 
SLC39A3 1.65 0.03 
NLRX1 1.64 0.00 
TYMS 1.64 0.01 
TOX 1.64 0.03 
SNORD35A 1.64 0.02 
MRPS28 1.64 0.01 
ARID1B 1.64 0.00 
ZNF639 1.64 0.01 
ZNF37A 1.63 0.01 
CDC7 1.63 0.01 
CLK4 1.63 0.04 
KIAA1598 1.63 0.02 
NUBP1 1.63 0.01 
MATK 1.63 0.01 
SLC25A26 1.63 0.04 
C3orf75 1.63 0.01 
CNTF 1.63 0.03 
DPH2 1.63 0.01 
CNNM1 1.63 0.05 
ST7 1.63 0.03 
IVNS1ABP 1.63 0.01 
IDNK 1.62 0.03 
KCNE3 1.62 0.05 
PARP8 1.62 0.00 
CNTLN 1.62 0.00 
IPO8 1.62 0.00 
CRISPLD1 1.62 0.01 
H2AFY2 1.62 0.02 
ADCK1 1.62 0.02 
PSMB10 1.62 0.01 
VPS36 1.62 0.00 
PISD 1.62 0.01 
LRFN4 1.62 0.00 
LIN9 1.62 0.04 
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LTV1 1.62 0.01 
COIL 1.62 0.00 
SLC29A2 1.61 0.03 
RAB11FIP2 1.61 0.01 
SLC19A1 1.61 0.01 
L3MBTL2 1.61 0.00 
NUDT15 1.61 0.02 
FASTKD2 1.61 0.02 
ATP11C 1.61 0.01 
CCDC101 1.60 0.02 
RRP15 1.60 0.01 
SLC25A15 1.60 0.03 
CREBBP 1.60 0.00 
ADNP 1.60 0.04 
GEMIN4 1.60 0.02 
KDM8 1.60 0.00 
SGK196 1.60 0.03 
TMEM168 1.60 0.01 
ITPA 1.60 0.02 
IFRD2 1.59 0.00 
ENTPD1 1.59 0.02 
BCL6 1.59 0.02 
TRRAP 1.59 0.02 
LTB4R2 1.59 0.02 
CTCF 1.59 0.00 
CUL4A 1.59 0.00 
AKT1S1 1.59 0.00 
SUV420H1 1.59 0.00 
GBE1 1.59 0.00 
BAG2 1.58 0.01 
GRB10 1.58 0.02 
SLC35F2 1.58 0.04 
EPDR1 1.58 0.00 
TIMELESS 1.58 0.01 
TCERG1 1.58 0.02 
GIMAP6 1.58 0.00 
FAM172A 1.58 0.03 
KRT79 1.58 0.00 
SIRPA 1.58 0.05 
UNG 1.58 0.00 
SLC8A1 1.58 0.01 
NCF2 1.58 0.04 
ARHGAP21 1.58 0.01 
LIG3 1.58 0.00 
WDFY4 1.58 0.04 
WDR74 1.58 0.00 
BCLAF1 1.58 0.02 
NQO1 1.57 0.03 
DNAJC2 1.57 0.03 
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TXNDC15 1.57 0.00 
ITGA4 1.57 0.02 
DPP3 1.57 0.01 
PTPRCAP 1.57 0.03 
SLC7A1 1.57 0.00 
RNLS 1.57 0.02 
AEN 1.57 0.02 
WDR4 1.57 0.03 
SLC20A2 1.57 0.00 
EMB 1.57 0.03 
C1orf31 1.57 0.00 
SLC9B2 1.57 0.03 
CYP20A1 1.57 0.02 
XPO4 1.57 0.00 
GNL3L 1.57 0.01 
ZNF582 1.57 0.00 
INTS6 1.57 0.01 
CWC22 1.57 0.01 
STAG2 1.57 0.00 
LOC390940 1.56 0.02 
DNAJB12 1.56 0.02 
EPB49 1.56 0.01 
COG7 1.56 0.01 
COX17 1.56 0.02 
ELOVL6 1.56 0.01 
YARS2 1.56 0.02 
KIAA0020 1.56 0.00 
ITPKB 1.56 0.03 
CCNJ 1.56 0.02 
STK39 1.56 0.02 
COX17 1.56 0.02 
ZNF32 1.56 0.01 
SEPHS1 1.56 0.02 
HDAC7 1.56 0.02 
MFSD2B 1.55 0.00 
C10orf32 1.55 0.02 
MSH3 1.55 0.00 
ZNF618 1.55 0.00 
MON1B 1.55 0.00 
MTAP 1.55 0.04 
TRMT11 1.55 0.01 
PIWIL3 1.55 0.04 
CST7 1.55 0.05 
C10orf2 1.55 0.02 
ALG13 1.55 0.01 
DHX37 1.54 0.00 
RPL7L1 1.54 0.00 
STXBP3 1.54 0.00 
PACRGL 1.54 0.03 
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SUMO3 1.54 0.01 
MRPL3 1.54 0.00 
SERF1A 1.54 0.01 
SERF1B 1.54 0.01 
SERF1A 1.54 0.01 
SENP6 1.54 0.05 
SAFB 1.54 0.01 
AKAP8 1.54 0.03 
QTRTD1 1.54 0.01 
KDM3B 1.54 0.00 
BTBD6 1.54 0.02 
METTL21A 1.53 0.01 
SLC43A1 1.53 0.03 
ACAT2 1.53 0.05 
TMEM204 1.53 0.00 
MRPL15 1.53 0.01 
SMEK1 1.53 0.04 
DTYMK 1.53 0.03 
DTYMK 1.53 0.03 
CCL23 1.53 0.03 
WDR6 1.53 0.01 
SPG20 1.53 0.01 
GAR1 1.53 0.05 
PPCS 1.53 0.02 
TSEN2 1.53 0.02 
PRDM15 1.53 0.00 
ZBTB40 1.53 0.02 
SRPRB 1.53 0.02 
TSPAN32 1.52 0.00 
NEFH 1.52 0.02 
OTUD4 1.52 0.03 
SIPA1L1 1.52 0.00 
EXOSC10 1.52 0.00 
TTC32 1.52 0.02 
PICK1 1.52 0.00 
LIMD2 1.52 0.00 
GRWD1 1.52 0.00 
DDX56 1.52 0.00 
PLD6 1.52 0.03 
TIMM44 1.52 0.00 
ZNF565 1.52 0.03 
XIAP 1.52 0.02 
ALG1 1.52 0.02 
ZNF660 1.52 0.03 
KIAA0240 1.52 0.01 
ARAF 1.52 0.01 
ZZZ3 1.52 0.00 
NUP35 1.52 0.01 
EXOG 1.52 0.03 
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ATAD2B 1.52 0.00 
IFNGR2 1.51 0.02 
ICA1L 1.51 0.01 
MMAB 1.51 0.01 
PNISR 1.51 0.04 
GPN1 1.51 0.00 
FUCA2 1.51 0.05 
FAM165B 1.51 0.00 
SREK1 1.51 0.00 
METTL16 1.51 0.02 
ARID2 1.51 0.01 
DNAJC11 1.51 0.01 
WIBG 1.51 0.03 
ZNF566 1.51 0.05 
C7orf29 1.51 0.01 
MNF1 1.51 0.02 
PTPRO 1.51 0.00 
ELAC2 1.51 0.00 
MANEAL 1.51 0.01 
AP5S1 1.51 0.00 
SLC35G1 1.51 0.01 
HIRIP3 1.51 0.02 
NSUN4 1.51 0.02 
SMG5 1.51 0.02 
PHF14 1.50 0.00 
UMPS 1.50 0.01 
CTPS2 1.50 0.03 
IAH1 1.50 0.03 
CLOCK 1.50 0.00 
TRMT1 1.50 0.02 
ZNF644 1.50 0.03 
SELPLG 1.50 0.04 
PCK2 1.50 0.03 
CPNE8 1.50 0.05 
MTMR1 1.50 0.01 
RYR3 1.50 0.00 
ZC3H7B 1.50 0.00 
RBM23 1.50 0.04 
TUBGCP5 1.50 0.00 
NR3C1 1.50 0.00 
CDK6 1.50 0.00 
PLK1 1.50 0.01 
MBNL3 1.42 0.00 
 
